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ABSTRACT 
Advances in directed monooxygenase evolution: From diversity generation and flow 
cytometry screening to tailor-made monooxygenases 
 
Directed Evolution became a powerful tool for proteins engineers to generate tailor-made biocatalyst. Directed 
protein evolution consist of the following three consecutive main steps, which are performed in iterative cycles; 
Step 1 the gene diversity generation, Step 2 the screening for improved variants and Step 3 the isolation of gene 
encoding for improved proteins. In this thesis, methodological advancements in the two key steps of the directed 
evolution, the diversity generation (SeSaM method) and high throughput screening (flow cytometer based 
screening technology) were performed and complemented by the evolution of P450 BM3 for alternative cofactor 
systems. Step 1 consisting of generation of high quality mutant libraries was advanced by developing an 
improved SeSaM protocol in which a universal base complementary to the P-base was employed to generate 
more diverse libraries. Step 2 was advanced by generating a whole cell high throughput screening assay for 
monooxygenases allowing to efficiently sample the diversity generated in Step1. Subsequently, the advanced 
protocols were applied to evolve P450 BM3 for alternative cofactor systems in iterative rounds (Step 3). These 
developed methods (flow cytometer assay for P450 BM3 and advanced SeSaM method) are of main interest for 
the researchers focusing on protein engineering. 
 
In Chapter I of the thesis, the application of the R-base as universal base complementary to P-base increase the 
amino acid sequence space that can be covered with the SeSaM method. SeSaM-P/R allows for the first time to 
introduce at all four nucleotides transversion mutations which are homogeneously distributed over the targeted 
gene and which mutate in an ideal case each nucleotide of a gene. Second approach to advance the SeSaM 
method has been undertaken via a modified base at the 3’ position of the sugar backbone. Through a chemical 
cleavable block the number of added bases was aimed to be controlled. The advanced SeSaM protocol is of 
general interest for researchers performing directed evolution experiments since a high quality mutant library 
with superior diversity than the standard epPCR is provided. 
  
In Chapter II of the thesis, the first flow cytometer based ultra-high throughput screening platform that can be 
applied in directed evolution campaigns of P450 monooxygenases was developed. A whole cell high throughput 
screening assay for P450 BM3 based on a coumarin derivative (7-Benzoxy-3-Carboxy-Coumarin Ethyl ester 
(BCCE)) was established. Furthermore, the presented screening platform is not only restricted to P450 BM3, the 
reported BCCE screening system will very likely be applicable to all P450 monooxygenases that can be 
expressed in E. coli and catalyze an O-dealkylation of coumarin derivatives (e.g. human CYP3A4). However, 
the flow cytometer-based ultra-high throughput screening assay for directed evolution of P450 BM3 towards 
improved mediated electron transfer with Zn-dust could not be developed. The inhibitory effect of the Zn-dust 
on the microbial grow was pre-dominent and excluded the use of the double emulsion technology for the 
evolution of P450 BM3 for mediated electron transfer (MET). 
 
In Chapter III, the advanced methods developed in Chapter I and II were employed to generate P450 BM3 
libraries to evolve the catalyst towards alternative cofactor systems. P450 monooxygenases have a remarkable 
catalytic capability of inserting one atom from molecular oxygen into inert CH bonds. This unique oxygen 
chemistry makes the P450s very attractive for organic synthesis in the chemical and pharmaceutical industries. 
The evolution of P450 BM3 for improved alternative cofactor systems allows a step forward to liberate P450 
BM3 from the requirement of expensive NADPH addition as cofactor which restricts the industrial use. The 
enzyme was evolved by generating random mutant libraries with the SeSaM method and by epPCR. The 
libraries were enriched with the flow cytometer screening system and subsequent screening in MTP format for 
improved mediated electron transfer. P450 BM3 M3 could further be engineered towards increased activity in 
presence of the alternative cofactor system Zn/Co(III)-sep. Indeed, new hot spots which were not reported before 
as relevant for the mediated electron transfer, could be identified. The second investigated alternative cofactor 
system, the direct electron transfer was explored by directed evolution to enhance the activity of the 
monooxygenase P450 BM3 in presence of a conducting polymer. Focus mutagenesis as well as random 
approach were performed, but no P450 BM3 variants with improved activity or new hot spots could be 
identified. Instead, an inhibitory effect by the conductive polymer could be demonstrated. Concluding, the P450 
BM3 has no activity with the conductive polymer Clevios P. The selected mutants in the screening were 
improved for resistance towards Clevios P or stability with NADPH but the activity for direct electron transfer 
and the electron transfer rate did not increase.  
 
Subsequently, collaborative P450 BM3 projects are summarized: the monooxygenase mutein database 
(muteinDB) was supported in which muteins altering substrate specificity are collected, the evolution of P450 
BM3 for substrate specificity was contributed and P450 BM3 muteins with surface modifications for 
electrochemical characterization were generated. 
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1.  Introduction  
 
1.1 Monooxygenase P450 BM3 from Bacillus megaterium  
 
Monooxygenases are present nearly in all organism (Bernhardt, 2006). They have been found 
in all eukaryotes, animals, plants and fungi as well as in some prokaryotes (Lewis and Lake, 
1996). In mammals, cytochromes are membrane-associated, but in several bacteria they can 
be found as cytosolic proteins (Peters et al., 2003). The cytochrome P450 superfamily was 
discovered in 1955 (Brodie et al., 1955). The term “cytochrome P450” was described for the 
first time in literature in 1962 (Omura, 1999). The name cytochrome P450 originates from its 
spectral properties, which reflects the presence of the heme b bound in the active center of the 
enzyme, the "P" stands for pigment and "450" refers to the wavelength absorption maximum 
of the reduced CO-bound complex (Nelson et al., 1996). These properties are also used for the 
determination of the P450-concentration. The new nomenclature used the term CYP to 
specify the class, followed by a series of numbers and letters, to classify the enzymes and 
identification of their degree of similarity (Example: P450 BM3 is coded as CYP102A1). 
Cytochrome P450s are part of the family of the external monooxygenases, involved in oxygen 
metabolism (Bernhardt, 2006). P450s are grouped in 10 classes, depending on the electron 
delivering system from NAD(P)H to the active site. Mitochondrial and most bacterial P450s 
are three-component systems comprising a P450, a ferredoxin and a NADH-dependent, FAD-
containing ferredoxin reductase (Hollmann et al., 2011; Whitehouse et al., 2012). 
 
Cytochrome P450 BM3 (CYP102) from Bacillus megaterium is a 118 kDa size, water 
soluble, NADPH-dependent fatty acid hydroxylase, that catalyzes the subterminal oxidation 
of saturated and unsaturated long-chain fatty acids (Narhi et al., 1988; Budde et al., 2004, 
2004; Bernhardt, 2006). P450 BM3 is more thermostable and easier to handle compared to 
other P450s (Bernhardt, 2006). P450 BM3 can be recombinantly expressed in E. coli (Narhi 
et al., 1988), facilitating the investigation its potential applications in synthesis of chemical 
precursors for pharmaceutical products or industrially relevant substrates. P450 BM3 is 
compared to other monoxygenases highly active with natural substrates, reaching turnover 
rates of thousands of substrate molecules per minute for specific fatty acids (arachidonic acid 
17 000 turnover min-1) (Cirino and Arnold, 2002). 
Structurally, P450 BM3 contains two distinct domains, the heme- and the reductase-domain, 
containing the FAD (Flavinadenindinucleotide) and the FMN (Flavinmononucleotide) 
binding domain, fused as a single polypeptide chain (Whitehouse et al., 2012). The structure 
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of P450 heme binding domain is fully resolved (Ravichandran et al., 1993) as well as the 
complex heme/FMN-binding domain (Sevrioukova et al., 1999a). However, the crystal 
structure of the full-length enzyme is currently not available (Sevrioukova et al., 1999b). The 
heme domain has been crystallized in the presence and absence of various substrates allowing 
to extend the understanding of structure-function relationships (Sevrioukova et al., 1999a). 
Recently, the crystal structure of the FAD/NADPH-binding domain of P450 BM3 has been 
reported (Joyce et al., 2012). 
P450 BM3 is described “to experience a substrate-induced thermodynamic switch that 
regulates the electron transfer” (Wong and Schwaneberg, 2003) (Fig. 1). In absence of 
substrate, no electron transfer from flavin mononucleotide (FMN) to heme occurs. “This 
control mechanism prevents the consumption of the electron donor (NADPH) avoiding the 
production of reactive and cell-damaging reactive oxygen species, such as hydrogen 
peroxide” (Wong and Schwaneberg, 2003). The electron transfer path is not yet defined; 
however, relevant amino acids are identified providing valuable information contributing to 
the investigation of P450s electron transfer properties and channel (Whitehouse et al., 2012).  
  
 
 
 
 
Fig. 1: Electron transfer mechanism of P450 BM3. TC = Thermodynamic control (adapted from Wong et al. 
(Wong and Schwaneberg, 2003)). 
 
1.1.1 Cytochrome P450 catalyzed reactions 
Cytochrome P450 monooxygenases have a remarkable catalytic capability of inserting one 
atom from molecular oxygen into inert C-H bonds (Bernhardt, 2006). The enzymes contain 
heme b in their active center, where the reaction (2) is taking place.  
 
RH + O2 + NAD(P)H+ H+ → ROH + H2O+NAD(P)+         (2) 
 
The catalytic mechanism was summarized by Urlacher et al. as follows: “The oxygen binds to 
the heme iron where the enzyme catalyzes the cleavage of the oxygen O-O bond. The 
essential step in the oxidation of substrate by P450 is the addition of one atom of molecular 
oxygen, which is activated by reduced heme iron, to the substrate. This reaction is usually a 
Cytochrom P450 BM3 
FAD FMN Heme b NADPH fatty acid 
TC
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hydroxylation reaction (2). The second oxygen atom is reduced to water, through accepting 
electrons from NAD(P)H via a flavoprotein or a ferredoxin” (Urlacher et al., 2004b). 
Divers reactions are catalyzed by more than 5000 monooxygenases already described, and 
constantly new enzymes are reported (Bernhardt, 2006). The sequence identity is often less 
than 20 % (Urlacher and Schmid, 2004) between P450 monooxygenases with similar 
structural organization. Only a few amino acids are conserved, which play a key role in 
catalysis (Munro et al., 2002).  
P450s can hydroxylate a broad range of substrates, from alkanes, phenols to complex 
molecules, such as steroids and fatty acids (Budde et al., 2006). Included are hydroxylation, 
epoxidation, deamination, desulphuration, dehalogenation, peroxidation (Bernhardt, 2006). 
An additional reaction that has also found an application in high-throughput screening 
methods of mutant libraries is the dealkylation reaction, using fluorogenic substrates such as 
alkyl-coumarins (Urlacher and Eiben, 2006) (Fig. 2).  
 
 
Fig. 2: Reaction catalyzed by P450 monooxygenases: C-H activation of sp³hybridized C-atoms (a), epoxidation 
of  C=C double bonds (b), hydroxylation of aromatic compounds (c), dealkylation reaction (d). (Urlacher and 
Eiben, 2006). 
 
1.1.2 Synthetic potential of P450 monooxygenases 
The unique oxygen chemistry makes P450s very attractive for organic synthesis in the 
chemical and pharmaceutical industries (Juchau, 1990). P450-catalyzed reactions are often 
stereoselective and difficult to achieve by chemical means, especially in aqueous 
environment, room temperature, under atmospheric pressure, and with molecular oxygen as 
oxygenation agent (Guengerich et al., 1996).  
Application of P450s in industrial scales already exists, the most prominent being: the 11ß-
hydroxalation of Reichstein s, a progesterone derivative to hydrocortisone, a process using 
P450s from the fungi Curcularia sp. (Petzoldt, 1982) [www.schering.de], produced at a scale 
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of 100 tons/year. A similar example is the conversion of progesterone to cortisone by P450s 
expressed by Rhizopus sp., which was commercialized by Pfizer [www.pfizer.com]. 
Additionally, the formation of dicarboxylic acids from alkanes, using endogenous P450 from 
an industrial Candida tropicalis strain, is reported with very high productivity (Picataggio et 
al., 1992; Jiao et al., 2001). In the future, this field will expand as soon as novel techniques 
will be applicable to ensure cost effective processes.  
The research and application fields of the cytochrome P450s is broad and not only restricted 
to the chemical industry; P450 are applied in microbiology, plant science and medicine. 
P450s play an important role in biosynthesis of secondary metabolites (Imaishi and Ohkawa, 
2002), where they are not only responsible for activation or biodegradation of xenobiotics, but 
also play a crucial role in biosynthetic pathways, such as metabolism of hormones, drugs, 
carcinogens, alkaloids, pesticides (Ingelman-Sundberg, 2004). P450s are also involved in 
physiological processes, such as steroidal hormones, vitamin D and bile acid biosynthesis. 
Without these physiological processes humans and most mammalians are not viable 
(Montellano, 2005). Additionally, therapeutical applications of P450s gain in significance as 
well as the use in biomonitoring techniques. On the other hand, defects in P450 could lead to 
metabolic conditions, like the Antley Bixhler syndrome (Iijima et al., 2009).  
 
Despite their many uses, the activity of P450 monooxygenases towards non-natural substrates 
is usually very low. P450s reach only a few thousand conversions per minute for artificial 
substrates. In contrast to enzymes involved in industrial applications, which reach thousands 
per second (for example phytases, proteases). This limits the commercial applications. 
(Urlacher et al., 2004). Additionally, P450s cannot tolerate common bioprocess conditions, 
such as the presence of organic cosolvents, and depend on an equimolar amount of NAD(P)H 
for each reaction cycle. This increases the costs of the processes (Urlacher and Eiben, 2006). 
The use of directed evolution to improve biocatalysts has been reported to successfully 
generate tailored P450 monooxygenase variants for specific applications. Engineered 
monoxygenases with increased activity in DMSO (Roccatano et al., 2005), increased organic 
solvent resistance (Montellano, 2005) (Wong et al., 2004a) or increased activity towards 
saturated hydrocarbon (octane) (Farinas et al., 2001) and gaseous alkane (propane) (Glieder et 
al., 2002) are reported. The affinity of P450 for non-natural substrates also has been 
increased, where the substrate specificity of P450 BM3 was shifted from C12 fatty acids to 
C10 and C8 (Fasan et al., 2008; Weber et al., 2011) or even to C3 (Glieder et al., 2002). 
Additionally, variants capable to hydroxylate inole (Appel et al., 2001) or oxidize substrates 
1.  Introduction               5 
as naphthalene, n-octane, and the oxidation of polycyclic aromatic hydrocarbons (PAHs) were 
generated (Carmichael and Wong, 2001; Li et al., 2001a, 2001b).  
Currently, an extended research field focused on the optimization of P450 monooxygenase to 
improve the industrial use of P450s. The reaction and substrate spectrum is extended, the 
regio- and stereo- specificity is controlled, the enhancement of thermal and process stability 
and the cofactor regeneration is developing (Urlacher and Eiben, 2006). Among these 
research foci, the substitution of the costly NADPH cofactor is of special interest. These is 
also the main focus of the P450 BM3 evolution performed in this thesis. 
 
1.1.3 Alternative cofactor systems for P450 BM3 
Besides the functional complexity, low activity and limited stability, the requirement of 
expensive (10 g/1500 Euro) NADPH as cofactor in equimolar amounts restricts the industrial 
use of P450 BM3 (Wong and Schwaneberg, 2003). In consequence, to allow the application 
of P450s in cell free systems, the regeneration (re-use) or substitution of NADPH is of high 
industrial relevance. In order to decrease processes costs due to NADPH, whole-cell systems 
for cofactor regeneration, enzyme-coupled and electrochemical cofactor regeneration systems 
have been developed. Electrochemical cofactor regeneration has been taken into account, 
however, the non-biological conditions (alkaline pH, alcohol solvents) make challenging for 
most enzymes (Urlacher and Eiben, 2006). 
Several proposed systems to substitute the NADPH are reported, such as mediated electron 
transfer (Nazor and Schwaneberg, 2006), light induced systems (Schröder et al., 1999), the 
“peroxide shunt pathway” (Joo et al., 1999) and electrochemically driven enzymes (Estabrook 
et al., 1996; Holtmann et al., 2009). Furthermore, NADPH regeneration systems have already 
been developed (Chefson and Auclair, 2006). The most used system in industrial processes is 
the enzyme-coupled NAD(P)H recycling, consisting of the addition of a dehydrogenase and a 
substrate that is oxidized to the system (for example formate dehydrogenase for the oxidation 
of formic acid to CO2), resulting in the regeneration of NAD(P)H from NAD(P)+ (Mouri et 
al., 2006). Limitation of this system is, besides the presence of two enzymes in the reaction, 
that most dehydrogenases use NAD+ contrary to NAD(P)H used by most P450s. To tackle 
this, P450 monooxygenases have been engineered to use NADH as cofactor instead of 
NADPH (Neeli et al., 2005). NADH has the advantage to be 10 times less expensive, more 
stable and can better be regenerated than NADPH. Switching from NADPH to NADH as 
cofactor facilitated also the application for whole cell approaches, because there is a higher 
amount of internal dehydrogenases and NADH, compared to NADPH in E.coli cells 
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(Hollmann et al., 2011). The regeneration of NADH or NADPH in whole cell systems was 
applied to camphor hydroxylation in aqueous solution in addition to a two-phase system with 
isooctane (Mouri et al., 2006). Whole-cell systems delivered the necessary cofactors, but 
presented other challenges such as limited substrate uptake and toxicity of the substrate and/or 
products (Urlacher and Eiben, 2006). 
Additional economical NADPH substitution systems have been developed. The “peroxide 
shunt pathway” was designed to exploit the natural ability of P450 to use peroxides, like 
H2O2, as an electron source. However, P450s (as most enzymes) are very sensitive to 
peroxides and are inactivated at higher concentrations (Joo et al., 1999; Cirino and Arnold, 
2002). In the recently reported light induced systems, the catalytic enzyme complex is directly 
reduced by light. A flavin-nucleotide, which is covalently bound to the enzyme, is photo-
activated. The activated riboflavin channels the electrons directly to the heme-domain, where 
the heme-iron complex is reduced (Schröder et al., 1999).  
Research in the development of electrically driven enzymes by immobilization on an 
electrode in order to replace NADPH by electrical sources has lately been increased to tackle 
the question of cofactor regeneration (Kazlauskaite et al., 1996). In addition to the direct 
coupling of enzymes to electrodes, systems integrating mediators became increasingly 
attractive. Both approaches have the advantage of using cost-effective and renewable energy 
sources, however, low Total Turnover Numbers (TTN) are reported for the system, thus 
limiting its industrial application (Wong and Schwaneberg, 2003).  
 
Mediated electron transfer (Schwaneberg et al., 2000; Nazor and Schwaneberg, 2006) and 
directed electron transfer (Nazor, 2007) have been proposed as alternative cofactor systems 
for NADPH. Common to both alternative cofactor systems, investigated in detail in this thesis 
and described below, is the replacement of NADPH by an artificial electron donor in solution. 
In the case of the mediated electron transfer approach, the artificial electron donor is zinc 
dust, and a mediator is needed to shuttle the electrons from the Zn-dust to the heme domain of 
the protein. The direct electron transfer approach is based on the direct interaction between a 
conductive polymer and the P450 monooxygenase.  
 
1.1.3.1 Mediated electron transfer system 
The mediated electron transfer was first reported by Estabrook et al. with Pt-electrodes 
(Estabrook et al., 1996) and applied for P450 BM3 by Schwaneberg et al. (Schwaneberg et 
al., 2000). In this system, Zn-dust is used as electron source and Cobalt (III)-sepulchrate (Co-
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sep) as mediator allowing the electron transfer from the Zn-dust to the protein. Fig. 3 shows 
the reaction scheme of the mediated electron transfer with the substrate para-
nitrophenoxycarboxylic acid (pNCA) and the Zinc/Co-sep-complex. The reaction takes place 
in solution, Zn2+ gets oxidized and the electrons are transfered via Co(II)-sep to the protein. 
Chloride ions (Cl-) are essential for the system, establishing a water-soluble complex with 
Zinc (ZnCl42-). The zinc ions are removed from the equilibrium and sufficient Zinc-dust can 
be dissolved (Schwaneberg et al., 2000). The Zinc-dust reduces the Co(III)-sep to Co(II)-sep. 
This promotes one electron to the P450 BM3 protein and can be used to reduce the substrate, 
in this case 12-pNCA to p-Nitrophenolate. 
 
In comparison to other electrochemical methods, the relative activity of P450 BM3 with this 
mediator is 77 % higher and up to 1000 times less expensive than NADPH. The turnover rate 
of the Zinc/Co(III)-sep system reaches 20 % of the NADPH activity (Nazor and 
Schwaneberg, 2006). Unfavorable are the possible side reactions, which occur due to the high 
electric potential (-0.75V) too. In this cases, reactive oxygen species (ROS) are generated, 
which limit the NADPH-regeneration and damage the enzyme.  
 
 
 
 
 
 
 
 
 
 
Fig. 3: Reaction scheme of mediated electron transfer with the substrate pNCA, the mediator Co(III)-sep and 
Zinc-dust as alternative electron donor (Schwaneberg et al., 2000). 
 
Screening systems in 96 well format, based on this alternative electron sources, were 
established (Nazor and Schwaneberg, 2006) allowing the directed evolution of the catalyst 
resulting in a variant showing a three-fold increase in catalytic efficiency (P450 BM3 M3: 58 
µm-1 min-1) (Nazor et al., 2008). Furthermore, recent studies report the first steps towards a 
Zn/Co-sep driven P450 BM3 reactor in which, after immobilization of P450 BM3 together 
with Zinc dust as electron source on DEAE-650S (diethylaminoethanol) sepharose and 
entrapped with K-carrageenan, the activity remained (Zhao et al., 2011).  
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1.1.3.2 Direct electron transfer using conductive polymers  
Direct electron transfer was first reported for determining initial activities of BM3 with the 
conducting polymer Baytron in buffer and absence of electrodes (Nazor, 2007). The 
conductive polymer acts as electron donating source and electrons are transferred directly 
from the charged conductive polymer into BM3. The electron transfer between conducting 
polymer and BM3 is not understood on the molecular level despite that a few amino acids 
were identified, which modulate BM3 activities in presence of conducting polymers (Nazor, 
2007).   
The reported conductive polymers are commercial available formulations, named Clevios or 
Baytron (H.C. Starck [www.baytron.com]) and contain as monomer often 3,4-
ethylenedioxythiophene (EDT or EDOT). The conductive polymer Poly(3,4-
ethylenedioxythiophene (PEDOT)-Poly(styrene sulfonic acid (PSS)) was discovered and 
produced by H. Shirakawa, A.G. MacDiarmid und A.J. Heeger (Groenendaal, 2000). The 
selected polymer is attractive for potential application as alternative cofactor system of BM3. 
PEDOT-PSS consists of PEDOT-segments (1-2.5 kDa), which bind to PSS-chains (Luo et al., 
2008)). PSS functions as counter-ion to balance charge, potential and solubility of PEDOT-
PSS and to prevent oxidation of the PEDOT component. Furthermore, it enables an equal 
repartition of the otherwise water-insoluble PEDOT. This structure builds among each other 
loose cross linkage. Conductivity level of doped PEDOT-PSS ranges between semiconductors 
and metals (around 10 S/cm), with up to 10²-10³ S/cm and an absorbance maxima around at 
610 nm [www.baytron.com]. The ratio of PSS to PEDOT and the PSS-chain length can be 
used to adjust conductivity of PEDOT-PSS, which decreases with reduced PSS chain length 
or increased PSS-PEDOT ratio (Groenendaal, 2000). Clevios P allows coating of glass or 
plastics surfaces with a conductive and durable PEDOT film employing micrometer sized gel 
particles (de Saint-Aubin et al., 2012). The polymer exhibits high conductivity, high 
transparency, high stability and an easy processing. Conductivity of Clevios coatings can be 
increased by supplementing polar compounds (ex. DMSO, glycerin, ethylen glycol) with high 
boiling points. Clevios is used for electrodes and for electrolytic capacitors (Zhi-Hui et al., 
2010), LED lamps and coatings on surfaces of lamps or photographic films (Groenendaal, 
2000). 
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Figure 4 shows the chemical composition of PEDOT-PSS and for BM3 biocatalysis, Clevios 
P was employed in solution (solid particle content 1.3 %). The ratio between PEDOT and PSS 
in Clevios P is 1:2.5 and the Clevios P suspension is dark blue [www.baytron.com]. 
 
 
 
 
 
 
 
 
 
Fig. 4a: Chemical composition of the conductive polymer Clevios P [taken from www.baytron.com]. Clevios P 
was investigated as alternative electron source to the natural cofactor (NADPH), which transfers hydrides in 
P450 BM3 catalyzed reactions. 
 
Conductive polymers would open novel opportunities for fine chemical production if activity 
and stability changes of electroenzymes could be overcome by tailoring enzyme properties 
through protein reengineering to application demands (Holtmann et al., 2009; Wong et al., 
2003).  
 
Protein engineering by directed evolution to improve electron transfer rates is the favored 
protein engineering strategy since it is rationally not understood how P450 BM3 has to be 
mutated to be driven more efficiently via conductive polymers. P450 BM3 variant (Y51F 
T577G) catalyzes the conversion of the substrate 3-phenoxytoluene to hydroxylated 3-
phenoxytoluene with 568 min-1 in presence of Baytron P and in absence of NADPH (Nazor, 
2007). A key for high conversions are matching redox potential of conductive polymer and 
monooxygenase and in a reduced state the conducting polymer can function as battery and 
can deliver a sufficient amount of electrons to the monooxygenase to determine initial 
activities. An important prerequisite for application is that the selected conductive polymers 
can be recharged by an electric potential to continuously provide electrons for the enzymatic 
reaction.  
The PEDOT/PSS polymer is generated through oxidative polymerization with Fe-salts and 
synthesized in its oxidized state, which would not be suitable to drive P450 BM3. The 
reductase of P450 BM3 has a formal redox potential of -388 mV. An efficient electron donor 
for P450 BM3 requires a redox potential, which is more negative than the P450 BM3’s redox 
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potential (< -400 mV). The formal redox potential of a PEDOT/PSS (Baytron P) solution is 
reported to be around -400 mV and because of existing reaction over potentials it is not 
suitable to function as electron donating “battery”. 
In case that PEDOT/PSS is generated by electrochemical polymerization under reducing 
conditions an insoluble and dark blue film is precipitating on the electrode. PEDOT/PSS can 
act as redox polymer and function as electron shuttle to an enzyme, when “actively” reduced 
on the electrode surface by an applied potential below the redox potential of the PEDOT/PSS 
(e.g. -750 mV).  
Promising conversions on electrode surfaces with in PEDOT/PSS films immobilized P450 
BM3 are reported (Holtmann et al., 2009; Güven, 2011), as well as electrochemical driven 
conversions of model substrates in presence of CoSep as mediator (Ley et al., 2012).  
Figure 4b shows the reaction scheme of mediated electron transfer setup from the electrode to 
CoSep and finally to P450 BM3, which drives the 12-pNCA conversion. The P450 BM3 
model reaction generates a yellow p-nitrophenolate product. The performed reaction with 
PEDOT/PSS is similar to the direct electron transfer system (Fig. 4a.) in which PEDOT/PSS 
would be used instead of CoSep to directly transfer electrons from the electrode over  
PEDOT/PSS to P450 BM3, which is immobilized in PEDOT/PSS. 
 
 
 
Fig. 4b: Reaction scheme of the electrochemical driven conversion of pNCA by P450 BM3 with CoSep as 
mediator.  
 
Reports on direct electron transfers via conducting polymers encouraged us to perform direct 
P450 BM3 evolution experiments to increase direct electron transfer of P450 BM3 using 
PEDOT/PSS mixtures as conductive polymers. 
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1.2 Directed evolution and generation of high quality mutant libraries 
Evolution was described by Charles Darwin in the 17th century. In nature, the evolution of 
organism occurs naturally in order to adapt populations to changing environmental conditions. 
Evolution is based on the principle, that randomly occurring DNA mutations generate 
organisms, which are “fitter”, more suitable and therefore survive to a selection pressure and 
provide the genetic constitution for the next generations. The procedure takes up to thousands 
of years (Campbell and Reece, 2009). Based in the same concept, the accelerated evolution of 
enzymes in vitro was described as directed protein evolution. Independent from the structural 
information, directed evolution can steer proteins properties artificially as it would occur 
naturally, except in very short time scales (~1 month to 1 year). Directed evolution comprises 
three main steps performed in iterative cycles to efficiently engineer proteins (Fig. 5). In Step 
I, the diversity is generated on the DNA level which is screened in the next step (Step II) for 
improved variants on the protein level. Finally, in the last step (Step III) the gene, encoding 
for the improved variants, is isolated and used for the next round of evolution (starting Step 1 
in the cycle) (Arnold and Volkov, 1999; Tee and Schwaneberg, 2007; Güven et al., 2010).  
 
 
 
Fig. 5: Directed evolution scheme. Step I: Diversity generation on DNA level. Step II: Screening for improved 
variants on protein level.  Step III: The gene, encoding for the improved variants, is isolated and used for the 
next round of evolution, starting with Step I (Güven et al., 2010).  
 
Key challenges in directed evolution are the generation of diverse mutant libraries and 
development of high-throughput screening systems to identify improved variants (Lutz and 
Patrick, 2004; Wong et al., 2006b). Numerous success stories were reported, demonstrating 
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that directed evolution is a powerful method for improving enzymes properties such as 
specificity, activity, enantioselectivity, pH and thermal resistance (Yuan et al., 2005; Kaur 
and Sharma, 2006; Tee and Schwaneberg, 2007). 
Advances in high throughput screening technologies are impressive as reports on flow 
cytometry (Bershtein and Tawfik, 2008; Yang and Withers, 2009; Prodanovic et al., 2011; Tu 
et al., 2011) or microfluidic screening devices (Agresti et al., 2010) prove. Despite achievable 
throughputs of (~108/day), it is impossible to sample through the combinatorial protein 
sequence space, since already 1.024*1013 different variants can be generated with a peptide of 
10 amino acids (Wong et al., 2007b; Shivange et al., 2009). Therefore, the quality of mutant 
libraries should be increased by generating functionally enriched mutant libraries to reduce 
screening efforts for identifying improved variants. For instance, a mutational bias elevating 
the number of charged residues can increase solubility of water insoluble proteins (Shivange 
et al., 2009). Computational algorithms, such as the Mutagenesis Assistant Program (MAP) 
(Wong et al., 2006a, 2007c), GLUE-IT and PEDEL-AA  (Firth and Patrick, 2008), are helpful 
tools to analyze the amino acid substitution patterns of random mutagenesis methods (MAP) 
and to develop promising strategies for high quality mutant library generation. The later can 
further be correlated to experimental setups by taking the coverage of explored protein 
sequence space into account (GLUE-IT/PEDEL-AA) (Volles and Lansbury, 2005; Firth and 
Patrick, 2008). Methods to generate focused mutant libraries target specific residues and are 
mainly employed to improve “localized” properties such as activity, specificity or selectivity. 
Focused mutant library generation requires often detailed structural information (Shivange et 
al., 2009). Properties which are rationally not understood or for which insufficient structural 
information is available are subjected to random mutagenesis. The subsequent analysis of 
obtained substitutions enables broadening our rational understanding and to find novel protein 
reengineering principles.  
Options to generate genetic diversity comprise enzymatic (Yuan et al., 2005), chemical 
(Singer and Kuśmierek, 1982) and whole cell methods (Neylon, 2004; Matsumura and Rowe, 
2005; Rasila et al., 2009) . The methods were summarized and classified by Wong at al.   
(Fig. 6) (Wong et al., 2006b). 
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Fig. 6: Classification of current random mutagenesis methods in the three main classes. I: Enzyme based 
methods. II. Synthetic chemistry based methods and III: Whole cell methods (Wong et al., 2006b). 
 
Chemical mutagenesis methods target one random nucleotide as point or as frameshift, 
deletion or insertion mutation. Chemical modification was used in vivo mutagenesis, a variety 
of reagents have been applied, including ethyl methane sulfonate (EMS), 
methylnitronitrosoguanidine (MNNG) and ethylnitrosourea (EMU). Only a few like EMS or 
hydroxylamine hydrochloride were reported as successfully used for in vitro mutagenesis. 
Depending on the application field and the properties of mutagenic substance, the effects were 
diverse, but the important role of tautomerism and rotation about the glycosyl bond of base 
has been reported (Singer and Kuśmierek, 1982). 
Error-prone polymerase chain reaction (epPCR) derived protocols are the most commonly 
used enzymatic methods for random mutagenesis (Cadwell and Joyce, 1992; Neylon, 2004). 
The performance criteria to improve the quality of a random mutant library (Vanhercke et al., 
2005) include an increase in the ratio of transversions to transitions mutations. The pattern 
and frequency of obtainable mutations by epPCR can be adjusted by varying the reaction 
conditions (e.g. unbalanced dNTPs, employed error-prone polymerases (Cline et al., 1996; 
Biles and Connolly, 2004), varied MnCl2 concentration (Cirino et al., 2003) or alternatively 
by supplementing nucleotide analogs (Spee et al., 1993; Zaccolo et al., 1996). The 
triphosphate derivatives of analog 8-hydroxy-dGTP (Zaccolo et al., 1996), dITP (Spee et al., 
1993), and dPTP (Zaccolo et al., 1996) are efficiently incorporated in PCRs, enabling high 
frequencies of nucleotide exchanges with predefined ratios between transitions and 
transversions at single positions in a codon. Other sequences dependent enzymatic random 
methods are transposon based (Kim et al., 2009), Staggered Extension Process (StEP) (Zhao 
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et al., 1998), Megaprimer PCR of Whole Plasmid (MEGAWHOP) (Miyazaki, 2003) or DNA-
shuffling (Stemmer, 1994; Abécassis et al., 2000). But methods to generate random mutant 
libraries in directed evolution are limited in diversity generation (Arnold and Volkov, 1999; 
Wong et al., 2007a; Rasila et al., 2009). In the case of epPCR this is due to a polymerase bias 
leading to 63 % transitions with A to G and T to C, going with a low transversion probability, 
in this method the mutation of only one nucleotide per codon can be reached. Subsequently, 
only 150 of 380 possible amino acid exchanges are accessible. A method that would allow the 
exchange of each of the 20 amino acids replaced by its respective 19 counterparts would 
deliver 380 possibilities (Wong et al., 2006a; Shivange et al., 2009).  
DNA polymerases display strong mutational preferences favoring the substitution of certain 
nucleotides over others. The result is a biased and reduced functional diversity in the 
generated mutant library. Along the different DNA polymerases classes and families, the 
conformation of the template binding domain, the catalytic center and the processivity is 
different. Polymerases having the ability to read over several mismatches have been reported, 
and used in the amplification of ancient DNA, which is highly degraded (d’Abbadie et al., 
2007). DNA polymerases have been genetically engineered to have a decreased 3’-5’ 
proofreading exonuclease activity, making them suitable for difficult templates such as those 
including non-standard nucleotides (Biles and Connolly, 2004). DNA polymerases resulting 
from the fusion of Pyrococcus-like enzyme with a processivity enhancing domain resulted in 
a variant (example Phusion polymerase from NEB) showing a high fidelity and processivity 
with a 50 fold lower error rate compared to the Thermus aquaticus DNA polymerase (Taq-
polymerase) (Cline et al., 1996). These polymerases are suitable for difficult and long 
templates like it occurs when GC rich regions are present. To point out one well established 
engineered DNA polymerase, Mutazyme is used in an epPCR-based method and often 
included in comparison of amino acid substitution pattern analysis (Cline et al., 1996). The 
method produces all possible transition and transversion mutations with minimal bias and its 
mutational spectrum is distinct from that of Taq DNA polymerase. 
Many methods are reported to improve the performance criteria of random mutant libraries, 
tunable mutation frequency, increased diversity and less biased libraries with an enriched 
transversion mutation spectrum were achieved (Vanhercke et al., 2005; Rasila et al., 2009). 
Still, a more or less strong bias towards transitions remains due to inherent DNA polymerase 
limitations. Therefore, the advancement of the diversity generation methods remains as a 
valuable research field. 
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1.3 Sequence Saturation Mutagenesis method (SeSaM) 
The Sequence Saturation Mutagenesis (SeSaM) method was reported as a four step random 
mutagenesis method designed to overcome the limitations of epPCR based random 
mutagenesis methods (Wong et al., 2004b). SeSaM targets in contrast to epPCR each 
nucleotide “equally” avoiding mutagenic hot spots, achieving subsequent mutations in a 
codon (up to 37 %) (Mundhada et al., 2011), and allowing to adjust mutational biases through 
employed universal bases (Wong et al., 2004b, 2005a; Mundhada et al., 2011). 
 
The method comprises four steps: In Step 1, a DNA fragment pool with random length is 
generated by the incorporation of nucleotides with phospohorotiolated cleavable bonds. In 
Step 2, the enzymatic elongation of the single stranded DNA fragments with the universal 
base occurs. In Step 3, the DNA fragments were elongated to full length gene and in Step 4, 
the universal base is replaced by unmodified nucleotides. The four steps are described below 
and summarized in Fig. 7-10 on the example of the universal P-base (Wong et al., 2004b).  
 
Step 1: Generation of ssDNA fragment pool with random length distribution. 
In the first step, a PCR amplification of the gene of interest is performed using a biotinylated 
primer and phosphorothiolated nucleotides to randomly incorporate cleavable bonds (Fig. 7, 
(Ruff et al., 2012a)). The phosphorothiolated bond can be cleaved by iodine treatment in 
alkaline solution generating a DNA fragment pool with random length. Based on the used 
biotinylated primer, the library is named foward or reverse library with the according base, 
which was targeted (for example: Fwd-A library). The cleaved single stranded fragments are 
separated and purified from the reaction mixture by the use of magnetic particles with a 
streptavidin-coated surface in a DNA melting solution reacting with the biotinylated primer. 
 
 
 
 
 
 
 
 
 
Fig. 7: SeSaM Step 1: Generation of ssDNA fragment pool with random length distribution. 
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Fig. 8: SeSaM Step 2: Enzymatic elongation of single stranded 
DNA with universal base.
Fig. 10: SeSaM Step 4: Replacement of universal bases. 
Step 2: Enzymatic elongation of single stranded DNA with universal base 
The single stranded DNA fragments 
generated in Step 1 are elongated 
with universal bases in a TdT 
(Terminal Transferase) catalyzed 
reaction (Fig. 8, (Ruff et al., 
2012a)). The reported and employed 
universal bases are mentioned in the 
next paragraph.  
 
Step 3: Synthesis of the full length gene 
The single stranded DNA fragments 
(from Step 2) are elongated to full 
length gene, using a template 
generated in a preliminary step  
(Fig. 9, (Ruff et al., 2012a)).   
 
 
 
 
Step 4: Replacement of universal bases 
The universal base is replaced by unmodified nucleotides by PCR amplification (Fig. 10, 
(Ruff et al., 2012a)). Based on the 
promiscuous base-pairing property of the 
employed universal bases, mutations are 
created. This number of cycles in the last 
step determines the number of 
transversion or transition per gene.  
 
The SeSaM method is at the current development stage designed to generate amino acid 
substitution patterns that are complementary to those of epPCR. Three degenerate bases P (6-
(2-deoxy-ß-D-ribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-C][1,2]oxazin-7-one), K (N6-
methoxy-2,6-diaminopurine), I (2’-deoxyinosine) (Wong et al., 2005a) were reported to 
control mutational ratios of transitions to transversions in SeSaM libraries. The P base was 
Fig. 9: SeSaM Step 3: Synthesis of the full length gene. 
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employed at A and G positions and yielded a ratio of six to four for T and C mutations and is 
well suited to introduce transversions at A and G positions. The bases K and I failed to 
complement the P base to maximize diversity at T and C positions (I yielded exclusive G 
mutations // K yielded an A to G ratio of 9 to 1) (Wong et al., 2008). 
 
The SeSaM method relies on the promiscusous base pairing ability and coding bias of the 
employed universal bases, which are purine or pyrimidine analogues to achieve mutations 
with tunable mutational bias. Fig. 11 shows for the A-base as example the principle, why the 
P-base is only used at A and G positions to introduce a transversion bias (part 1) and how the 
transition bias is obtained at T and C positions on the example of T-base (part 2).  
1) When the P base is introduced randomly at A or G position, the opposite base would be 
incorporated according to the base pairing properties of the P-base, pairing with G or A, and 
not with T as it occurs naturally opposite an A base. Opposite of the P base As and Gs are 
therefore introduced in the PCR amplification of the opposite strand. When in the last step the 
artificial base gets replaced by a natural base, the P is replaced by C and T bases (which pair 
with G and A). This principle allows obtaining transversion from A to C or T in the mutated 
gene. Step 2 is not displayed, as this step is the attachment of the artificial base to the single 
stranded fragments and doesn’t have an impact on the occurring mutagenesis.  
2) When P would be introduced at the T positions, only transversions from T to T or C would 
occur (see Fig. 11, part (2) below).  
 
 
 
(1)  
 
 
 
 
 
 
 
 
 
 
(2) 
 
 
 
 
 
 
 
 
Fig. 11: Mutational bias obtained when the P-base is used at A position (1) or T position (2). 
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The nucleoside ribavirin (1-ß-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; in short R-base) 
is a well-known antiviral drug for hepatitis C (Crotty et al., 2000). R-base functions 
chemically as a purine analog pairing with T and C in a ratio of 1:1 (Crotty et al., 2000; Maag 
et al., 2001; Vo et al., 2003).  The small size of the R-base and 1:1 ratio of T and C makes the 
respective nucleotide dRTP attractive for application in SeSaM and for complementing the P 
base. Combining P- and R-base would in SeSaM experiments generate at all four nucleotides 
transversions in a given sequence with an unmatched chemical diversity.  
Previous studies demonstrate that HCV RNA polymerase can incorporate ribavirin 
triphosphate as a nucleotide analog of either ATP or GTP and ribavirin itself can serve as a 
template base for incorporation of cytidine and uridine with equal efficiency (Vo et al., 2003). 
Once ribavirin is in the RNA, it is presumably trapped in the „anti“ conformation and readily 
forms base pairs with incoming pyrimidines. This indicates, that incorporation of ribavirin 
into RNA should be mutagenic to viral RNA, promoting transitions of A to G and G to A 
(Crotty et al., 2000). The pseudo base (1,2,4-triazole-3-carboxamide) of ribavirin (R) pairs 
equally with cytosine and uracil and was proved not to be a chain terminator. Across from R, 
CTP and UTP could be incorporated, with CTP being more efficient than UTP. Neither GTP 
nor RTP could be incorporated. ATP was incorporated across from R even in the absence of 
template (Maag et al., 2001).  
 
In the SeSaM method the R-base would be incorporated exclusively at T and C position to 
insure a transversion bias. If R would have been introduced at all 4 nucleotides, a transition 
and transversion bias would have been generated at A and G positions. For a transversion bias 
at A and G positions, the P-base was introduced in previous SeSaM developments. The figure 
below (Fig. 12) shows for the T-base as example the principle, why the R-base is only 
introduced at C and T positions to introduce a transversion bias (part 1) and on the example of 
the A-base how a transition bias is obtained at A and G positions (part 2).  
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Fig. 12: Mutational bias obtained when the R-base is used at T position (1) or A position (2). 
   
1.4 High throughput screening systems  
Enzymes provide a broad variation of catalytic activities enabling reactions that are highly 
desirable for organic chemists such as regio- and stereoselective hydroxylation of non-
activated carbon atoms, which are for instance catalyzed by cytochrome P450 
monooxygenases (Hollmann et al., 2011). Tailoring catalyst properties by directed evolution 
to specific application demands in terms of stability, enantioselectivity or stereoselectivity, 
became a standard approach in biocatalysis, medical science as well as in synthetic biology 
(Kaur and Sharma, 2006; Wong et al., 2006b; Shivange et al., 2009). Rational and evolutive 
protein engineering strategies employ focused mutant (OmniChange (Dennig et al., 2011), 
CASTing (Reetz et al., 2006)) or random mutant libraries (Bornscheuer and Pohl, 2001; 
Shivange et al., 2009). The theoretically generated diversity exceeds the possible throughput 
of high throughput screening platforms in respect to the number of variants that can be 
screened (Shivange et al., 2009). For instance, in focused mutant libraries with five 
simultaneously NNK-randomized codons 108 clones have to be sampled for 99 % coverage 
(PEDEL AA & GLUE-IT (Volles and Lansbury, 2005; Firth and Patrick, 2008), OmniChange 
(Dennig et al., 2011)). Compared to the few thousand clones screened usually in microtiter 
plates (Wong et al., 2007a) not only the throughput is significantly increased, but also the 
costs and time requirements are reduced dramatically (Agresti et al., 2010). The availability of 
reliable and efficient pre-screening systems (>104 clones per day) is the main limitation to 
identify beneficial variants in diverse mutant libraries (Tee and Schwaneberg, 2006). 
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In the past decade innovative ultra-high throughput screening platforms based on flow 
cytometry (Griffiths and Tawfik, 2006; Bershtein and Tawfik, 2008; Yang and Withers, 2009) 
or microfluidic devices (Agresti et al., 2010) have been developed. Flow cytometer-based 
screening systems enable to sample more than 108 clones per day with excellent accuracy 
(Griffiths and Tawfik, 2006). The throughput is commonly 4 orders of magnitude higher than 
commonly employed microtiter plate based screening platforms and accuracy is usually 
higher than agar plate based pre-screening systems (Bernath et al., 2004a; Turner, 2006; Link 
et al., 2007). Fluorescent screening systems have in general a high sensitivity which ensures 
that active and inactive clones can reliably be separated even in very small reaction volumes 
(femto liter droplets) (Bernath et al., 2004b). A key requirement in every directed evolution 
campaign is to keep the link between phenotype and genotype, which is usually ensured by 
compartmentalization of mutant libraries, for instance in emulsions or whole cells (Olsen et 
al., 2000; Bernath et al., 2004b; Griffiths and Tawfik, 2006). In case of whole cell screening 
systems a main challenge lies in entrapping the product within the cell and thereby avoiding 
cross contamination (Bernath et al., 2004a). In case of emulsion systems a main limitation 
often lies in the requirement to generate double emulsions (water/oil/water), so that sorting in 
aqueous solution with a flow cytometer is possible. In double emulsions often more than one 
single emulsion droplet is entrapped reducing the fraction of active variants, that are sorted 
out. Nevertheless, flow cytometry based screening systems have successfully been used to 
enrich the active population in mutant libraries (Bernath et al., 2004a; Griffiths and Tawfik, 
2006; Stapleton and Swartz, 2010) and to identify in successive rounds of sorting and/or 
diversity generation improved variants, for instance improving specificity (Santoro et al., 
2002), inhibitor resistance (Tu et al., 2011) and activity (Aharoni et al., 2005a) of enzymes. 
For P450 monooxygenases (CYPs) (>5000 cloned members (Bernhardt, 2006)) colorimetric 
and fluorescence-based high throughput screening platforms based on microtiter plates (MTP) 
are available with a reported throughput of 103-105 clones per day (Wong et al., 2005b; Tee 
and Schwaneberg, 2007). Fluorescence based screening systems in MTP format were reported 
for monooxygenase with excellent sensitivities (900 fold increased activity; detection limit in 
nM-range) (Lussenburg et al., 2005). Among the fluorescence based screening systems for 
P450 monooxygenases, coumarin-derivates are used preferentially (Cheng et al., 2009; Park 
et al., 2010; Reinen et al., 2011). Coumarin-derivates have  furthermore been employed 
successfully in directed evolution campaigns of cellulases, lipases and phosphatases (Wu et 
al., 2010).  
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1.5   Objectives 
 
In this thesis entitled “Advances in directed monooxygenase evolution: From diversity 
generation and flow cytometry screening to tailor-made monooxygenases”, the main focus 
was the development of novel methods for increasing diversity (SeSaM-R base, Chapter I) 
and throughput screening (flow cytometry based screening system, Chapter II), which were 
validated for P450 BM3. Along with the main focus on methodological advancements in the 
two key steps of the directed evolution, the directed protein evolution of P450 BM3 for 
improved activity towards alternative cofactor systems was performed.  
 
Directed evolution comprises three main steps and is performed in iterative cycles to 
efficiently reengineer proteins. In Step I, the diversity is generated on the DNA level, which is 
screened in the next step (Step II) for improved variants on the protein level and finally, in the 
last step (Step III), the gene encoding for the improved variants is isolated and used for the 
next round of evolution. Not only the evolution of P450 BM3 for alternative cofactor systems 
was performed, but each step of the directed evolution method was advanced and is 
considered in one chapter. Step 1, consisting of generation of high quality mutant library, was 
advanced by developing an advanced SeSaM protocol, in which a universal base, 
complementary to the P-base, was employed to generate more diverse libraries. Step 2 was 
advanced by generating a whole cell high throughput screening assay for monooxygenases 
allowing efficiently sampling of the diversity generated in Step1. Subsequently, the advanced 
protocols suitable for the directed evolution methods were applied to evolve P450 BM3 for 
alternative cofactor systems in iterative rounds (Step 3).  
The thesis was sub-divided in three main chapters tackling each step of directed protein 
evolution.  
 
In Chapter I of the thesis, the application of the R-base as universal base complementary to P 
to further increase fraction of the theoretical amino acid sequence space, that can be covered 
by the SeSaM method, is reported. An advanced SeSaM method, in which a protocol for 
implementing the R base in a SeSaM experiment was developed and optimized. Optimized 
steps comprise Step 2 (incorporation of dRTP), Step 3 (polymerase for R-base elongation), 
and Step 4 (polymerase for amplification) of the SeSaM method. SeSaM libraries with R-base 
of the Enhanced Green Fluorescent Protein (EGFP) were generated and the transversion 
preference and the AS substitution pattern was determined. The R-base protocol was 
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subsequently combined with the P-base for generating for the first time transversions at all 
four nucleotides in a combined protocol.  
In Chapter II of the thesis, a flow cytometer based whole cell high throughput screening 
system for P450 BM3 was developed using as substrate a coumarin derivative (7-Benzoxy-3-
Carboxy-Coumarin Ethyl ester (BCCE)). In the first step the P450 BM3 variant F87A was 
employed in investigating the signal to noise ratio in crude cell extracts and in a whole cell 
flow cytometry setup. In the second step the mutant P450 BM3 M3 (R47F F87A M354S 
D363H), previously evolved for improved electron transfer via mediators38,39, was randomly 
mutated (epPCR) and populations were sorted to identify more active variants. The flow 
cytometry based BCCE screening system was used as pre-screen to recover the population 
containing the most active variants in order to enrich the population of active P450 BM3 
variants. The sorted variants were subsequently screened in 96 well microtiter plates to 
identify P450 BM3 variants improved in BCCE conversion and to validate the developed 
BCCE-flow cytometer screening system.  
 
In Chapter III, the advanced methods developed in Chapter I and II were employed to 
generate P450 BM3 libraries to evolve the catalyst towards alternative cofactor systems. 
Random mutant libraries were generated using SeSaM and epPCR, enriched with the BCCE 
flow cytometer assay and screened with the BCCE as fluorescent substrate in MTP for 
improved mediated electron transfer. P450 BM3 was also evolved for a second alternative 
cofactor system, the direct electron transfer. Focused as well as random mutagenesis libraries 
of P450 BM3 were generated and screened for improved activity in the presence of a 
conductive polymer (Clevios P).  
 
Additionally, in the Appendix Chapter the collaborative P450 BM3 projects are summarized 
in which the PhD candidate was involved. These projects were part of the 7 framework 
funded by the European union project Oxygreen focused on the effective redesign of 
oxidative enzymes for green chemistry. Within Oxygreen the monooxygenase mutein 
database (muteinDB) was supported in which muteins altering substrate specificity are 
collected, the evolution of P450 BM3 for substrate specificity was contributed and P450 BM3 
muteins with surface modifications for electrochemical characterization were generated. 
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2.   Material and Methods 
 
Materials were used according to supplier’s recommendation. Molecular biological methods 
were performed according to the protocols reported in Molecular Cloning (Sambrook and 
Russell, 2001). Directed Evolution methods were applied with small changes according to the 
protocols reported in Directed Enzyme Evolution and Directed Evolution Library Creation 
(Arnold and Georgiou, 2003). 
 
2.1 Chemicals 
All chemicals were of analytical grade or higher quality and purchased from Sigma-Aldrich 
Chemie (Steinheim, Germany), AppliChem (Darmstadt, Germany) and Carl Roth (Karlsruhe, 
Germany). Chemicals purchased from other suppliers or restricted to this use are mentioned. 
  
ABIL EM 90 Evonik, Marl, Germany 
Aminolevunilic acid (ALA) Sigma Aldrich, Saint-Louis, USA 
BCCE Home made (section 2.14.2) 
BCC-acid  Home made (section 2.14.2 ) 
Catalase  Merck, Darmstadt, Germany 
Carboxymethylcellulose (CMC)  Sigma Aldrich, Saint-Louis, USA 
Cobalt(III)sepulchrate (Co(III)-sep)  Sigma Aldrich, Saint-Louis, USA 
Jod  Sigma Aldrich, Saint-Louis, USA 
Light Mineral Oil (LMO)  Sigma Aldrich, Saint-Louis, USA 
Sodium hydrosulfite Sigma Aldrich, Saint-Louis, USA 
Zinc-dust  Carl Roth, Karlsruhe, Germany 
 
2.2  Devices 
Centrifuges 5810R  Eppendorf, Hamburg, Germany 
CyFlow Space flow cytometer  Partec, Münster, Germany 
Fluoreszent microscope, Orthoplan   Leitz Wetzlar, Wetzlar, Germany 
Microplatereader Infinite M1000   Tecan Group, Männedorf, Switzerland 
Microplatereader Sunrise  Tecan Group, Männedorf, Switzerland 
Microtiter plate shaker Microtron  INFORS, Heinsbach, Germany 
NanoDrop ND-1000  Thermo Fischer Scientifics, Willmington, USA 
PCR-Cycler Mastercycler pro S  Eppendorf, Hamburg, Germany 
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Spectrophotometer Varian Cary 50 UV  Agilent, Waldbronn, Germany 
Shaker CERTOMAT S-II  Sartorius, Göttingen, Germany   
Shaker TIMIX 5   Edmund Bühler, Hechingen, Germany 
Lyophilizer ALPHA 1-2 LDplus  CHRIST, Osterode am Harz, Germany 
Sonotrode Sonoplus HD200 Bandelin, Berlin, Germany 
Sorvall RC-6 Superspeed Cenrtifuge  Thermo Fischer Scientific, Bonn, Germany  
Ultra Thurax – Disperser T10 basic  IKA-Werke, Staufen, Germany 
Resin Dispenser 48 Position Mettler-Toledo, Columbus OH, USA 
High Pressure Homogenizer Avestin, Ottawa ON, Canada 
Äktaprime plus GE Healthcare, Uppsala, Sweden 
GC-2010-plus Shimadzu, Duisburg, Germany 
GCMS-QP2010S  Shimadzu, Duisburg, Germany 
Rotavapor-IKA HB10 basic VWR, Darmstadt, Germany 
Camera DC50  Nikon, Düsseldorf, Germany 
Geldocumentation U:Genius  Syngene, Cambridge, UK 
 
2.3  Other materials 
Emulsion tubes (PS, 16 x 65 mm) Nerbe plus, Winsen/Luhe, Germany 
Analyzer cups – CyFlow (PS, 55 x12 mm) Sarstedt, Nümbrecht, Germany 
Microtiter plates, 96 deepwell 2.2 ml Eppendorf, Hamburg, Germany 
Microplates, 96 well, MICROLON 200 Greiner Bio-one, Frickenhausen, Germany 
Microplates, 96 well, black, Fluotrac 200 Greiner Bio-one, Frickenhausen, Germany 
 
2.4  Enzymes 
Restriction enzymes were purchased from Fermentas (St. Leon-Rot, Germany), polymerases 
and terminal deoxynucleotidyl transferase (TdT) from New England Biolabs (Frankfurt, 
Germany). PhuS-Polymerase (derived from the Pfu-Polymerase), 3D1-polymerase 
(d’Abbadie et al., 2007), and Taq-polymerase were home made in the Institute. 
 
2.5  Kits 
QIAprep Spin Miniprep kit Qiagen, Hilden, Germany 
QIAquick PCR Purification kit Qiagen, Hilden, Germany 
QIAquick Gel Extraction kit Qiagen, Hilden, Germany 
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Rapid DNA Dephos & Ligation kit Roche, Mannheim, Germany 
NucleoSpin Plasmid kit Macherey Nagel, Düren, Germany  
NucleoSpin Gel and PCR Clean-up kit Macherey Nagel, Düren, Germany 
NucleoSpin Extract II kit Macherey Nagel, Düren, Germany 
Experion RNA HighSens Analysis kit BioRad, München, Germany 
Experion Pro260 Analysis kit  BioRad, München, Germany 
BCA Protein Assay kit Thermo Fischer Scientific, Bonn, Germany 
 
 
2.6 Media 
LB Medium: Peptone 1%, Yeast Extract 0.5%, NaCl 1% in deionized H2O.  
TB Medium: Solutions A and B were autoclaved separately and mixed under sterile 
conditions to prepare 1L of TB media. Solution A: Peptone 12 g, Yeast Extract 24 g, and 
Glycerol 4 g were dissolved in 800 ml deionized H2O.  Solution B: KH2PO4 2.31 g, and 
K2HPO4 12.54 g were dissolved in 200 ml deionized H2O. 
SOB Medium: Peptone 2%, Yeast Extract 0.5%, NaCl 0.05% in deionized H2O + 1% (V/V) 
KCl (1 M, pH=7 with NaOH) + addition of 0.5 % (V/V) MgCl2 (2 M) after autoclaving. 
SOC Medium: SOB medium + 2% (V/V) Glucose (1M). 
 
2.7 Media additives 
Trace Elements Solution (SEL) (Stock 1000X): CaCl2. 2H2O 0.5 g, ZnSO4. 7H2O 0.18 g, 
MnSO4. H2O 0.10 g, Na2-EDTA 20.10 g, FeCl3. 6H2O 16.70 g, CuSO4. 5H2O 0.16 g, CoCl2. 
6H2O 0.18 g were dissolved in 1000 ml deionized H2O, filtered sterile through a 0.22 µm 
filter, and stored at 4⁰C.  
ALA (Aminolevulinic acid) Stock-solution (1000X): 0.5 M ALA in deionized H2O, filtered 
sterile through a 0.22 µm filter, and stored at -20°C. 
IPTG (Isopropyl-β-D thiogalactopyranoside) Stock-solution (1000X): 0.1 M in deionized 
H2O, filtered sterile through a 0.22 µm filter, and stored at -20°C. 
Kanamycin Stock-solution (1000X): 50 mg/mL in deionized H2O, filtered sterile through a 
0.22 µm filter, and stored at -20°C. 
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Thiamine Stock-solution (1000X): 100 g/L in deionized H2O, filtered sterile through a 0.22 
µm filter, and stored at -20°C. 
 
2.8 Nucleotides 
Nucleotide analogs (dRTP, 3’-I-dATP, 3’-ac-2’dRTP, MANT-dATP, 3’-O-NH2-2’-dATP) 
and phosphorothioated nucleotides (dATPαS, dCTPαS, dTTPαS, dGTPαS) were generously 
provided by BIOLOG Life Sciences Institute (Bremen, Germany). The dNTP mix was 
purchased from Fermentas (St. Leon-Rot, Germany). 
 
2.9 Primers 
Unmodified and biotinylated oligonucleotides were purchased from Eurofins MWG Operon 
(Ebersberg, Germany) in salt-free form and diluted in milli-Q water to a final concentration of 
100 µM. Oligonucleotides containing dRTP were synthesized by Biomers (Ulm, Germany). 
Synthetic constructs (S1-S6) differing in 3 nucleotides were purchased from Eurofins MWG 
Operon (Ebersberg, Germany), and used for generating short template-DNAs. All primers and 
synthetic constructs used are summarized in Table S1 (see Appendix 6.1). PCRs were 
performed in 0.2 ml thin-walled PCR tubes from Sarstedt (Nümbrecht, Germany) employing 
a Mastercycler Gradient PCR-machine from Eppendorf (Hamburg, Germany). DNA was 
quantified by a NanoDrop photometer from NanoDrop Technologies (Wilmington, USA DE).  
 
2.10 Vectors and strains  
The commercial available vector pET28a(+) from Merck (Darmstadt, Germany) as well as the 
vector pCWori(+) (Barnes, 1996) and pALXtreme-1a (home made in the institute) were used 
as expression vector. pALXtreme-1a is a shortened pET28a(+) derivative which lacks the 
LacIQ1 gene. The vector maps are enclosed in the Appendix 6.3.  
The strain E. coli Bl21(DE3) Gold was used to express genes cloned in the pET vector 
system, and the strain E. coli Bl21(DE3) Gold LacIQ1 was used for pALXtreme-1a. The strain 
E. coli DH5α was used for expression of the pCWori(+) vector as well as for intermediated 
cloning steps.  
All strains and plasmids employed in this thesis and their characteristics are summarized in 
Table S2 (Appendix 6.1).  
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2.11   Microbiological methods 
 
2.11.1  E. coli cultivation and P450 BM3 expression 
P450 BM3 mutein expression in flasks and in deep-well microtiter plates was performed as 
described previously by Nazor (Nazor and Schwaneberg, 2006). For MTP expression, a 
master plate and overnight culture was prepared prior to expression. The master plate was 
prepared by picking single freshly transformed colonies into 96 well flat bottom microtiter 
plates (Greiner Bio-One, Frieckenhausen, Germany), containing 150 l LBKan (50 µg/ml). 
The plate was covered with a lid and was sealed with parafilm. The cells were cultivated at 
900 rpm, 37°C, 14 – 16 hrs and 70% humidity with Microtrone shaker (INFORS, Heinsbach, 
Germany). After addition of 100 l autoclaved 50% glycerol solution (v/v) to the overnight 
culture, the plate was stored at –80°C. For overnight culture, the master plate, after thawing at 
room temperature for 20 minutes, was replicated using a 96-pin replicator into a 96-well flat 
bottom microtiter plate containing 150 μl LB/Kan. The plate was sealed with a lid and 
parafilm. The overnight culture was incubated at 900 rpm, 37°C and 70% humidity overnight 
(14 – 16 hrs). Protein was expressed in sterile 2 ml 96 deepwell microtiter plates (Eppendorf, 
Hamburg, Germany). Each well of a deep well plate was filled with 600 µL of TB-medium 
containing Kan (50 µg/ml), 1 x trace elements solution, ALA (0.5 mM), IPTG (0.1mM), 
thiamine (0.3 µM). The overnight saturated culture was replicated in the prepared deep well 
plate by pipetting 6 µL of the overnight culture into each well of the deep well plate using a 
transfer pipette. The plates were covered with a lid cleaned with 70% EtOH and sealed with 
parafilm tightly. Protein was expressed at 700 RPM, 30°C and 70% humidity for 20 hours in 
Microtrone shaker (INFORS, Heinsbach, Germany). For flask expression, the preculture 5 
mL LBkan (50 µg/ml) was inoculated with a single colony from agar plate and incubated 
overnight at 37°C, 250 rpm. The expression culture in flasks, TB-medium supplemented with 
respective antibiotics (kanamycin (50 µg/ml)) and 1 x trace elements solution was inoculated 
with 2% of the overnight culture and incubated at 30°C, 250 RPM until OD600 reaches 0.8-
1.0. The culture was supplemented with Aminolevulinic acid (ALA) (0.5 mM) and thiamine 
(0.3 µM) and expression was induced by the addition of IPTG (0.1 mM).  Cells were 
expressed for 20 h at 30°C, 250 rpm on CERTOMAT S-II shaker (Sartorius, Göttingen, 
Germany) and harvested by centrifugation (4°C, 4000 rpm, 20 min, Eppendorf, Hamburg, 
Germany). 
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2.11.2  Fluorescence microscopy 
Fluorescence microscopy analysis was performed with the microscope ORTHOPLAN (Leitz, 
Wetzlar, Germany). The cell culture (~10 µl) was evenly spread on a microscope slide which 
was covered with a glass slide. A droplet of oil was applied and the sample was analyzed 
under UV-light at λex of 350 nm or 405 nm (objective: 100/1.30). The images were recorded 
with the camera DC50 (Nikon, Düsseldorf, Germany). 
 
2.11.3  Cryocultures 
Escherichia coli overnight culture (37°C, 250 rpm, 14h) was supplemented in a ration of 1:1 
with sterile glycerol (50% w/v in H2O) and stored at -80°C. Cryocultures in MTP consist of 
150 µl overnight culture (14h, 900 rpm, 37°C, 70% humidity) supplemented with 100 µl 
sterile  glycerol solution (50% w/v in H2O).  
 
2.12   Molecular biological methods 
 
2.12.1  Validation of dRTP as universal base for SeSaM method 
 
SeSaM Step 2: Acceptance and optimization of the dRTP incorporation by terminal 
deoxynucleotidyl transferase (TdT). 
The optimization of TdT catalyzed incorporation of deoxyribonucleotides dRTP to 3’-OH of a 
fluorescent labeled oligonucleotide (P15) was performed by varying the reaction conditions. 
The incubation times (15, 30, 60, 120 min), the amount of TdT (10-20 U), concentration of 
CoCl2 (0 mM-2.5 mM), concentration of ZnCl2 (10 µM, 100 µM), and the molar ratio of 
template-DNA to dRTP (1:5, 1:10, 1:20, 1:40) were varied. The R-tailed fluorescent labeled 
oligonucleotides were separated on a 36% TBE-acrylamid gel (150 V, 13 h) in 1 x TBE buffer 
(89 mM tris, pH 8, 89 mM boric acid, 2 mM EDTA) running in Mini-Protean Tetra Cell 
system from Bio-Rad (München, Germany). The gel was visualized on a FLA-3000 
phosphorimager (excitation 494 nm; emission 518 nm) from Fujifilm (Düsseldorf, Germany) 
and DNA fragments were quantified using the AIDA 4.0 gel analysis software. In  Step 2 up 
to 3 R-bases were incorporated (molar ratio of 1:5 (template-DNA to dRTP), TdT (10 U), 
CoCl2 (0.25 mM); 37°C; 15 min) followed by heat inactivation (30 min; 75 °C).  
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SeSaM Step 3 and Step 4: selection of suitable polymerases though the “read” and “write” 
activity assays 
The R-“read” activity assay was performed similarly as reported for the P-base (Wong et al., 
2008) with the following differences: Primers were designed to yield PCR-products that can 
be distinguished through size from each template-DNA and further PCR products.  
Differences occurred since in contrast to the P-base (Wong et al., 2008) write and read 
activities assays two different templates-DNA had to be generated (Template-600 and 
Template-600-2). The Template-600 (Fig. 13; 1) was used in the read activity assay (Fig. 13; 
2) and analyzed by gel electrophoresis. The latter analysis could be performed without a 
cloning step. For the write activity assay (Fig. 13; 4) a single stranded template-DNA had to 
be generated (Fig. 13; 3) and subsequently be used as template-DNA (Fig. 13; 4). Prerequisite 
to perform the write activity assay is the removal of the Template-600-2 (see Fig. 13; 3). For 
removal via DpnI digest the Template-600-2 has to be methylated. To obtain methylated 
DNA, the plasmid pALXtreme-1a was amplified in vivo. pALXtreme1a was isolated from a 5 
ml cell culture (LBkan, 14h, 37°C, 250 rpm) using the Nucleospin Extract II kit (Macherey 
Nagel, Düren, Germany). The methylated Template-DNA generation was achieved by 
isolation from the plasmid pALXtreme-1a of the double stranded Template-600-2 through 
restriction enzyme digest with XmnI/HaeII (Fig. 13; 1). The complementary strand to 
Template-600-2 is not shown in Fig. 13 and did not cause detectable interference with the 
write activity assay. The detailed experimental procedures for step one to five are described in 
the following paragraphs (represented graphically in Fig. 13; 1-5). 
 
Preliminary template-DNA generation 
Preliminary plasmids were constructed by PCR amplification of six synthetic primers (P16, 
Table S1, Appendix 6.1) of equal sequence and differing by 3 nucleotides CCC, TTT, AGA, 
GAG, AAA, GGG (shown with “XXX” in Fig. 13; 1). The PCR products were column 
purified by Nucleospin Extract II kit (Macherey Nagel) and hybridized in pALXtreme-1a 
vector by PLICing (Blanusa et al., 2010b). PCRs (50µl) contained: 2 U Phusion High-Fidelity 
DNA polymerase, 1 x Phusion HF buffer, 0.5 µM of each primer (P6, P7), template-DNA 50 
ng, 0.2 mM of each dNTP. PCR protocol: 98°C for 30 sec (1 cycle); (98°C for 10 sec, 55 °C 
for 30 sec, 72 °C for 30sec) (15 cycles); 72°C for 5 min (1 cycle). This preliminary plasmids 
were used to generated the two starting templates-DNA Template-600 and Template-600-2. 
Template-600 was amplified by PCR using Primer P8 and P9 (Table S1, Appendix 6.1), DpnI 
digested (10 U DpnI, 120 min at 37°C) and purified (Nucleospin Extract II kit).  
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Read activity assay: Elongation of R-tailed oligonucleotides by a polymerase catalyzed 
reaction. 
Read activity assay aim to test ability of various polymerases to elongated R, RR or RRR-
tailed oligonucleotides pairing with a template-DNA containing match CCC or TTT as well 
as mismatch AGA, GAG, AAA or GGG. Six PCRs were performed in parallel, each with one 
template-DNA ( CCC, TTT, or AGA, GAG, AAA, GGG) and a one R tailed primer (P12). A 
negative control was prepared with same PCR-setup without addition of any DNA 
polymerase. This read activity assay was performed for every polymerase listed using RR- 
(P13) or RRR–(P14) tailed primers (Table S1, Appendix 6.1). PCR-products were analyzed 
by gel electrophoresis. Elongated primers generated 460 bp fragments, which could easily be 
distinguished from the template-DNA (600 bp). (Fig. 13; 2). DNA polymerases were 
classified as having a “good” or “poor” read capability, depending on PCR efficiencies.  
Following DNA polymerases were tested with read activity assay: Taq, Deep Vent (exo-), 
Vent, Vent(exo-), DyNAzyme EXT, 9°NM, Phusion High-Fidelity from New England 
Biolabs (NEB) (Frankfurt, Germany), AmpliTaq, AmpliTaq Stoffel Fragment from Applied 
Biosystems (Darmstadt, Germany), 3D1 (d’Abbadie et al., 2007). PCRs were done in 
suppliers buffer according to suppliers recommendations. PCRs (12.5 µl) contained: 40 ng 
Template-600 (CCC, TTT, or AGA, GAG, AAA, GGG), 0.5 µM R-tailed primer, 1 x buffer, 
2-5 U polymerase, 0.2 mM of each dNTP. PCR conditions: Vent, Vent (exo-): 95°C for 2 min 
(1 cycle); ( 95°C for 30 sec, 55°C for 30 sec, 72°C for 30 sec) ( 40 cycles); 72°C for 10 min 
(1 cycle); 3D1: 94°C for 2 min (1 cycle); (94°C for 30 sec, 52°C for 30 sec, 72°C for 1 min)   
(40 cycles); 72°C for 10 min (1 cycle); DyNAzyme EXT and AmpliTaq, Deep Vent (exo-), 
9°NM, Phusion High-Fidelity, Taq: 94°C for 2 min (1 cycle); ( 94°C for 30 sec, 55°C for 30 
sec, 72°C for 1 min) ( 40 cycles); 72°C for 10 min (1 cycle); AmpliTaq Stoffel Fragment: 
95°C for 2 min (1 cycle); ( 95°C for 1min , 55°C for 1 min, 72°C for 1 min) ( 40 cycles); 
72°C for 7 min (1 cycle). 
 
Template-DNA generation for write activity assay. 
As template-DNA for the write activity assay, a ssDNA PCR-product generated by the read 
activity assay is needed. To generate this template-DNA the read activity assay was 
performed as described above but using Template 600-2. The PCR-products of read activity 
assay were DpnI digested (20 U DpnI, 37 °C, overnight) and purified (QIAquick PCR 
purification kit Qiagen). This procedure assured that no starting plasmid remained in the 
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mixture, so only elongated R-tailed oligonucleotides are present in the PCR-setup for the 
write activity (Fig. 13; 3).  
 
Write activity assay: Replacement of R-base by standard nucleotides. 
Aim of the write activity assay was to test if polymerases possess the ability to replace 
incorporated R-bases by standard nucleotides. The write activity assay was performed for 
each polymerase listed above. PCR products were analyzed by gel electrophoresis. Amplified 
oligonucleotides generated a 250 bp fragments, which could easily be distinguished from 
template-DNA (= PCR-product of Step 3-template-DNA (460 bp)) (Fig. 13; 4). PCRs (12.5 
µl) contained: 30 ng purified ssDNA (from Step 3), 0.5 µM primer (P10) 1 x buffer, 2-5 U 
polymerase, 0.2 mM of each dNTP, 1 x buffer. PCR conditions: Vent, Vent (exo-): 95°C for 2 
min (1 cycle); ( 95°C for 30 sec, 55°C for 30 sec, 72°C for 30 sec) ( 25 cycles); 72°C for 10 
min (1 cycle); DyNAzyme EXT and AmpliTaq, Deep Vent (exo-), 9°NM, Phusion High-
Fidelity, Taq, 3D1: 94°C for 2 min (1 cycle); ( 94°C for 30 sec, 55°C for 30 sec, 72°C for 1 
min) ( 25 cycles); 72°C for 10 min (1 cycle); AmpliTaq Stoffel Fragment: 95°C for 2 min     
(1 cycle); ( 95°C for 1 min , 55°C for 1 min, 72°C for 1 min) ( 30 cycles); 72°C for 7 min     
(1 cycle). 
 
Cloning of PCR-products from write activity assay. 
Write activity assay was repeated with a modified PCR protocol to generate the PCR-products 
for cloning. First the PCR-products from read activity assay (Template-600-2) were linearly 
amplified by Taq polymerase using the primer P10 for 15 cycles, followed by an exponential 
amplification for 10 cycles after addition of reverse primer P11 (Table S1, Appendix 6.1). 
Primer design allowed the direct hybridization of the PCR-products after purification by 
QIAquick PCR Purification kit (Qiagen) in adequately prepared pALXtreme-1a vector by 
PLICing (Blanusa et al., 2010b). Hybridization mixture was transformed in chemical 
competent E. coli BL21 Gold (DE3) cells and grown on LB kanamycin agar-plates. Thirty 
clones were randomly picked, grown in 5 ml LB kanamycin overnight and send for 
sequencing after plasmid isolation (Nucleo Plasmid kit from Macherey Nagel (Düren, 
Germany) (Fig. 13;5). 
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Scheme of the “read” and “write” activity assay used for the advancement of the SeSaM 
method: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13: Step one to five of the “read” and “write” activity assay. 
 
- 
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2.12.2  SeSaM-R method 
Preliminary step: Preparation of double stranded template-DNA for Step 1 and Step 3. 
PCRs (50 µl) contained: 1 x Phusion HF buffer, 0.2 mM of each dNTP, 0.5 µM of each 
primer (P2 and P1 for Step 1 template-DNA, and P3 and P5 for Step 3 template-DNA), 0.5 U 
Phusion High-Fidelity DNA polymerase (New England Biolabs, Frankfurt, Germany) and 50 
ng pEGFP plasmid (Clontech, Mountain View, CA, USA). PCR protocol: 98°C for 30 sec    
(1 cycle); 98°C for 10 sec, 55°C for 30 sec, 72°C for 30 sec/kb of the SeSaM template-DNA 
(15 cycles); 72°C for 5 min (1 cycle). The PCR products were digested with DpnI (20 U, 
37°C, 3 h) and gel-purified (Nucleospin Extract II kit from Macherey Nagel, Düren, 
Germany). 
 
Step 1: Generation of ssDNA fragment pool with random length distribution. 
The preliminary generated EGFP-SeSaM Step 1 template-DNA was amplified by PCR in 
presence of dCTPαS and dTTPαS to randomly incorporate chemical cleavable 
phosphorothioate bonds (Wong et al., 2004b). PCRs (50 µl) contained: 1 x ThermoPol buffer, 
0.5 µM of each primer (P1 and P4), 5 U Taq DNA polymerase, 360 ng/kb of the SeSaM 
template-DNA (preliminary prepared in Step 1). According to the desired library the 
following nucleotide combinations were used: C-libraries: 0.2 mM of each dATP, dGTP, 
dTTP, and 0.07 mM dCTPαS, and 0.13 mM dCTP; T-libraries: 0.2 mM of each dATP, dGTP, 
dCTP, and 0.08 mM dTTPαS, and 0.14 mM dTTP. For both setups the same PCR protocol 
was performed: 94°C for 2 min (1 cycle); 94°C for 15 sec, 65°C for 30 sec, 72°C for 30 
sec/kb of the SeSaM template-DNA (15 cycles); 72°C for 3 min (1 cycle). PCR products were 
purified (Nucleo Extract II kit) and eluted (80 µl NE-buffer). The cleavage of 
phosphorothiodiester bonds was performed in ThermoPol buffer (1x), supplemented with 
iodine (10 µl, 20 mM in EtOH) and incubated (30 min, 70°C). Cleaved biotinylated DNA 
fragments were isolated by magnetic streptavidin beads (M-PVA SAV1, Chemagen, 
Baesweiler, Germany) and ssDNA was purified employing the NTC binding buffer 
(Nucleospin Extract II kit). 
 
Step 2: Enzymatic elongation of single stranded DNA with dRTP. 
Single-stranded DNA fragments generated in Step 1a and 1b were elongated by TdT 
catalyzed incorporation of dRTP (37°C, 15 min) and terminated by heat inactivation (30 min, 
75°C). Reaction mixtures (25 µl) contained: 1 x TdT buffer, 0.25 mM CoCl2, 1 pmol of 
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ssDNA fragment (from Step 1b), 5 pmol dRTP and 10 U TdT. The ssDNA was purified with 
Nucleo Trap Extract II kit using the NTC buffer. 
 
Step 3: Synthesis of the full length gene. 
Full length EGFP were generated by PCR using the dRTP-elongated DNA fragments of   
Step 2 as primers and the preliminary generated Step 3 template-DNA. The PCRs (50 µl) 
contained: 50 ng/kb of the ssDNA of Step 2, 50 ng/kb of the preliminary generated dsDNA 
SeSaM Step 3 template-DNA, 1 x TermoPol buffer, 0.2 mM of each dNTP, 2 U Vent (exo-) 
DNA polymerase. PCR protocol: 94°C for 2 min (1 cycle); 94°C for 10 sec, 55°C for 30 sec, 
72°C for 2 min/kb SeSaM template-DNA (30 cycles). PCR products were purified 
(NucleoTrap Extract II kit). The SeSaM-R-3D1 protocol was identical to the SeSaM-R 
protocol described above, except that 3D1 (d’Abbadie et al., 2007) DNA polymerase (5 U) 
and the respective 3D1-buffer were used. 
 
Step 4: Replacement of universal bases. 
Universal bases were replaced by standard nucleotides during PCR amplification. The PCRs 
(50 µl) contained: 0.5 U Phusion High-Fidelity DNA polymerase, 0.5 µM of each primer    
(P2 and P3), 50 ng full-gene length DNA from Step 3, 0.2 mM of each dNTP, 1 x Phusion HF 
buffer. The following PCR protocol was employed: 98°C for 30 sec (1 cycle); 98°C for 10 
sec, 58°C for 15 sec, 72°C for 30 sec/kb of the SeSaM template-DNA (30 cycles); 72°C for 
10 min (1 cycle). The PCR products were gel purified with QIAquick Gel Extraction kit 
(Qiagen, Hilden, Germany) to eliminate the “non-mutated” template-DNA supplemented in 
Step 3. 
 
Cloning of EGFP-SeSaM libraries 
PCR products (from Step 4) were digested with EcoRI/HindIII (10 U of each in 1 x 
FastDigest buffer (Fermentas, St. Leon-Rot, Germany)), purified (QIAquick PCR purification 
kit; Qiagen), and cloned into EcoRI/HindIII-digested and dephosphorylated pEGFP vector 
(Rapid DNA Dephos & Ligation kit; Roche, Mannheim, Germany). Subsequently, the 
ligation mixtures were transformed into chemical competent E. coli DH5 cells and plated on 
LB agar plates containing ampicillin (100 µg/ml). Thirty clones were randomly picked and 
sequenced. 
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2.12.3  SeSaM-P/R method 
The SeSaM-P/R protocol allows recombination of SeSaM forward R-libraries with the 
SeSaM reverse P-libraries or vice versa. SeSaM Step 2 fragments with dPTP were prepared as 
described in the SeSaM-Tv+ protocol (Wong et al., 2008). SeSaM Step 2 fragments with 
dRTP were generated according to the above described SeSaM-R protocol. 
 
Step 3: Recombination of R- or P-tailed SeSaM Step 2 fragments by PCR.  
Step 2 fragments of forward R- and reverse P-libraries were hybridized and elongated to full 
length gene fragments by PCR. PCR conditions: Step 2 templates-DNA of each 50 ng (Step 2: 
R or P fragments), 1 x ThermoPol buffer, 0.2 mM dNTP, 2 U Vent(exo-) DNA polymerase. 
PCR protocol: 94°C for 2 min (1 cycle); 94°C for 1 min, 55°C for 1 min, 72°C for 2 min/kb 
of the targeted gene length (15 cycles); 94°C for 1 min, 65°C for 1 min, 72°C for 3 min/kb of 
the targeted gene length (15 cycles); 72°C for 5 min (1 cycle). PCR products were purified by 
QIAquick PCR purification kit (Qiagen). 
 
Step 4: Replacement of universal bases.  
In the SeSaM-P/R protocol the PCRs in Step 4 were performed as described in Step 4 of the 
SeSaM-R method. Gel purification could be omitted and was replaced by employing the 
QIAquick PCR Purification kit since no EGFP DNA was required to serve as template-DNA 
in Step 3. Cloning of SeSaM libraries was performed as described in the SeSaM-R protocol.  
 
 
2.12.4  Agarose gel electrophoresis 
DNA-fragments were separated by agarose gel electrophoresis running in 1x TAE-buffer 
(TAE-Puffer (50x): 2 M Tris 100 mM EDTA in H2O pH=8,0 adjusted with HCl) for 30-60 
min at 60-120V depending on fragment size and gel concentration (0.8-3%). Samples (50-100 
ng DNA) were mixed with 1x loading dye (Loading dye (stock 6x): 6,7 ml glycerin, 10 mg 
bromphenolblau, 1 ml 10x TAE-puffer filled up to 10 ml with H2O) and were applied on a 1% 
agarose gel  (1% agarose in 1x TAE-buffer) with the DNA ladder (GeneRuler 1kb DNA 
Ladder, Fermentas, St. Leon-Rot, Germany) as reference for fragments between 250-10000 
bp and the GeneRuler 50bp Ladder (Fermentas, St. Leon-Rot, Germany) on a 2% agarose gel 
for fragments between 50-1000 bp. Gel staining occurred with ethidiumbromid staining after 
separation (40 μl EtBr-Stock solution in 1000 ml H2O) or by Gelred staining during the run 
0.01% GelRed-solution (Stock dilute 1:3,  Biotium, Hayward, CA USA) was added to the 
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agarose solution before casting. In both cases the gel was analyzed and documented on a UV-
lamp with the geldocumentation device (U:Genius, Syngene, Cambridge, UK). 
 
2.12.5  Polymerase Chain Reaction (PCR) 
PCRs were performed in 0.2 ml thin-walled PCR tubes from Sarstedt (Nümbrecht, Germany) 
employing a Mastercycler Gradient PCR-machine from Eppendorf (Hamburg, Germany). 
DNA was quantified by a NanoDrop photometer from NanoDrop Technologies (Wilmington, 
USA DE). As negative control the PCR reaction mixture without template-DNA was carried 
along. If not mentioned otherwise, standard PCR was used.  
 
2.12.5.1  Standard PCR 
PCR contained (50 µl: template DNA 50 ng, Taq-buffer 1 x, dNTPs 0.2 mM, Taq-polymerase 
5 U, each primer 0.5 pmol/µl. 
PCR protocol:  94°C for 1 min (1 cycle), 94°C for 30 sec, 55°C for 30 sec, 68°C for 1 min/kb 
(25 cycles), 68°C for 10 min (1 cycle). 
 
2.12.5.2  Colony PCR 
Colony-PCR was used to check if after transformation E. coli colonies carried the plasmids 
with desired insert. As template 10 µl overnight culture was mixed with 40 µl ddH2O and 
incubated for 15 min at 95°C. To amplify the whole P450 BM3 gene the primer PP1 and PP2 
were used or the P87/P88 to amplify the multiple cloning site of the vector pET28a(+) (see 
supplementary Table S1 in Appendix 6.1). 
Colony-PCR (12.5 µl) contained: template DNA 2.5 µl, Taq-buffer 1 x, dNTPs 0.2 mM, Taq-
polymerase 5 U, each primer 0.5 pmol/µl. 
PCR protocol:  94°C for 1 min (1 cycle), 94°C for 30 sec, 58°C for 30 sec, 72°C for 1 min/kb 
(30 cycles), 72°C for 10 min (1 cycle). 
 
2.12.5.3  Overlap extension PCR 
The overlap extension PCR was used to generate the simultaneous SSM at 2 positions (Ho et 
al., 1989; An et al., 2005).  Three fragments were generated by standard PCR and annealed by 
an additional PCR amplification step.  
PCR contained (50 µl): Template DNA 100 ng (each fragment 30 ng), PfuS-buffer 1 x, 
dNTPs 0.2 mM, PfuS-polymerase 5 U, each primer 0.5 pmol/µl. 
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PCR protocol:  94°C for 1 min (1 cycle), 94°C for 30 sec, 58°C for 30 sec, 72°C for 1 min/kb 
(30 cycles), 72°C for 10 min (1 cycle). 
 
2.12.5.4  EpPCR library generation  
EpPCR-libraries of P450 BM3 were constructed according to protocols from Cirino and 
Arnold (Arnold and Georgiou, 2003; Cirino et al., 2003) with variable MnCl2 concentrations 
0.05 mM, 0.1 mM, 0.2 mM. Gene specific primers PP1 and PP2 (see supplementary Table S1 
in Appendix 6.1) were used for insert amplification. A standard epPCR master mix of 50 µl 
contained: Template plasmid DNA 1 ng/µl, Taq-buffer 1x, dNTPs 0.2 mM, Taq-polymerase  
5 U, each primer 0.3 pmol/µl, MnCl2 0.05-0.4 mM. EpPCR protocol: 94°C for 30 sec (1 
cycle); 94°C for 30 sec, 60°C for 1 min, 72°C for 1 min/kb (30 cycles); 72°C for 10 min (1 
cycle). For vector amplification the primers P3 and P4 (see supplementary Table S1, 
Appendix 6.1) were used. The PCR products were DpnI digested (20 U; 37°C, 3 h) and 
purified using the Nucleospin Extract II kit (Macherey Nagel, Düren, Germany). Vector-PCR 
(50 µl) contained: Template DNA 50 ng/µl, HF-Buffer 1x, dNTPs 0.2 mM, Phusion High-
Fidelity DNA Polymerase  (NEB) 5 U, each primer 0.5 pmol/µl. PCR protocol: 98°C for 30 
sec (1 cycle); 98°C for 10 sec, 55°C for 30 sec, 72°C for 1 min/kb (25 cycles); 72°C for 5 min 
(1 cycle). PCR products were hybridized by using the PLICing cloning method (Blanusa et 
al., 2010b). 
 
2.12.5.5  Site directed (SDM) and site saturation mutagenesis (SSM) - PCR  
Site directed and site saturation mutagenesis were done according to a modified QuickChange 
Mutagenesis (QCM) protocol (Hogrefe et al., 2002). The procedure consists of two steps. In 
the first step, two extension reactions are performed in separate tubes, containing either the 
forward or the reverse primer. Subsequently, the two reactions are mixed and the standard 
QCM procedure was carried out. PCR (50 µl) in step 1 contained: Pfu buffer 1x, dNTP mix 
0.2 mM, Pfu DNA polymerase 1 U, primer (forward or reverse) 0.2 µM. PCR protocol for 
step 1: 95°C for 30 sec (1 cycle), 95°C for 30 sec, 55°C for 1 min, 68°C for 2 min/kb            
(3 cycles). Equal amounts of Step 1 were mixed and 1 U Pfu DNA polymerase was added 
before next PCR-reaction was started. PCR protocol for step 2:  95°C for 30 sec (1 cycle), 
95°C for 30 sec, 55°C for 1 min, 68°C for 2 min/kb (15 cycles), 68°C for 60 min (1 cycle). 
PCR products were DpnI digested overnight at 37°C (10 U DpnI/50 µl PCR mixture) and 
purified with PCR-Purification Kit before transformation. Primer used for SDM and SDM are 
listed in supplementary Table S1 (Appendix 6.1). 
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2.12.6   Cloning 
 
2.12.6.1  Preparation of chemical competent cells  
Chemical competent cells were prepared by inoculation of 5 ml overnight culture in LB-
media (at 37°C, 250 rpm, 14h). Main culture of 200 ml LB-media in 1 L flask was inoculated 
with 2% of the preculture and incubated at 37°C, 250 rpm until reach of OD600 =0.4. The 
culture was cooled down on ice and centrifuged at 4°C, 3000 rpm, for 10 min (Eppendorf, 
Hamburg, Germany). All following steps were carried out on ice. The pellet was resuspended 
in 15 ml sterile filtered cooled TFB1-solution (30 mM K-Acetat, 50 mM MnCl2, 100 mM 
RuCl2, 10 mM CaCl2, 15% glycerin in H2O, pH=6.8 adjusted with KOH/HCl) and incubated 
for 10 min. Cells were centrifuged at 4°C, 3000 rpm, 10 min (Eppendorf, Hamburg, 
Germany) and pellet was resuspended in 2 ml sterile filtered cooled TFBII-solution (10 mM 
MOPS, 75 mM CaCl2, 10 mM RuCl2, 15% glycerin in A.dest, pH=6.8 adjusted with 
KOH/HCl). Competent cells were divided in 100 µl aliquots and stored at -80°C. 
 
2.12.6.2  Digestion with restriction enzymes 
Restriction enzyme digestion was used for cloning purpose or to check integrity of genetic 
constructs. Reaction mixtures contained 1 µg DNA, 5 U of each enzyme, 1 x restriction 
buffer. Digestion was performed following suppliers recommendation at 37°C for 2 h (NEB) 
or at 37°C for 10 min (Fermentas) followed by heat inactivation (20 min at 65 °C) or by 
purification with PCR Purification kits. The digestion mixture was separated and visualized 
by agarose gel ectrophoresis. 
 
2.12.6.3  PLICing  
The PLICing method (Blanusa et al., 2010b) was used as alternative cloning method to 
hybridized DNA constructs in adequately prepared vector. For hybridization of P450 BM3 in 
pET28a(+) or pALXtreme-1a, the vectors were amplified with the primers PP3 and PP4 and 
the insert with the primers PP1/PP2 (see supplementary Table S1 in Appendix 6.1). The PCR 
products were digested with DpnI (20 U; 37°C, 3 h) and purified (Nucleospin Extract II kit 
from Macherey Nagel, Düren, Germany). PCR (50 µl) contained: Template DNA 50 ng/µl, 
Taq-buffer 1x, dNTPs 0.2 mM, Taq-polymerase 5 U, each primer 0.5 pmol/µl. PCR protocol: 
98°C for 30 sec (1 cycle), 98°C for 10 sec, 55°C for 30 sec, 72°C for 1 min/kb (25 cycles), 
72°C for 5 min (1 cycle). For the iodine cleavage step, the vector-DNA was diluted to 0.03 
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pmol/µl and the insert-DNA to 0.05 pmol/µl. The iodine-cleavage reaction contained 4 µl of 
the sample and 1 µl of the iodine cleavage master-mix (5 µl 10x iodine cleavage buffer (500 
mM Tris, pH 9.0) and 3 µl 100 mM iodine were dissolved in 99% ethanol and 2 µl ddH2O) 
and was incubated for 5 min at 70°C. DNA-hybridization was carried out by mixing 5 µl of 
the cleaved vector and 5 µl of the cleaved insert and incubation for 5 min at RT.  
 
2.12.6.4  Transformation 
Before transformation competent E. coli cells were thaw on ice. 100 µl chemical competent E. 
coli cells were mixed with 50 ng plasmid DNA or 200 ng ligation mixture and incubated 20 
min on ice. The heat-shock was carried out at 42°C for 45-60 s. Samples were immediately 
cooled down on ice 1 min, for regeneration filled up to 1 ml with pre-tempered LB-media and 
incubated for 45 min at 37°C, 250 rpm. The cells were plated on LB agar plates with 
corresponding antibiotics and incubated over night at 37°C. For validation a negative control 
consisting of H2O and a positive control consisting of plasmid DNA were carried along. 
 
2.12.6.5  Sequencing 
DNA-sequencing was done at GATC Biotech (Konstanz, Germany) and Eurofins MWG-
Operon (Ebersberg, Germany) and analysis of the resulting sequencing data was performed 
with the Clone Manager 9 Professional Edition Software (Scientific & Educational Software, 
Cary, NC, USA). 
 
2.13  Biochemical methods 
 
2.13.1  Activity assay in MTP format 
 
2.13.1.1  NADPH consumption assay  
Crude extracts prepared by Lysozyme digestion from cells expressed in flasks or MTP were 
used for NADPH consumption assay. In a flat bottom MTP plate following sample and 
control was setup and mixed well. Sample contained 25 µl DMSO with substrate 
concentration of 2 mM-10mM, 75 µl KPi buffer (0.1 M, pH 7.5), 100 µl crude extract. 
Control was setup identically without the addition of substrate. After 5 min incubation, 
conversion was started by addition of 50 µl NADPH (0.8 mM) and immediately the 
absorption was measured at 340 nm over 15 min with 30 sec interval in a microtiter plate 
spectrophotometer. NADPH consumption assay was also performed with purified protein, in 
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this case the amount of buffer and enzyme solution was adjusted to have between 0.5 µM and 
10 µM P450 BM3 in the reaction.  
 
2.13.1.2  4-Aminoantypirin activity assay (4- AAP assay) 
The frozen cell pellets expressed in MTP were thawed. Cell lyze was done by addition of 140 
µl lysomix (1g lyzozym /200 ml KPI pH 7.5) to each well and incubate at 900 rpm, 37°C, 
70% humidity for 60 min in microtiter plate shaker Microtrone (INFORS, Heinsbach, 
Germany). The assay was carried out by adding:  340 l of 50 mM phosphate buffer pH = 7.5,  
25 l  substrate (50 mM 11-phenoxyundecanoic acid in DMSO or 5 µl 3-phenoxytooluene 
(90 mM in DMSO)) and 5 µl catalase-solution (46 mg/ml catalase from bovine liver 1558 
U/mg dissolved in H2O) and incubated under shaking (800 rpm) at room temperature for 5 
min. The conversion was started by the addition of 5 l Clevios P or 50 µl (1 mM NADPH) 
and incubated at room temperature for 60 min at 800 rpm. After incubation, the plates were 
centrifuged (Eppendorf Centrifuge 5810 R, Hamburg, Germany) at 4000 rpm, 4°C for 15 min 
and 180 l of the reaction mixture were transferred to a flat bottom microtiter plate. The 
reaction was stopped by adding 35 l quenching buffer (4M urea in 0.1M NaOH), followed 
by intensive mixing. The 4-AAP assay (colorimetric reaction) was proceeded by adding in 
this order: 20 l (10 mg/ml in H2O) 4-AAP and 20 l (10 mg/ml in H2O) potassium 
peroxodisulfate and incubated at room temperature for 35 min and 800 rpm. The bubbles were 
removed using a bunsen burner and the absorbance was measured at 509 nm and 600 nm 
using a microtiter plate reader.  
When cell lysate prepared from protein expressed in flasks is used, after the enzymatic 
conversion and before centrifugation, 10 µl of lysozyme (50 mg/ml) were added to the 
reaction mixture and incubated 5 min at 800 rpm RT to precipitate the conductive polymer in 
the reaction mixture. 
The reaction mixture was centrifuged (Eppendorf Centrifuge 5810 R, Hamburg, Germany) at 
4000 rpm for 5 min and 180 l were transferred to a flat bottom microtiter plate, filled with 
35 l of the quenching buffer. The colorimetric reaction was proceeded like described above.  
 
2.13.1.3  BCCE activity assay  
The assay was performed analog to the MTP-assay described by Nazor and Blanusa (Nazor 
and Schwaneberg, 2006; Blanusa, 2010a) with minor modifications. The harvested cells in 
deepwell plates were resuspended in 300 µl Tris/HCl-buffer (0.1 M, pH 8.2). After addition  
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of 5 µl polymyxin B sulfate (3.6 mM), the 96well plates were incubated for 15 min at RT at 
1000 rpm. 100 µl of the lysate were pipetted into a black flat bottom 96 well MTP (Greiner 
Bio-one, Frickenhausen, Germany) and incubated for 5 min (700 rpm shaking) with 2 µl of 
BCCE (2 mM in DMSO). The conversion of BCCE was initiated by addition of 50 µl 
NADPH (1 mM). The remaining 200 µl were used for the MET and supplemented with 
Cobalt(III)sepulchrate (8 µl, 15 mM), the plate briefly mixed and incubated (RT, 1000 rpm, 
15 min). The reaction was started by the addition of the electron donor, in case of the MET,   
5 mg Zn was added in each well using the Resin Dispenser (Mettler-Toledo, Columbus OH, 
USA). The fluorescent signal was recorded for 20 min every 20 sec (λEx 400 nm, λEm 440 nm) 
using a fluorescent microtiter plate reader. 
 
2.13.1.4  pNCA activity assay  
The pNCA activity assay (Schwaneberg et al., 1999a) was carried out in the same deepwell 
plates as used for the protein expression. The pellets were thaw and resupended in 230 µl 
pNCA-assay buffer (50 mM Tris-HCl / 50 mM phosphate buffer / 0.25 M KCl (1:1:1)). After 
addition of 5 µl polymyxin B sulfate (3.6 mM), the plate was incubated for 20 min at RT, 
1000 rpm (TIMIX 5 Shaker). The substrate pNCA (15 mM) 5 µl and 5 µl catalase (46 mg/ml) 
were added and the plate was incubated (RT, 1000 rpm, 5 min). The reaction was started by 
the addition of the electron donor, 50 µl NADPH (1 mM) or in case of the MET, the mediator 
Cobalt(III)sepulchrate (8 µl, 15 mM) was added, the plate briefly mixed and incubated (RT, 
1000 rpm, 15 min) and then 5 mg Zn was added in each well using the Resin dispenser 
(Mettler-Toledo, Columbus OH, USA). The conversion was carried out at RT, 1000 rpm, for 
60 min and stopped by adding 200 µl NaOH (1 M). The plate was centrifuged (RT, 4000 rpm, 
20 min) and 200 µl of the supernatant was carefully transferred into a flat bottom MTP. The 
absorbance was measured at 405 nm with the MTP-spectrophotometer. 
 
2.13.2  Flow cytometry screening systems 
 
2.13.2.1  Whole cell flow cytometry screening system  
Cell populations subjected to be analyzed by flow cytometry were expressed in flasks. Cells 
expressing the empty vector were used as negative control. After centrifugation of the culture 
(4000 rpm, 20 min, 4°C), cells were washed in PBS-buffer and the pellet was resuspended in 
sterile PBS-buffer (in 1/10 of the culture volume). Reaction mixture (300 µl) contained 25 µl 
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resuspended cells, 1 µl BCCE (200 mM in DMSO), PBS-buffer (0.03 M NaCl, 2.7 mM KCl, 
0.01 M Na2HPO4, 1.8 mM KH2PO4, pH 7.4 adjusted with HCl) and was incubated 90 min. 
The reaction mixture was diluted 1:10 in PBS-buffer and filled in 3.5 ml analysis tubes 
(Sarstedt, Nümbrecht, Germany). The prepared cells were analyzed in a CyFlow Space 
flowcytometer (Partec, Münster, Germany) at a liquid flow-speed of 5 µl/min, using PBS-
buffer as sheet fluid. Data of SSC, FSC and UV-laser emission (FL3: λEx 350 nm and λEm 450 
nm) were recorded. Sorting of desired populations occurred under size triggering and gating 
the UV-laser emission response with a trigger delay of 2, pulse of 10 and a sorting speed of 
300-500 events/min. Sorted cells were collected, plated on LBkan (50 µg/ml) agar plates and 
incubated overnight at 37°C. Enriching for active clones was achieved by washing the sorted 
and recovered colonies away from the agar plates and expressing the cells in flasks followed 
by another round of sorting. 
 
2.13.2.2  Flow cytometry activity assay with w/o/w-emulsion 
Cells subjected to analysis in water in oil in water emulsion (double emulsion) were prepared 
like described for flow cytometry assay with whole cells. The cell number was adjusted to 
3x108/ml by microscopic counting in a counting chamber. Emulsion mixture was prepared by 
mixing 80 µl of the cell suspension, 10 µl PMB (3.6 mM), 20 µl NADPH (10 mM) and 4 µl 
BCCE acid (200 mM), subsequent vortexing and keeping on ice. Instead of NADPH, 9 µl 
Co(III)-sep (15 mM) and 5 mg Zn-dust can be added. Optionally fluorescin (60 µM) or EGFP 
expressing cells can be added to primary emulsion mix as internal control dye to increase the 
analysis and sorting rate of true double emulsions (Blanusa, 2010a). 100 µl of the emulsion 
mixture were transferred in emulsion tubes (Nerbe plus, Luhe, Germany) and primary 
emulsions were prepared by addition of 1ml W1-emulsion solution (1.45 g ABIL EM 90 
dissolved in 50 g LMO stored in the dark at RT) and emulsified 5 min at  10000 rpm with the 
Ultra Thurax on ice. The secondary emulsions were generated by addition directly on top of 
the primary emulsions of 1 ml W2-emulsion solution (0.6 g CMC and 0.8 ml tween 20 
dissolved in 40 ml PBS, stored in the dark at RT) and the mixture was emulsified for 3 min at 
8000 rpm on ice. Double emulsions were incubated 3 h in the dark. After 30 min, 1 h, 2 h and 
3 h the emulsions were diluted 1:1000 with PBS buffer in analyzer tubes and were analyzed in 
a CyFlow Space flowcytometer (Partec, Münster, Germany) at a liquid flow-speed of             
5 µl/min, using PBS-buffer as sheet fluid. Data of SSC, FSC and UV-laser emission (FL3: λEx 
350 nm and λEm 450 nm) were recorded. Sorting of desired populations occurred under size 
triggering and gating the UV-laser emission response with a trigger delay of 2, pulse of 10 
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and a sorting speed of 300-500 events/min. Sorted cells were collected, plated on LBkan       
(50 µg/ml) agar plates and incubated overnight at 37°C. 
 
 
2.13.3  Protein purification 
P450 BM3 variants were purified according to published protocol (Schwaneberg et al., 
1999b) by anion-exchange-chromatography using an ÄKTAprime plus pumping system (GE 
Healthcare, München, Germany) with a Kronlab ECOplus TAC 15/125PE5-AB-2 column 
(YMC Europe, Dinslaken, Germany) packed with Toyo Pearl 650 S-DEAE Sepharose Matrix 
(Tosoh bioscience, Tokyo, Japan). The column was washed with 5 column volumen (CV) 
ddH2O and equilibrated with 5 CV buffer A (0.1 M Tris/HCl, pH 7.8) before loading the cell 
lysate. A flow rate of 5 ml/min was applied and all employed solutions were filtered and 
degassed. The crude cell lysate was injected after filtration through 0.45 µM filter (Carl Roth, 
Karlsruhe, Germany) into the 5 ml loop and loaded twice onto the column. Unbound protein 
was washed out with buffer A until the baseline was reached. Protein elution was performed 
in a stepwise gradient. Unspecific binding proteins were eluted with 150 mM NaCl equal to 
7% buffer B (0.1 M Tris/HCl and 2 M NaCl, pH 7.8). The desired P450 protein was eluted 
with 13% of elution buffer B (260 mM NaCl) and fraction were collected. After elution, 
residual proteins were eluted with 100% buffer B (2 M NaCl) and the column was washed 
with ddH2O, NaOH (0.2 M) and 20% ethanol, 5 CV each before storage.  
The collected fractions were analyzed by SDS-PAGE (10%) for protein purity. Fractions 
containing the highest amount of pure P450 BM3 monooxygenase were recombined and 
concentrated using an Amicon Centrifugal Filter Units (30 kDa cut-off membrane; Millipore, 
Billerica, USA). Desalting of the purified BM3 variants was carried out using a PD-10 
Desalting Column (GE Healthcare, Uppsala, Sweden) equilibrated in Tris/HCl buffer (0.1 M, 
pH 7.8). Protein solutions were frozen in liquid nitrogen before lyophilization for 48 h in a 
Christ ALPHA 1-2LD plus lyophilisator (Christ, Osterode am Harz, Germany).  
 
2.13.4  Polyacrylamide gel electrophoresis (SDS-page) 
Proteins were separated on 10% sodium dodecyl sulphat (SDS) (Laemmli, 1970) – 
polyacrylamide gel (24 mA, 90 min) in 1 x SDS-buffer (0.3% Tris, 1.5% Glycin, 0.1% SDS 
in H2O, no pH adjustment) running in Mini-Protean Tetra Cell system from Bio-Rad 
(München, Germany). Resolving gel (5 ml) contained 1.9 ml ddH2O, 1.7 ml 40% acrylamide-
mix, 1.3 ml 1.5 M tris (pH 8.8), 0.05 ml 10% SDS, 0.05 ml 10% APS and 0.002 ml TEMED. 
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The gel was covered with isopropanol and after polymerisation, the isopropanol was removed 
and the stacking gel (1 ml) 0.68 ml ddH2O, 0.17 ml 40% acrylamide-mix, 0.13 ml 1.0 M tris 
(pH 6.8), 0.01 ml 10% SDS, 0.01 ml 10% APS and 0.001 ml TEMED was casted. Samples 
were prepared by mixing with 1 x Roti-Load and heating at 95°C for 5 min. In each slot 4-10 
µl sample or 2 µl marker (PageRuler Prestained Protein Ladder, Fermentas, St. Leon-Rot, 
Germany) were pipetted. For protein visualization, the gel was stained 20 min in staining 
solution (0.25% Coomassie, 45.5% methanol, 9.2% acetic acid, in H2O) afterwards destained 
1h in destaining solution (30% methanol, 10% acetic acid in H2O) and stored in storage 
solution (8% methanol, 10% acetic acid, in H2O) until the background was decolored. 
 
 
2.13.5  Determination of P450 concentration by CO-gassing  
The P450 concentration in solution was determined by carbonmonoxide (CO)-gassing 
(Omura and Sato, 1964a).  The protein solution was diluted in KPI-buffer (50 mM, pH 7.5). 
After addition of one spatula sodiumhydrosulfit, the tube was vortexed and the solution 
splitted in two equal volumen. One part served as reference, the other was bubbled with CO-
gas for 30 sec with low volumetric flow. The absorption spectrum from 400 to 600 nm of the 
reference and the sample was recorded with the spectrophotometer Varian Cary 50 and the 
P450 concentration was calculated according to the following formula (3) (Omura and Sato, 
1964a, 1964b). 
 
P450 concentration [mM] = (A 450nm –A 500 nm ) x dilution factor                          (3)
          ε   
 = extinction coefficient (for P450 = 91 mM-1cm-1) 
 
 
2.13.6  Kinetic characterization of P450 BM3 variants  
Kinetic parameters for BCCE 
For kinetic characterization with BCCE a reaction mixture in a black flat bottom MTP 
contained: 196 µl tris/HCl-buffer (0.1 M, pH 7.8, 60-160 nM purified enzyme, 2 µl of BCCE 
and 5 µl catalase (12000 U/ml). Estimation of km and Vmax were achieved by varying BCCE 
concentrations from 0 to 20 mM.  The MTP was incubated for 5 min at 800 rpm, before 
reaction was started by addition of 50 µl NADPH (1 mM). For MET, the reaction was 
supplemented with 8 µl Co(III)-sep and incubated for 15 min at 800 rpm before the reaction 
2. Material and Methods  45 
 
 
was started by transferring 100 µl of the reaction mixture in a black MTP containing 5 mg Zn-
dust in each well. The fluorescent signal (λEx 400 nm, λEm 440 nm) was recorded using an 
Infinite M1000 microtiter plate reader (Tecan Group, Männedorf, Switzerland). All 
measurements were done in triplicates. Concentration of the product was calculated from a 
standard curve obtained for 7-Hydroxy-3-Carboxy Coumarin Ethyl ester (3-CCE). Fitting of 
kinetic parameters was achieved using Origin 7.0 software (OriginLab Corporation, 
Northampton, MA, USA). 
 
Kinetic parameters for pNCA 
For kinetic characterization with pNCA a reaction mixture in a flat bottom MTP contained: 
125 µl assay buffer (50 mM Tris-HCl / 50 mM phosphate buffer / 0.25 M KCl (1:1:1)), 60-
160 nM purified enzyme, 5 µl of pNCA (in DMSO) and 5 µl catalase (12000 U/ml). 
Estimation of km and Vmax were achieved by varying pNCA concentrations from 0 to 5 mM.  
The MTP was incubated for 5 min at 800 rpm, before reaction was started by addition of 50 
µl NADPH (1 mM). For MET, the reaction was supplemented with 6 µl Co(III)-sep and 
incubated for 20 min at 800 rpm before the reaction was started by addition of 5 mg Zn-dust 
in each well with the Resin Dispenser. The MTP was incubated for 30 min at 600 rpm and 
RT. To stop the reaction 100 µl of 1M NaOH were added and the MTP was centrifuged at 
4000 rpm for 5 min at RT. Carefully, 200 µl of supernatant were aspirated, pipetted into a 
new, flat bottom MTP and the absorbance at 405 nm was recorded using a microtiter plate 
reader. All measurements were done in triplicates. Concentration of the product was 
calculated from a standard curve obtained for p-nitrophenol. Fitting of kinetic parameters was 
achieved using Origin 7.0 software (OriginLab Corporation, Northampton, MA, USA). 
 
2.14   Analytic and chemical methods 
 
2.14.1  GC and GC-MS 
The enzymatic reaction mixture was extracted in 2 volumes chloroform and if necessary 
concentrated with rotavapor (IKA HB-10, VWR, Darmstadt, Germany) to obtain maximal 
400 µl samples. Products were separated on GC-2010-plus (Shimadzu, Duisburg, Germany) 
and GCMS-QP2010S equipped with a Supreme 5 column (5% phenylpolysilphenylensiloxan) 
using hydrogen (GC-FID) and helium (GC-MS) as carrier gas at linear velocity of  30 cm/sec. 
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Column oven temperature program for separation of 3-phenoxytoluene products: 120°C for 1 
min; 120°C to 250°C at 20°C min-1; 250°C for 2 min. Peak identification occurred by 
comparison to pure standard and hydroxylation products were identified by their characteristic 
MS fragmentation patterns.  
 
 
2.14.2  Substrate synthesis (Chilvers et al., 2001; Sun, 2008; Blanusa, 2010a) 
Step 1 – Synthesis of 3-carboxy-coumarin ethyl ester (3-CCE) 
8.4 g (60.82 mmol) of 2,4-dihydroxybenzaldehyde was dissolved in 45 ml of anhydrous 
methanol. Solution was stirred and 8.7 g (54.32 mmol) of diethyl malonate was supplemented 
and refluxed. 450 mg (5.16 mmol) of morpholin and 150 mg (2.49 mmol) of acetic acid were 
supplemented to 2 ml of methanol and stirred until the precipitate fully dissolved. This 
solution was subsequently transferred to the refluxed reaction mixture and reflux was 
continued for another 3 hours. After cooling, the product was filtered and re-crystallized from 
boiling methanol (~300 ml). 
 
 
Step 2 – Preparation of sodium salt 3-carboxy-coumarin  
For this step, 1.5 g (6.81 mmol) of 3-CC ethyl ester were dissolved in toluene (50 ml), stirred 
and heated (120°C) and concentrated by evaporation to 5 ml (30-60 min). After cooling the 
mixture to room temperature, 0.5 g (10.84 mmol) of NaH was supplemented. The mixture 
was heated to 120°C and stirred until toluene evaporated (1-2 hours). The obtained salt was 
dried in vacuum overnight. 
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Step 3 – Attaching benzyl group to 3-CC ethyl ester 
3 g (12.39 mmol) of prepared 3-CC methyl ester sodium salt was dissolved in 200 ml DMF 
(dried with molecular sieves). Mixture was heated to 120°C. During heating, 2.138 g (12.5 
mmol) of benzyl bromide was supplemented. Mixture was stirred gently and kept at 120°C 
for 2 hours.  One g of benzyl bromide (5.85 mmol) was supplemented and conversion 
continued at 120 °C for 4-6 hours and the same procedure was repeated once more 
(supplementing of 0.7 g, 4.09 mmol benzyl bromide; 1 h 120°C). Subsequently the reaction 
mixture was cooled to room temperature and poured into 400 ml of ice cold water. After 
precipitation (30-60 min), the suspension was filtered, rinsed with water, dried and re-
dissolved in CH2Cl2. The organic phase was extracted twice with water, filtered, concentrated 
(Rotavap) and the precipitate was dried overnight in vacuum. The targeted compounds were 
purified by chromatography employing silica gel (DC60). Sample was dissolved in CH2Cl2 
and elution was performed with an ethyl acetate : CH2Cl2 (1:20) mixture. Purity was 
monitored on TLC using same solvent system and main fractions were pooled according to 
TLC. 13C-NMR and 1H-NMR spectra were recorded using a Bruker AV400 (Bruker, 
Madison, WI, USA). 
 
 
Step 4 – Preparation of BCC-acid  
A mixture of BCCE (18.2 mg, 58 µmol) and barium hydroxide octahydrate (powdered, 7.35g, 
23.4 mmol) in MeOH (8 ml) was stirred at room temperature for 24 h. The heavy white 
suspension was diluted with brine (3ml) and acidified with 1M HCl to give a clear solution of 
pH 3-4. This aqueous solution was extracted with EtOAc (2x50 ml +1x20 ml) and the 
combined organic extracts washed with brine (10 ml) and three times with H2O until no white 
precipitate was formed, dried (MgSO4) and concentrated (Rotavap). (Inoue and Sakai, 1977; 
Paterson et al., 1995; Kocieński, 2005) 
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7-Hydroxy-3-Carboxy-Coumarin Ethyl ester (3-CCE): 1H NMR (400 MHz, DMSO) δ 1.29 (t, 3H, J = 
7.2 Hz, CH3); 4.26 (q, 2H, J = 7.2 Hz, CH2); 6.73 (s, 1H, ArH); 6.84 (d, 1H, J = 8.5 Hz, ArH); 7.75 (d, 
1H, J = 8.8 Hz, ArH); 8.67 (s, 1H, ArH) ppm. 13C NMR (400 MHz, DMSO) δ 14.09, 60.76, 101.75, 
110.39, 112.09, 113.95, 132.06, 149.38, 156.35, 157.06, 162.90, 164.01 ppm. 
7-Benzoxy-3-Carboxy-Coumarin Ethyl ester (BCCE): 1H NMR (400 MHz, CDCl3) δ 1.32 (t, 3H, J = 
7.0 Hz, CH3); 4.31 (q, 2H, J = 7.0 Hz, CH2); 5.07 (s, 2H, CH2); 6.80 (d, 1H, J = 8.7 Hz, ArH); 7.38-7.17 
(m, 5H, Ph-Ring); 7.42 (d, 1H, J = 8.7 Hz, ArH); 8.41 (s, 1H, ArH) ppm. 13C NMR (400 MHz, CDCl3) δ 
13.26, 60.69, 69.75, 100.34, 110.77, 113.20, 113.22, 125.33, 126.45, 126.46, 127.54, 127.81, 129.72, 
134.28, 147.89, 156.11, 156.42, 162.39, 163.13 ppm. 
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3. Results and Discussions 
 
The results and discussions section is divided in three chapters. The main focus of this thesis 
was the methodological advancements in diversity generation (SeSaM method) and high 
throughput screening (flow cytometer based screening technology), which was complemented 
by the evolution of P450 BM3 for alternative cofactor systems. Directed protein evolution 
experiments consist of the three main steps performed in iterative cycles. Each step of the 
directed evolution method was advanced and is considered in one chapter. In Chapter I, the 
advancement of Step 1 consisting of generation of high quality mutant libraries is reported. 
Step 1 was advanced by developing an advanced SeSaM protocol, in which a universal base 
complementary to the P-base was employed to generate more diverse libraries. In Chapter II, 
Step 2 was advanced by generating a whole cell high throughput screening system for 
monooxygenases allowing efficiently to sample the diversity generated in Step1. 
Subsequently, the advanced protocols suitable for the directed evolution methods were 
applied to evolve P450 BM3 for alternative cofactor systems in iterative rounds (Step 3), 
reported in Chapter III.  
 
Chapter I: Advancement of SeSaM  
 
Methods to generate random mutant libraries in directed evolution are limited in functional 
diversity generation. The Sequence Saturation Mutagenesis (SeSaM) method was reported as 
a four step random mutagenesis method overcoming the limitations of epPCR based random 
mutagenesis methods (Wong et al., 2004b). SeSaM targets in contrast to epPCR each 
nucleotide “equally” avoiding mutagenic hot spots, achieving subsequent mutations in a 
codon (up to 37%) (Mundhada et al., 2011), and allowing to adjust mutational biases through 
employed universal bases (Wong et al., 2004b, 2005a; Mundhada et al., 2011). 
The advancement of the SeSaM method was investigated in two approaches. In section 2.1, 
an advanced SeSaM method is reported in which a protocol was developed and optimized for 
implementing the R (ribavirin) base in a SeSaM experiment. The R based protocol was 
afterwards combined with the original P base SeSaM protocol. Combining P and R base 
allows in SeSaM experiments to generate transversions at all four nucleotides of a given 
sequence with an unmatched chemical diversity. Subsequently, in section I.2, Step 2 should 
be further optimized by the use of a blocked base to allow the control of the number of added 
bases by the TDT.     
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I.1 dRTP and dPTP a complementary nucleotide couple for the Sequence 
Saturation Mutagenesis (SeSaM) method1 
 
In this chapter, an advanced SeSaM method in which a protocol for implementing the R base 
in a SeSaM experiment was developed and optimized is report (Fig. 14). The R-based 
protocol was subsequently combined with the P base for generating for the first time 
transversions at all four nucleotides in a combined protocol.   
 
 
 
 
 
 
 
 
 
Fig. 14: Graphical abstract summarizing the work performed in Chapter II, section 2.1: IdRTP and dPTP a 
complementary nucleotide couple for the Sequence Saturation Mutagenesis (SeSaM) method.  
 
The results section is divided into four parts. In the first part, preliminary experiments were 
performed to evaluate the applicability of dRTP in the SeSaM method. In Step 1 cleavage 
positions for subsequent chemical fragmentation are generated by PCR through incorporation 
of phosphorthioated bases. Optimized steps comprise Step 2 (incorporation of dRTP), Step 3 
(polymerase for R-base elongation), and Step 4 (polymerase for amplification) of the SeSaM 
method. In the second part, an optimized dRTP-SeSaM protocol was validated by generating 
a GFP mutant library. In the third part the P- and R-libraries were combined in Step 3 to 
maximize transversions. In the fourth part, a MAP analysis for the diversity generated by 
SeSaM-R, SeSaM-P and SeSaM-P/R is performed (http://map.jacobs-university.de (Wong et 
al., 2006)). 
 
 
                                                 
1 Results partially published: Anna Joëlle Ruff, Jan Marienhagen, Rajni Verma, Danilo Roccatano, Hans-Gottfried Genieser,  
Percy Niemann, Amol V. Shivange, Ulrich Schwaneberg, dRTP and dPTP a complementary nucleotide couple for the 
Sequence Saturation Mutagenesis (SeSaM) method, 2012, Journal of Molecular Catalysis B: Enzymatic 
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1.1   SeSaM Step 2 optimization of dRTP incorporation 
Requirement for an application of ribavarin in the SeSaM method is the acceptance of the 
nucleotide dRTP by TdT. The TdT catalyzed incorporation of dRTP at 3’-OH of a 5’-FITC- 
labeled oligonucleotide served as model experiments to determine conditions leading an 
effective incorporation of dRTP by TdT into ssDNA fragments in libraries. The number of 
incorporated R-nucleotides can be visualized and quantified on an acrylamide gel analysis 
(see Experimental Procedures). The acrylamide gel (36%; Fig. 15) shows the 5’-FITC-
oligonucleotide and each step in the ladder represents the addition of one R-nucleotide. The 
stepwise incorporation proves that TdT accepts dRTP well.  Fig. 15 shows up to four distinct 
bands which represent the addition of up to four R bases.  
 
Fig. 15: a) Phosphorimager analysis of 3’-tailed FITC-oligonucleotides, separated on 36% polyacrylamide gels. 
Lane I, FITC only (control), lane II FITC with TdT catalyzed addition of dRTP (ratio of dRTP to template-DNA 
of 1:5), lane III FITC with TdT catalyzed addition of dPTPαS. b) Quantification of TdT catalyzed stepwise (+1, 
+2, +3) incorporation of dRTP in a fluorescent (FITC) labeled oligonucleotide. Panel B, shows an enlargement 
of Fig. 15 panel A Lane II, to allow better visualization of distinct bands. The incorporated nucleotides are 
marked with the corresponding number of stepwise addition (from 0 to +7). 
 
The quantification of the bands was performed with the AIDA software for image analysis.  
dRTP is incorporated by TdT much faster compared to dPTP which shortens the incubation 
time from 120 min (dPTP) to 15 min (dRTP) (Fig. 15: lane III, indicates the dPTP 
incorporation under the suitable conditions). In addition, the CoCl2 concentration was 
elevated from 0.05 mM to 0.25 mM and the TdT concentration was reduced from 1.6 Uµl-1 to 
0.4 Uµl-1 (total volume 25 µl). In contrast to other unnatural bases, the number of added R-
bases can be adjusted by varying the molar ratio between template-DNA and dRTP (Fig. 15; 
lane II) For an efficient random mutagenesis, the dRTP incorporation conditions should be 
adjusted to up to three dRTP nucleotides to ensure efficient elongation in Step 3. Additionally 
polymerases were previously reported to elongate fragments with subsequent dPTP 
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inefficiently (Mundhada et al., 2011). Fig. 15 panel B, shows an enlargement of Fig. 15 Lane 
II, to allow better visualization of distinct bands. A template-DNA to dRTP ratio of 1:5 leads 
to the addition of two to three R-bases (Fig. 15; lane II) compared to the 5’-FITC-
oligonucleotide without addition (Fig. 15; Lane I). 
 
1.2   SeSaM Step 3 optimization:  Polymerases for elongating R-tails  
Fig. 13 (experiment 2 and 3) (see section 2.12.1) shows the detection system used to 
investigate the abilities of polymerases to elongate ssDNA fragments by dRTP incorporation. 
In total, ten polymerases (Taq, Vent, Deep Vent(exo-), Vent(exo-), DyNAzyme EXT, 9°NM, 
Phusion High-Fidelity, AmpliTaq, AmpliTaq Stoffel Fragment, 3D1) were selected based on 
proof-reading, amplification of “difficult” templates-DNA (GC rich) and experiences from 
dPTP amplification (Wong et al., 2008; Mundhada et al., 2011). Five polymerases (Taq, Deep 
Vent (exo-), Vent(exo-), DyNAzyme EXT, 3D1) could elongate oligonucleotides tailed with 
one R-base independently from the nucleotide in the opposite strand (Fig. 16, a) and Two 
polymerase were not able (Fig. 16, b). Three polymerases (Vent, 9°NM, Phusion High-
Fidelity) were able to elongate the fragments tailed with three consecutive R-bases to a full 
length gene (Fig. 16, c). The elongation efficiency was high, but sequencing results showed 
that an A-base was incorporated at all three R positions. Incorporation of A at R-base 
positions has for instance been reported for RNA-polymerases (Vo et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 16: Gel electrophoresis of the PCR Products generated in the Read activity assay (Fig. 13; in Material and 
Methods section 2.12.1). a) DyNAzyme EXT polymerase, b) AmpliTaq polymerase, c) Phusion High-Fidelity. 
DNA-templates (AAA, GGG, CCC, TTT, GAG, AGA) of 720 bp and generated PCR products of 460 bp 
(indicated by the red frame).  N= negative control, PCR reactions without primers.  
 
Exonuclease activity for R-tailed oligonucleotides was confirmed by incubating R-tailed 
oligonucleotides under PCR condition in absence of dNTPs. On acrylamid gels the truncation 
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of the primer could be observed (Fig. 17 b, lane 3). The R-tailed primers were monitored on 
acrylamide gels to verify the purity of the synthesized primers and to confirm the attachments 
of only one, two or the presence of three R-bases (Fig. 17 a). The two polymerases (3D1 and 
Vent (exo-)) were finally selected for Step 3 of the SeSaM-R method since both were able to 
elongate R-tailed oligonucleotides fragments to full length genes efficiently and lack an 
exonuclease activity. 
 
 
 
 
 
 
 
Fig. 17: Polyacrylamid gels of R-base tailed nucleotides. a) Primer of 23 bp tailed at the 3’-end with R, RR or 
RRR. b) Exonuclease activity check for R-tailed oligonucleotides, Lane 1: Primer tailed with one R-base, Lane 
2: Primer tailed with two R-Bases, Lane 3: Primer tailed with three R-bases after treatement with Vent 
polymerase under PCR conditions (36% polyacrylamid gels stained with Ethidiumbromid). 
 
1.3. SeSaM Step 4 optimization: Polymerases for nucleotide incorporation 
opposite of the R-base 
In Step 4, the R-bases were replaced by a standard nucleotide in the complementary DNA 
strand during PCR amplification (Mundhada et al., 2011). The latter, as “write” termed 
polymerase activity (see 2.12.1 Material and Methods) enables through PCR a product 
formation which allows selecting polymerases capable of replacing R by a standard 
oligonucleotide. All employed polymerases, except AmpliTaq Stoffel Fragment, were able to 
efficiently replace the incorporated R-base by 
unmodified nucleotides and Taq polymerase was the 
most efficient one (Fig. 18). Deep Vent could also be 
used yielded a lower amount of PCR products than 
Taq. For Taq polymerases the ratio of incorporated T 
and C was determined to be ~1.5 to 1 after sequencing 
of 30 randomly selected clones. 
 
 
 
Fig. 18: PCR product of 250 bp generate in the write activity assay and used for cloning and sequencing analysis 
(see Fig. 13;5 in section 2.12.1). Lane 1: 1 kDa DNA Ladder in bp; Lane 2-7: templates used in the read activity 
assay to elongate primers tailed with one R-base, respectively: AAA, TTT, CCC, GGG, GAG, AGA.  
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1.4   SeSaM-R method of EGFP 
Five SeSaM-R libraries of EGFP were generated by targeting T and C bases. The five EGFP 
libraries differ in the polymerase employed in Step 3, (Vent (exo-), three libraries; and 3D1, 
two libraries) and the molar ratio of template-DNA to dRTP (1:5, 1:10 and 1:20 Vent (exo-); 
1:10 and 1:20 3D1). SeSaM libraries with 3D1-polymerase revealed a high fraction of 
unmodified template-DNA (45%; 20 sequenced clones), a notable number of deletions (15%; 
20 sequenced clones) and transversions (31%). Statistical analysis on mutations generated by 
dRTP incorporation in Step 2 was performed by sequencing 29 clones of Vent (exo-) libraries 
with varied molar ratios of DNA EGFP fragment library to dRTP (1:5; 1:10; 1:20). The molar 
ratio of 1:5 (DNA EGFP fragment library to dRTP; 10 sequenced clones) yielded for random 
mutant library generation the preferred results in terms of transversions, deletions, and PCR 
yields. Table S3 (Appendix 6.2.) contains the sequencing results of the 29 clones and Fig. 19a 
shows the obtained amino acid substitution. Only 1 clone had a frameshift mutation and no 
deletion or subsequent mutation could be observed in any clone. The fraction of non-mutated 
EGFP was 27% (8 clones) and 45% of the mutations were transversions. The total number of 
mutations in 29 clones was 33 (1.13 mutations per gene; see Table S3 in Appendix 6.2.).  
 
1.5   SeSaM-P/R method 
In the SeSaM-P/R protocol, the P- and R-base libraries are combined in Step 3 to generate 
transversions at all four nucleotides for increasing chemical diversity. Out of 55 clones 
sequenced, only 3 (5.4%) were non-mutated and 12.7% (7 clones) contained frameshifts or 
deletions. Seven clones (12.7%) had consecutive nucleotide exchanges and 49.5% of all 
mutations were transversions. A total number of 113 mutations with an average of 2.05 
mutations per gene was obtained (Table S3, Appendix 6.2.). 13.2% of the amino acid 
substitutions that are unobtainable by a standard epPCR-method (see Fig. 19b).  
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Fig. 19: a) Obtained amino acid substitution patterns of EGFP, generated by the SeSaM-R method (colored 
fields) calculated with MAP based on the mutational biased determined by sequencing of 29 randomly picked 
clones. b) Obtained amino acid substitution patterns of EGFP, generated by SeSaM-P/R method (colored fields) 
calculated with MAP based on the mutational biased determined by sequencing of 55 randomly picked clones. 
The Y-axis shows the original amino acid species and the X-axis shows the substitution patterns. The 
substitution patterns for 20 amino acid species is indicated from light gray (lowest probability) to dark gray 
(highest probability). Amino acid substitutions that do not occur are colored in white. 
 
 
An additional important performance parameter of random mutagenesis methods is the 
distribution of mutations over the targeted gene. In contrast to the previously reported 
distribution (Wong et al., 2004b), a more homogenous distribution of the mutations could be 
achieved in the SeSaM-P/R method, especially at the last third of the EGFP gene (Fig. 20).  
 
 
 
Fig. 20: Distribution of the mutations generated by the SeSaM-P/R method for EGFP. 
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Fig. 21: Scheme of the SeSaM method. Underlying differences and advancements between previous protocols 
(left column) and the SeSaM-P/R method (right column). SeSaM includes 4 steps: Step 1: A ssDNA fragment 
pool with random length is generated by PCR-amplification with random incorporation of nucleotides with 
phosphorothioate cleavable bonds. Step 2: The ssDNA fragments are tailed by a terminal transferase catalyzed 
reaction with a universal base. Step 3: These tailed fragments are elongated by PCR amplification to full length 
genes. Step 4: Replacement of the universal bases by standard nucleotides through PCR leading to mutant 
libraries with randomly distributed mutations. 
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1.6   MAP analysis of amino acid substitution patterns for SeSaM-R and SeSaM-P/R 
Fig. 22 shows the amino acid substitution patterns calculated by MAP for the mutation biased 
determined by sequencing of randomly selected clones in the mutant libraries of SeSaM-P 
(100 clones), SeSaM-R (29 clones) and SeSaM-P/R (55 clones). Fig. 22 shows on the Y-axis 
for all naturally occuring 20 amino acids in the EGFP wild-type and obtainable amino acid 
substitution patterns (X-axis). The deepening in color represents the probability of amino acid 
substitution which occurs in general at different amino acid positions. Amino acid substitution 
that do not occur are colored in white. Substitutions colored in orange or red are practically 
unobtainable in directed evolution experiments by screening a few thousands clones.  
Comparison of Fig. 22a and Fig. 22b shows that both differ significantly in their amino acid 
substitution patterns. The SeSaM-P/R protocol in which both degenerated bases are employed 
represents from the determined mutational bias that P- and R-substitutions are balanced 
represented in the combined protocol despite a highly modified protocol (Fig. 21). Since as 
basis for calculation the determined mutational biases of randomly picked clones is used one 
could observe a few differences in the amino acid substitution patterns (R  P, E  V, N  
Y, W  S, G  A).  
Comparison of the mutational spectra obtained from random library (Fig. 22a, 22b, and 22c) 
pointed out that the amino acid exchange from hydrophobic to charged and charged to 
charged amino acid is higher in the SeSaM-R method compared to SeSaM-P method.  
 
Fig. 222: Amino acid substitution patterns for EGFP calculated by MAP server. a) SeSaM-P method, b) SeSaM-
R method and c) SeSaM-P/R method. Y-axis shows 20 amino acids that occur in the EGFP wild-type. For the 
MAP-calculation the experimental determined bias from 55 sequenced clones (SeSaM-P/R) and 29 sequenced 
clones (SeSaM-R) of EGFP was employed. Each of the 20 amino acids is shown as one “specie” which takes 
into account all codons encoding the same amino acid. These codons are subjected to three random mutagenesis 
method (SeSaM-P, SeSaM-R and SeSaM-P/R) and the X-axis shows the obtainable substitution patterns for each 
amino acid “specie”. It should be noted that on a single codon level not all shown substituitons are obtainable 
since an average each amino acid specie is encoded by ~3 different codons. Amino acid substitutions that do not 
occur are colored in white.  
                                                 
2 MAP analysis generated by Prof. Dr. D. Roccatano and Rajni Verma (Jacobs University Bremen) 
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Substitutions from charged to hydrophobic amino acid are not possible or occur with low 
probability in even the R or P method but occurs with high probability in the SeSaM-P/R 
method. Additionally, substitution from aliphatic to aromatic (I  F) was possible with 
SeSaM-P/R method suggesting the mutational spectra obtained using both bases (P/R) is more 
diverse compared to using a single universal base in the SeSaM method. 
 
1.7  Discussion 
The SeSaM random mutagenesis method was developed to overcome the main three 
limitations of PCR based random mutagenesis methods which are commonly employed in 
directed evolution experiments. EpPCR based methods produce mainly transitions (A  G 
and T  C) and few transversions (Cadwell and Joyce, 1992). A transition bias has a 
significantly lower chemical diversity on the protein level than a transversion bias (Wong et 
al., 2007b). Additionally, epPCR based methods lack subsequent mutations due to low 
mutation frequencies mutating therefore statistically only one nucleotide of a codon. The 
latter reduces the obtainable amino acid substitutions dramatically (Tee and Schwaneberg, 
2007). SeSaM targets each nucleotide “equally” and therefore avoids mutagenic hot spots. 
The diversity generation is independent from employed DNA-polymerases (Wong et al., 
2004b) and control over mutational bias is achieved in the SeSaM method through application 
of universal bases (Wong et al., 2005a). Increasing the fraction of transversions was identified 
as an attractive goal to improve the chemical diversity of random mutant libraries (Wong et 
al., 2008; Mundhada et al., 2011) and to produce amino acid substitution patterns which are 
complementary to those of epPCR methods. The P-base offered to introduce a transversion 
bias at A and G bases of a gene and the reported R-base complements the transversion bias of 
the P-base by introducing transversions exclusively at T and C bases (see Introduction section 
1.3.). EpPCR methods are often transition biased which limits the chemical diversity on the 
protein level due to the organization of the genetic code and single mutations of epPCR 
methods in a codon substitute for instance hydrophobic amino acids preferentially by 
hydrophobic amino acids (Wong et al., 2007a). SeSaM-Tv-II (Mundhada et al., 2011), in the 
current manuscript referred to SeSaM-P, incorporates transversions (66.2% of transversions at 
A- and G-nucleotide positions (Mundhada et al., 2011)). Fig. 21 (right) shows the 
advancements obtained by employing the universal base R to introduce transversions at T and 
C positions and to incorporate the SeSaM-R protocol to a novel SeSaM-P/R protocol. 
Advancements in Step 1 and 2 led to more diverse fragmentations patterns, in Step 3 the 
single stranded template-DNA is omitted and diversity is increased due to parallel 
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employment of the P- and R-base. EGFP was used as model gene to ensure that the results of 
the developed advanced SeSaM protocols were comparable to previous reports (Wong et al., 
2004b; Mundhada et al., 2011). 
In detail, in Step 1 the SeSaM-P/R method is improved compared to SeSaM-P by addressing 
all four nucleotides and not only A and G nucleotides (Fig. 21). As a consequence the 
fragment library should ideally contain all possible fragment sizes of EGFP and not only 
cleaved fragments at A and G positions. In Step 3, the preparatory step of a single stranded 
template-DNA, to elongate the fragment library of Step 2 to the full length gene, could be 
omitted. The latter is achieved through generation of a forward and reverse library with 
complementary strands. Being able to generate fragments from the 5-prime end and the 3-
prime end doubles the mutation frequency (1.1 SeSaM-R; 2.1 SeSaM-P/R) which can further 
be adjusted within the purification steps (Wong et al., 2008). This can be attributed to 
annealing of complementary forward and reverse strands both harboring for instance a 
universal base (Step 3). The latter can be observed for example at nucleotide position 34, 
which is replaced by different nucleotides in the clones numbered 5, 13, 15, and 22 (Table S3, 
Appendix 6.2.). Exchange of the same nucleotide position to different nucleotides was not 
observed in SeSaM-P or SeSaM-R mutant libraries. Notably, the distribution of the mutations 
within EGFP remained homogenous in the SeSaM-P/R method (Fig. 20).  
 
Comparison of key performance parameters of SeSaM-P, SeSaM-R and SeSaM-P/R  
Table 1 summarizes the key performance parameters of SeSaM-P, SeSaM-R and SeSaM-P/R. 
A comparison of the SeSaM-P (targeting A- and G-nt) to the SeSaM-R (targeting T- and C-
nt) shows that the employed Vent (exo-) can generate 27.7% subsequent mutations at P-base 
positions whereas no subsequent mutation could be obtained in the SeSaM-R library. 
Therefore, achieving subsequent mutations with the R-base represents a main target to 
increase the diversity in SeSaM-P/R further. In addition, the ratio of Ts to Tv is nearly 
doubled in the P-library when compared to the R-library (0.51 for SeSaM-P and 1.2 SeSaM-
R; Table 1). Varying the R-base concentration, altering the number of PCR cycles in Step 3 
and Step 4, and investigating two polymerases (3D1 & Vent (exo-)) did not reduce the Ts/Tv 
ratio below 1.2. SeSaM-P/R has a balanced transition to transversion ratio of 1.0 which is in 
between the ratios of SeSaM-R and SeSaM-P. Fig. 22 shows the main advantages of the 
SeSaM-P/R which lie in the complementary amino acid substitutions patterns of SeSaM-P 
and SeSaM-R. In the diverse SeSaM-P/R protocol (Table 1), the ratio of unmutated DNA is 
reduced compared to SeSaM-R and SeSaM-P, the mutation frequency is nearly doubled and 
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the ratio of unobtainable substitution by epPCR is increased. The fraction of transitions 
(50.5%) remains however significant in the SeSaM-P/R method. The latter can likely be 
attributed to the employed polymerases (3D1, Vent (exo-), Taq in Step 3 and 4) which lack or 
have a “low” proof reading activity.  
 
Table 1: Key performance parameters of SeSaM-P, SeSaM-R and SeSaM-P/R 
 
Aspect SeSaM-Pa SeSaM-R SeSaM-P/R
 
Universal base  
Fragment library generation at nucleotide positions 
Universal base (bias) 
Distribution of mutations 
Single stranded template required in Step 3 
Deletions(%) - frameshifts (%) - Unmutated DNA(%) 
Fraction Ts to Tvb (bias indicator) 
Mutations frequency (substitution / base) 
Fraction of consecutive mutations in sequenced clones (%)
Unobtainable amino acid substitutions by epPCRc 
 
P 
A/G 
1.6 : 1 
Homogeneous
YES 
0 - 0 - 20 
0.51 
1.37 x 10-3 
27.7 
7.2 
 
R 
T/C 
1.5 : 1 
Homogeneous 
YES 
0 - 3.4 - 27 
1.2 
1.57 x 10-3 
0 
3.0 
 
P and R 
A/G/T/C 
- 
Homogeneous 
NO 
0 - 12.7 - 5.4 
1.0 
2.8 x 10-3 
12.7 
13.2 
a Ref.:(Mundhada et al., 2011) 
b Ts = transition, Tv = transversion 
c Does not take into account the probability of each mutations. In other words the stated fraction can be regarded as a “minimal” 
difference. 
 
Decisive for researchers performing directed evolution experiments is the benefit that the 
SeSaM methods provide over epPCR methods. EpPCR methods have been very successful in 
improving enzyme properties despite their limited chemical diversity (Bershtein and Tawfik, 
2008). Fig. 22 compares the amino acid substitutions that are obtainable by SeSaM-P, 
SeSaM-R and SeSaM-P/R. It is important to note that amino acid substitutions with low 
probability (orange; red) are included despite that they are practically not found in directed 
evolution experiments in which a few thousand variants are screened. Differences in the 
amino acid substitutions are therefore higher than the values shown in Table 1 for 
“unobtainable amino acid” substitutions. In addition, the SeSaM protocols allow in contrast to 
epPCR to generate subsets of mutations for instance by only targeting A positions with a bias 
that excludes stop codons or targets only GC positions to AT mutations to reduce the GC 
content in GC rich genes.  
A transition biased method might especially be beneficial for enzyme properties that require 
subtle chemically changes in amino acid substitutions. The amino acid exchanges as a result 
of a transition biased random mutagenesis method are limited in their chemical diversity (e.g. 
hydrophobic to hydrophobic residues). The latter might be beneficial for improving 
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“localized” enzyme properties such as activity, selectivity, or specificity, which require often 
subtle changes. Enzyme properties like solubility, stability (thermal resistance or pH 
resistance) can however likely be improved more efficiently by transversions, which lead to 
chemically more diverse amino acid substitutions (e.g. hydrophobic to charged) (Wong et al., 
2007a). 
 
1.8  Conclusions 
SeSaM-P/R allows for the first time to introduce at all four nucleotides transversion mutations 
which are homogeneously distributed over the targeted gene and which mutate in an ideal 
case each nucleotide of a gene. Advancements compared to SeSaM-P lie in the more diverse 
fragmentations patterns, omitting the use of template-DNA (Step 3), doubling the mutation 
frequency, and chemical diversity due to parallel employment of the P- and R-base.  
The SeSaM-P/R method nearly doubles the number of by epPCR unobtainable amino acid 
substitutions (Table 1) when compared to previous SeSaM methods. Transversions cause 
amino acid substitutions that are naturally not or barely occurring leading to chemically 
diverse amino acids substitution patterns. The latter mutational bias might become beneficial 
for protein reengineering challenges such as improving solubility of proteins in water, 
increasing thermal resistance or stability in organic solvents.  
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I.2  Advancement of the SeSaM method including nucleotide analogs    
 
In the SeSaM method, a crucial step is the elongation of single stranded DNA fragments by 
TdT (Terminal transferase) with a universal base in Step 2 (see section 1.3 and I.1 for 
description of the main steps of the SeSaM method). When more than one base is 
incorporated by TdT the polymerases in Step 3 are not anymore able to elongate the “tailed” 
fragments. This leads to a high ratio of non mutated template in the mutant libraries and 
reduces or prevents the introduction of consecutive mutations. Therefore, the application of 
modified bases by protection groups to control and limit the number of added bases in Step 2 
of the SeSaM method was investigated.  
 
2.1  Nucleotide analogs with chemical cleavable blocks 
A blocked base is a deoxyribonucleotide modified at 3’position of the sugar backbone by 
attaching a chemically cleavable block (Vaghefi, 2005). Different modified bases were 
synthesized by BIOLOG and the enzymatic additions by TdT were investigated in this thesis. 
A key step is the selection a suitable protection group as functional “chemical block”, because 
the catalysis mechanisms of the TdT is highly conserved and restricted by the 3’ end of the 
base (Beabealashvilli et al., 1986; Delarue et al., 2002). If modification occurs at the base, the 
TdT might not be able to elongate the fragments anymore. In Fig. 23 an overview of the 
synthesized and tested bases is given. To simplify investigations BIOLOG synthesized 
blocked dATP (instead of blocked universal bases P or R), which can be used as model base 
and should make no difference in the experimental setup or in the evaluation of the TdT 
performance. In principle, the addition of only one base is expected, if the concept of the 
chemical cleavable block is successful. After the enzymatic elongation by TdT the reaction 
mixture is treated with a de-blocking solution ensuring removal of the chemical block under 
mild conditions without damaging of DNA. After purification these fragments should be 
elongated once more using TdT in a second reaction to generate fragments in which the 
number of bases can be determined by the number of repeated elongation cycles. The 
necessary purification after de-blocking allows the elongation by the polymerase in step 3 of 
the SeSaM method. The experimental setup is described in section 2.12.1, the same FITC-
labeled oligonucleotide (P15, Table S1, Appendix 6.1) was used. 
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    3’-I-xylo-dATP       3’-I-ribo-dATP 
 
 
 
 
 
 
 
 
 
    MANT-dATP      3’-ac-2’dRTP  
 
 
 
 
 
 
 
 
 
 
              3’-O-NH2-2’-dATP 
 
Fig. 23: Overview of the by BIOLOG synthesized blocked bases. Deoxyribonucleotides with chemically 
cleavable blocks attached on the 3’position.  
 
 
2.1.1  MANT-dATP and 3’-ac-2’dRTP 
 
Previously, the MANT-dATP and the 3’-ac-2’dRTP were investigated in several experimental 
setups. The attached chemical blocks were not a hindrance for the TdT and the fragments 
were elongated by several bases (see Fig. 26: lane 5, similar results were obtained). The 
condition to obtain the addition of only one base could not be achieved. 
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 1          2           3          4          5          6 
2.1.2  3’-I-dATP  
 
In contrary, the third analyzed base 3’-I-dATP (2’,3’-dideoxy-3’-iodo-β-D-xylofuranosyl-
adenine-5`-O –triphosphate) could not be added (Fig. 24: lane 3-6) by TdT. The addition of 
the two possible conformations (3’-I-xylo and the 3’-I-ribo-dATP) by TdT was investigated, 
differing by the attachment of the iodine to the sugar backbone (Fig. 23). Several reaction 
parameters were modified, the concentration of TdT (0.4 U/µl to 1.6 U/µl ), the CoCl2 
concentration (0-0.5 mM), the incubation time (increased from 15 min to 180 min), and 
finally the concentration of the base was varied between 2.4 µM and 360 µM. However, all 
attempts remained unsuccessful. Fig. 24 shows the obtained result of one of the analyzed 
conditions; all further results are similar (gels not shown). No band above the fluorescent 
labeled oligonucleotide could be observed, concluding that the TdT is not able to elongate 
fragments with the 3’-I blocked bases.   
 
 
 
 
 
 
 
 
Fig. 24: Terminal transferase (TdT) catalyzed 3‘-tailing with the blocked base 8-xylo-dATP. A 5‘-fluorescein-
labeled oligonucleotide served as model DNA fragment to visualize the 3‘-tailing with a phosphoimager (lane 1). 
Reaction mixtures were separated on acrylamid gels (36%). Lane 2: dPTPα as positive control, lane 3-6: 8-xylo-
dATP at different concentrations.  
 
 
2.1.3  3’-O-NH2-2’-dATP 
 
The fourth investigated blocked base was 3’-O-NH2-2’-dATP. In preliminary experiments the 
addition to a fluorescent labeled oligonucleotide by TdT was performed under the same 
condition as used for the R- and P-base. Fig. 25 shows the addition of the blocked base at 
different concentrations (12 to 96 µM) on a 36 % acrylamide gel. At low concentrations (12 
µM) no addition could be observed, but with increasing concentration a narrow band appears 
with increasing intensity. This leads to the deduction that the base was added by the TdT, but 
the current conditions were not optimal.  
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Fig. 25: Terminal transferase (TdT) catalyzed 3‘-tailing with the blocked base 3’-O-NH2-2’-dATP at different 
concentrations visualized on acrylamid gels (36 %). Lane 1: fluorescent labeled oligonucleotide, lane 2: dPTPα 
as positive control, lane 3 to 6: 3‘-O-NH2-2‘-dATP at different concentrations, respectively 12 µM, 24 µM, 48 
µM, 96 µM. The red arrow indicates the band which appears by addition of one base.  
 
The experimental setup was repeated with addition of CoCl2 (0.25 mM), increasing the 
amount of TdT (from 0.4 to 1.6 U/µl) and the elongation time (from 15 min to 180 min) (Fig. 
26). Increasing the amount of TdT and the elongation time improved significantly the addition 
of more than one 3’-O-NH2-2’-dATP. Fig. 26 shows several bands appearing above the FITC 
labeled oligonucleotide. Each stair of the ladder corresponds to the addition of one base. The 
amount of remaining template is still important. It might be that the base gets deblocked by 
the CoCl2 and for this reason can be added by TdT. The efficiency of base addition can be 
estimated by the number of added bases under identical conditions. In Fig. 26 (lane 2, reaction 
with dPTPαS) single bands cannot be identified, a diffuse smear shows the addition of many 
bases under the modified reaction conditions (increased amount of TdT and incubation time), 
whereas the reaction condition were suitable for the blocked base. Thus, incorporation of 
dPTPαS is more efficient than of blocked bases. When comparing the elongation of dPTPαS 
to dATP, dATP incorporation is even more efficient, underlying the clear-cut inefficiency of 
the blocked base elongation.  
 
 
 
 
 
 
 
 
 
Fig. 26: Terminal transferase (TdT) catalyzed 3‘-tailing with the blocked base 3‘-O-NH2-2‘-dATP visualized on 
acrylamid gels (36 %). Lane 1: fluorescent labeled oligonucleotide, lane 2: dPTPα as positive control, lane 3 to 
5: 3‘-O-NH2-2‘-dATP at different concentrations, respectively 48 µM, 144 µM, and 240 µM. 
 1             2             3             4            5          
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The same experimental setup was repeated without addition of CoCl2 (Fig. 27: lane 2 and 5) 
and with addition of Na-acetate (Fig. 27: lane 3 and 4). Na-acetate and Na-nitrite solution     
(1 M Na-acetate and 0.7 M Na-nitrite) are used for de-blocking of the base. The processivity 
of the TdT was slightly reduced in the absence of CoCl2 and drastically by the addition of 1 M 
Na-acetate. As control, the addition of unmodified dATP was performed. (Fig. 27: lane 4 with 
addition of Na-acetate, lane 2 without addition). Only after long incubation times (>120 min) 
fine bands appeared (similar to Fig. 27). Most likely, the long incubation time or due to buffer 
components of the TdT the base gets partially de-blocked and allows the addition by TdT. 
Another explanation might be that the TdT is able to elongate the base but very inefficiently 
compared to unblocked dATP and dRTP. Furthermore, the de-blocking method is not 
applicable since the inhibition of the TdT activity is problematic for later applications in the 
SeSaM method. A supplementary step to remove the de-blocking reagent is necessary. Under 
the same reaction conditions, dATP is easily elongated by TdT (Fig. 27: lane 2) but only few 
additions were observed after supplementing Na-acetate to the reaction (Fig. 27: lane 4). No 
dRTP elongation (Fig. 27: lane 3) could be observed in presence of Na-acetate compared to 
unmodified reaction parameters, at which 2-3 bases additions were obtained (Fig. 27: lane 5). 
 
 
 
 
 
 
 
 
 
 
Fig. 27: Terminal transferase (TdT) catalyzed 3‘-tailing with the blocked base 3‘-O-NH2-2‘-dATP with addition 
of Na-acetate visualized on acrylamide gels (36 %). Lane 1: fluorescent labeled oligonucleotide, lane 2: dATP as 
positive control, lane 3: dRTP with addition of Na-acetate; lane 4: dATP with addition of Na-acetate; lane 5: 
dRTP.  
 
Nevertheless, the de-blocking procedure was applied and the addition of a second base after 
purification was investigated. The experimental setup included several controls: 
1. Addition of the base without modification of the reaction parameters and without 
addition. 
2. Addition of the de-blocking solution. 
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3. Addition of the de-blocking solution before purification followed by a second 
elongation by TdT. 
4. Addition of the de-blocking solution after purification followed by a second 
elongation by TdT. 
5. Second elongation by TdT without any modification of the sample after first 
elongation. 
In all samples, the elongation by TdT was not observed after addition of de-blocking solution. 
Even without treatment no second addition could be observed. The ratio in the purified 
sample of elongated fragments is very low compared to the amount of non-elongated. 
Additionally, the purification of the reaction mixture after TdT elongation had a very low 
yield after supplementing the de-blocking solution.  
 
2.2   Discussion 
The application of a blocked base in the SeSaM method was the basic concept to control and 
limit the number of added bases in Step 2. Four employed nucleotide analogs (3’-O-NH2-2’-
dATP, 3’-I-dATP, MANT-dATP and 3’-ac-2’dRTP) which were modified on the 3’ position 
of the sugar backbone by the attachment of chemical cleavable blocks with different 
properties were probed for acceptance by the TdT. 
The MANT and the acetyl modification on the base were not a hindrance for the TdT, several 
nucleotides could be added to the FITC-labeled oligonucleotide. The hydrogen bond 
formation which is crucial for the TdT reaction was present (Beabealashvilli et al., 1986; 
Delarue et al., 2002). 
The use of an iodine as cleavable block leads to no incorporation of the nucleotide analog. An 
explanation might be the impossibility of forming essential hydrogen bonds or the decreased 
flexibility in the binding site of the TdT. Looking at the structure of the TdT in presence of 
3’-I-dATP, a sterical clash between the iodine on the 3’ position of the sugar backbone and a 
α-helice of the TdT catalytic center was observed (Fig. 28).   
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Fig. 28: Structure of TdT with I-dATP in the active center. Lila ball displays the I on the 3’ position of the sugar 
backbone.  
 
The incorporation of 3’-ac-2’dRTP was observed, but with very low efficiencies compared to 
the usually used bases dATP and dPTP. When CoCl2 was present in the reaction, the addition 
of several bases was shown. In addition, only one base addition and no increase of the 
incorporated amount over time could be observed without the addition of CoCl2. Leading to 
the conclusion that CoCl2 removed the cleavable block allowing the incorporation of the base 
(Chang and Bollum, 1990). Similar, the nucleotide analogs probably contains some 
impurities, as well as remaining unmodified dATP which can get incorporated and represents 
the band observed on the acrylamide gel. Nevertheless, the de-blocking procedure was tried 
and led to several problems, the recovery after purification was very low and the second 
enzymatic reaction could not be performed because remaining de-blocking solution was 
inhibiting the TdT. The recovered amount of elongated fragments after purification was too 
low for an application in SeSaM. The nucleotide amounts necessary to perform a qualitative 
SeSaM library are commonly 100 fold higher (200 ng). 
 
2.3  Conclusions 
The application in the SeSaM method of modified base on the 3’ position of the sugar 
backbone through protection groups to control and limit the number of added bases in Step 2 
was investigated. The concept of subsequently attached bases by adding one blocked base by 
TdT, followed by de-blocking and incorporation of a second base and a second de-blocking 
was not applicable for the SeSaM method. Further investigations on selected blocked base, 
de-blocking and purification of products from the TdT catalyzed elongation reaction are 
required to improve the yield and to proof a single base addition in each performed step.  
3. Results – Chapter II: Flow cytometry based screening system for P450 BM3 69 
 
Chapter II: Flow cytometry based screening system for P450 BM3 
 
The availability of reliable and efficient pre-screening systems is the main limitation to 
identify beneficial variants in diverse mutant libraries. To accelerate the evolution of P450 
BM3, a flow cytometry based screening system was developed. In this chapter, in the first 
part the whole cell assay based on the conversion of a coumarin derivative is described. 
Furthermore, to provide high throughput screening systems for the alternative cofactor 
systems, a flow cytometer assay based for meditated electron transfer was investigated in the 
second part.  
 
II.1  High throughput screening system for accelerated directed evolution of 
P450 monooxygenases3  
 
In this chapter, the first whole cell ultra-high throughput screening systems for P450 
monooxygenases employing a flow cytometer allowing efficient sorting and enrichment of 
active variants from random mutant libraries with a throughput of 500 events per second is 
reported. The developed flow cytometry screening system does not require double emulsions 
for sorting since the converted fluorogenic substrate 7-Benzoxy-3-Carboxy-Coumarin Ethyl 
ester (BCCE) is retained within the E. coli BL21(DE3) Gold expression host. The ethyl ester 
is cleaved to the corresponding carboxylic acid in E. coli which cannot due to its negative 
charge penetrate easily by diffusion through E. coli membranes in contrast to the 
corresponding ester (Kanaya et al., 1998; Henne et al., 2000). The monooxygenase P450 BM3 
(CYP102A1) (variant F87A) (Schwaneberg et al., 1999a) was selected for development of the 
screening system as model monooxygenase due to its industrial attractiveness and broad 
substrate profile (Appel et al., 2001; Tee and Schwaneberg, 2007; Whitehouse et al., 2012).  
 
1.1  Assay development and proof of principle 
BCCE was synthesized (see section 2.14.2 Material and Methods) and fluorescence was 
recorded upon hydroxylation (see Fig. 29) via O-dealkylation, as previously described for 7-
benzoyloxy-trifluoromethyl coumarin by Cheng et al. using P450 3A4 (Cheng et al., 2009).  
 
                                                 
3 Reprinted (adapted) with permission from Anna Joëlle Ruff, Alexander Dennig, Georgette Wirtz, Milan Blanusa, Ulrich 
Schwaneberg, Flow cytometer-based high throughput screening system for accelerated directed evolution of P450 
monooxygenases, 2012, ACS-Catalysis 2, 2724-2728. Copyright 2012 American Chemical Society. 
3. Results – Chapter II: Flow cytometry based screening system for P450 BM3 70 
 
 
 
 
 
 
 
 
Fig. 29: Scheme of the 7-Benzoxy-3-Carboxy-Coumarin Ethyl ester (BCCE) conversion catalysed by P450 
BM3 variants (Ruff et al., 2012b). 
 
The flow cytometry screening system was developed in two steps. In the first step the variant 
P450 BM3 F87A was employed in investigating the signal to noise ratio in crude cell extracts 
and in a whole cell flow cytometry setup. In the second step the mutant P450 BM3 M3 DM 
(R47F F87A M354S D363H R471C N543S) was randomly mutated (epPCR) and sorted to 
identify more active variants. The mutant M3 DM was evolved for improved electron transfer 
via mediators starting from the reported variant P450 BM3 M3 (R47F F87A M354S D363H). 
(Nazor and Schwaneberg, 2006; Nazor et al., 2008). The flow cytometry based BCCE 
screening system was used as pre-screen to sort out the most active variants and enrich the 
population of active P450 BM3 variants. The sorted variants were subsequently screened in a 
96-well microtiter plate to identify P450 BM3 variants with higher activity towards 
hydroxylation of BCCE (Tab. 2) and to validate the developed BCCE-flow cytometer 
screening system.  
 
Table 2: Kinetic characterization of P450 variants converting 7-Benzoxy-3-Carboxy-Coumarin Ethyl ester. 
Novel substitutions in the parent P450 BM3 M3 DM are highlighted as bold letters. 
Variant kcat [a] Km [µM] Keff [b] 
P450 BM3 M3 DM (R471C N543S) [c] 0.07 ± 0.005 25.2 ± 4.2 0.17 
P450 BM3 M3 DM-1 (R255H)  0.48 ± 0.05 25.3 ± 5.5 1.14
P450 BM3 M3 DM-2 (R203H I401V F423L) 0.24 ± 0.01 34.3 ± 3.4 0.42
[a] [mmol product s-1 mmol–1 P450]; [b] Catalytic efficiency in [min-1 µM-1]; [c] Starting variant P450 BM3 M3 DM = P450 BM3 M3 
(Nazor et al., 2008) + N543S R471C 
 
 
BCCE conversion of P450 BM3 variants displayed a detectable fluorescence (λEx 400 nm and 
λEm 440 nm) and the control samples (pET28a(+)/lacking P450 BM3 gene) (Fig. 30A) 
revealed a low noise-to-signal ratio in MTP. No fluorescence could be detected for E. coli 
cells harboring the pET28a(+) vector without the P450 BM3 gene. Fig. 31 shows a control 
population lacking P450 BM3 F87A (left) and a population expressing P450 BM3 F87A in E. 
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coli (right). The flow cytometer analysis illustrates that both populations can clearly be 
distinguished (Fig. 31; fluorescence intensity and distribution) and yielded a final signal-to-
noise ratio of ~10:1 (Fig. 31; λEx 350 nm and λEm 450 nm).  
 
 
 
 
 
 
 
Fig. 30: Conversion over time of BCCE using cell free lysates with adjusted protein concentration by CO 
titration (Omura and Sato, 1964a, 1964b) (A) and whole cells (B). pET28a(+) (♦) as background signal, variant 
P450 BM3 M3 DM (R47F F87A M354S D363H R471C N543S) (■) and the obtained mutant P450 BM3 M3 
DM-2 (x) (R47F F87A M354S D363H R471C N543S R203H I401V F423L) and P450 BM3 M3 DM-1 (▲) 
(R47F F87A M354S D363H R471C N543S R255H). Novel substitutions in bold and fluorescent signals were 
measured in a 96-well microtiter plate reader. 
 
 
 
Fig. 31: Overlay of the emitted fluorescence from two different cell populations (A; flow cytometer analysis: 
blue cells representing the negative control (E. coli BL21 (DE3) Gold & empty vector pET28a(+) and in orange: 
E. coli BL21 (DE3) Gold cells expressing active P450 BM3 F87A). B: flow cytometer analysis after conversion 
of BCCE with P450 BM3 F87A expressing E. coli  BL21 (DE3) Gold cells and pET28a(+) harboring E. coli 
BL21 (DE3) Gold cells (as negative control). R1 (C) shows the gated population; Side scatter (SSC; log3 scale), 
Forward scatter (FSC; log3 scale) and UV-laser (FL3: λEx 350 nm and λEm 450 nm; log4 scale) were recorded. 
(Ruff et al., 2012b).   
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Additionally, a whole cell conversion of BCCE by P450 BM3 F87A in E. coli (5 x 106 
cells/µl) was visualized and microscopic analysis proved entrapment of the coumarin derivate 
in E. coli (Fig. 32). Fig. 30A shows that conversion in crude cell extracts follows the same 
trend as in whole cells for the variants DM, DM-1 and DM-2 (Fig. 30B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 32: Light microscopy (a1, b1) and fluorescence microscopy (a2, b2) of E. coli cells after incubation with 
BCCE. Figures show results using an empty pET28a(+) vector (a1, a2) and a pET28a(+) vector expressing P450 
BM3 F87A (b1, b2). Fluorescence could be observed in P450 BM3 F87A expressing cells whereas in the 
negative control only a low background fluorescence was observed (Ruff et al., 2012b). 
 
For further evaluation mixed populations consisting of varied ratios of active (P450 BM3 
F87A) to inactive population (pET28a(+) without P450 gene) were merged (ratios of 9:1 and 
1:1) and sorted (threshold >50-fold pET28a(+) RFU). After sorting of both mixed 
populations, cells were plated without further concentration on LBkan-agar plates and 
incubated overnight (37°C). 60 clones were picked and investigated for BCCE conversion in 
96 well microtiter plates. Ratio 9:1 yielded 100 % of active population and ratio 1:1 resulted 
in an increase from 50 to 82 % of active variants after only one round of sorting. This 
demonstrates that the BCCE based flow cytometry screening system can efficiently enrich the 
population of active variants and thereby fulfills requirements postulated for high throughput 
screening systems (Bernath et al., 2004a; Bershtein and Tawfik, 2008). As a final proof, error-
prone PCR libraries (0.05 mM, 0.1 mM, 0.2 mM MnCl2) were generated based on the P450 
BM3 M3 DM variant (R47F F87A M354S D363H R471C N543S). The P450 M3 DM library 
(~104 variants) was sorted and enriched three times. After each round of enrichment the 
percentage of active clones was determined by measuring the BCCE-activity of 90 clones in a 
a1 
a2 
b1 
b2 
E. coli pET28a(+) P450 BM3 F87A
E. coli pET28a(+) P450 BM3 F87A
E. coli pET28a(+) 
E. coli pET28a(+) 
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96 well MTP. After the third enrichment, 600 clones were picked, expressed and subjected to 
activity measurements in MTP employing BCCE as substrate. The “true” standard deviation 
of P450 BM3 activity in 96 well MTP format was determined to be 10 % ensuring a reliable 
detection of improved variants (Wong et al., 2005b). Around 8 % of the re-screened variants 
displayed increased P450 monooxygenase activity for BCCE when compared to the starting 
variant P450 BM3 M3 DM. The three most active variants were sequenced and two turned 
out to have identical substitutions (P450 BM3 M3 DM-1 & P450 BM3 M3 DM-3: R255H, 
P450 BM3 M3 DM-2: R203H I401V F423L). Variants P450 BM3 M3 DM-1 and P450 BM3 
M3 DM-2 were purified and finally used for kinetic characterizations applying varying 
concentrations of BCCE as shown in Figure 33.  
 
 
 
 
 
 
 
Fig. 33: BCCE conversion with purified P450 BM3 M3 DM-1 (R255H) with varied concentration (Ruff et al., 
2012b). 
 
Sequencing results revealed that all four identified substitutions in P450 BM3 M3 DM-1 & 
DM-2 are located in the heme domain of P450 BM3 (R255H & R203H I401V F423L) 
(Whitehouse et al., 2012). Out of four mutated positions, the positions R203H and F423L 
seems not have been reported to influence any P450 BM3 property. Position R255S improves 
alkane hydroxylation (Glieder et al., 2002), whereas position I401P influences electron 
transfer and coupling efficiency of P450 BM3 (Whitehouse et al., 2009). Remarkable 
improvements could be found in variant P450 BM3 M3 DM-1 (R47F F87A M354S D363H 
R471C N543S R255H) where kcat was increased 7 fold and Km remained unchanged (Table 
2). Characterization of variant P450 BM3 M3 DM (R47F F87A M354S D363H R471C 
N543S), P450 BM3 M3 DM-1 (R47F F87A M354S D363H R471C N543S R255H) and P450 
BM3 M3 DM-2 (R47F F87A M354S D363H R471C N543S R203H I401V F423L) 
demonstrates that the developed flow cytometer screening system is capable of identifying 
improved variants in random mutant libraries. A BCCE turnover of >0.07 s-1 can be regarded 
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as lower detection limit and therefore as a prerequisite for flow cytometer sorting of 
population with active and non-active monooxygenase variants. The library of sorted active 
variants can furthermore be used in standard microtiter plate screening systems for P450 BM3 
monooxygenase properties such as organic solvent resistance (Wong et al., 2004a), improved 
selectivity (Tee and Schwaneberg, 2006) and/or activity towards non-natural substrates 
(Reinen et al., 2011).  
 
1.2  Conclusions 
In summary, the first flow cytometer based high throughput screening platform that can be 
applied in directed evolution campaigns of P450 monooxygenases was developed. All 
requirements for an efficient high throughput screening platform were fulfilled and optimized 
(reliable fluorescent reporter; compartmentalization in whole cells and therefore direct link of 
gene- and phenotype). Sorting and enrichment was possible at an excellent throughput of 500 
events per second with an average sampling time of 4 min, corresponding to 1.2 x 105 
screened events per run (theoretically 3.6 x 107 events per day). Variants with up to 7-fold 
increased activity (P450 BM3 DM-1) could be identified from a random mutant library. A 
main advantage of the reported BCCE screening system is the direct sorting of fluorescent 
whole cell (E. coli) omitting the preparation of double emulsions and thereby simplifying 
screening procedures. Furthermore, the presented screening platform is not only restricted to 
P450 monooxygenases, but also could find applications in metagenomic screenings, 
improving protein expression, screening of recombination libraries or electron transfer 
partners. Specifically, P450 monooxygenases that catalyze an O-dealkylation of coumarin 
derivatives (e.g. human CYP3A4) could be employed in the flow cytometer based BCCE 
screening system. Additionally, cellulases, lipases and phosphatases are also capable to 
hydrolase coumarin derivatives.  
 
 
 
 
 
3. Results – Chapter II: Flow cytometry based screening system for P450 BM3 
 
75
II.2  Flow cytometry assay based on w/o/w-emulsification for mediated 
electron transfer   
 
In a flow cytometry screening system, compartmentalization is the essential prerequisite to 
ensure the link between genetic information (genotype) and activity (phenotype) as well as 
enrichment of fluorescent particles (cells) within a population (Griffiths and Tawfik, 2006; 
Bershtein and Tawfik, 2008). Three basic strategies have been developed in the past: 1. Phage 
display, 2. Emulsification (water-in-oil=w/o; water-oil-water=w/o/w) of a catalyst, substrate 
and genetic information and 3. Trapping the fluorescent product within a cell (whole cell 
assay) (Farinas, 2006; Hardiman et al., 2010). Besides handling and further experimental 
requirements, the major drawbacks of emulsification are: a) Encapsulation of multiple cells 
during emulsion preparation (false positive clones) and b) Difficulties in recovery of genetic 
information due to required permeabilization of bacterial membranes for substrate delivery 
(Aharoni et al., 2005b). Consequently, whole cell assays are generally preferred due to easy 
handling, homogeneous shape and volume of the reaction compartment as well as simple 
recovery of cells on agar plates (Griffiths and Tawfik, 2006). These advantages were used to 
develop the whole cell flow cytometry screening system for directed evolution of P450 
monooxygenases (section II.1).  
Emulsions (w/o and w/o/w) can be used to compartmentalize and screen large gene libraries 
for a specific property. The emulsification process (w/o) enables to entrap the protein and 
subsequent products for reporting enzymatic activity in aqueous solution. A second (re-) 
emulsification (w/o/w) generates droplets containing fluorescent markers, which can be 
isolated by fluorescence activated cell sorting (FACS) (Bernath et al., 2004a, 2004b). 
Successful directed evolution of several biocatalysts (e.g. protease, thiolactonase) employing 
emulsification and sorting by flow cytometry are reported (Aharoni et al., 2005a; Wu et al., 
2010; Tu et al., 2011). 
 
2.1  Emulsification of P450 BM3 in presence of Zinc-dust 
The evolution of P450 BM3 for mediated electron transfer requires the compartmentalization 
of the protein in presence of the alternative cofactor (Zn/Co(III)-sep), which cannot be applied 
in whole cell screening systems. A flow cytometry assay based on w/o/w-emulsification for 
mediated electron transfer, would require not only a substrate staying in the water phase but 
potential products have to remain inside the compartment avoiding cross-contamination 
within a population of cells. Therefore, it was significant that the permeabilized P450 BM3 
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expressing cells allowed the conversion of the substrate in presence of Zn-dust and mediator, 
both remaining within the emulsion in the water phase together with the permeabilized cells. 
The substrate BCCE which was used in the whole cell assay could not fulfill this requirement 
as the substrate was hydroxylated by P450 BM3 but had a poor solubility in water. The 
modification of the coumarin derivates by attaching a COOH group lead to more polar 
molecules (Kanaya et al., 1998; Henne et al., 2000). Therefore BCC-acid was synthesized and 
used as substrate in the emulsion as the charge substrate remains in the water phase (the 
synthesis is reported in the experimental section). P450 BM3 expressing cells permeabilized 
with polymixin B were able to convert the substrate with similar efficiency to the BCCE 
substrate in the MTP (Fig. 34).   
 
 
 
 
 
 
 
 
 
 
Fig. 34: Scheme of the BCC-acid conversion by P450 BM3 in presence of the alternative cofactor system 
Zn/Co(III)-sep instead of the natural cofactor NADPH.  
 
The entrapment and the compartmentalization of EGFP expressing cells in w/o/w-emulsion 
and in presence of Zn-dust as well as the mediator served to identify the number of entrapped 
cells and evaluate the shape of the emulsion. The emulsification was performed according to a 
published protocol (Tu et al., 2011) and reported in Material and Methods (section 2.13.2.2). 
Microscopy analysis showed that an average of 1-2 cells was entrapped within the emulsions 
which were equally in roundness and with variable size of around 10-20 µm.  
Finally, the entrapment of P450 BM3 expressing cells (permeabilized with polymixin B), the 
substrate BCC-acid, the water soluble mediator Co(III)-sep and Zn-dust in w/o/w-emulsion 
was performed. When Zn-dust (particle size <63 µm obtained from Carl Roth (Karlsruhe, 
Germany)) applied in microtiter plates was used, the emulsions were sticky and 
inhomogeneous since a “S” shaped population in the flow cytometer is present (Fig. 35). 
Sticky means the emulsions were attached to each other by the oil phase laying around and 
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poorly mixed with the water phase. The “S” shape population can be observed in the plot of 
the FSC against the SSC (Fig. 35). The “S” shape appears after 30 min of incubation and 
increases over time, concluding that the emulsions were degraded during incubation. The 
activity is represented in the plot of the FL3 laser against the FSC, showing the fluorescence 
of the detected particles (Fig. 35). The gated population (Q2) is used to evaluate the increase 
in fluorescent events. But no activity increase over time could be observed as the percentage 
of fluorescent elements present in the gated population Q2 decreased from 1.7% to 0.92%.  
 
a) 
 
 
 
 
  
 
 
 
 
     
     0 min          30 min   90 min    120 min 
b)  
 
 
 
 
 
 
 
 
 
 
     0 min          30 min    90 min    120 min 
 
Fig. 35: FACS-plots of double emulsions, containing  cells, BCC-acid and Zn/Co(III)-sep after 0 min, 30 min, 90 
min and 120 min  incubation. a) emulsion of cells lacking the P450 BM3 gene, b) emulsion containing P450 
BM3 F87A expressing cells. R1 and Q2 show the gated population. Side Scatter (SSC), Forward Scatter (FSC) 
and UV-laser [RFU in Log scale] (FL3: λEx 350 nm and λEm 450 nm) were recorded.   
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Reducing the size of the Zn-dust particles from <63 µm to 5 µm (Zn-dust special 615 from 
Conmet) and 3.5 µm (Zn-dust Superfine 620 from Conmet) in the reaction set up, a clear 
influence on the shape and distribution of the generated emulsion particles was visible. The 
emulsions had a homogenous size distribution but a dispersive SSC (shape) distribution (Fig. 
36). The distribution of the particles in the FSC (size) was in a narrow range but the SSC 
(granulosity) was spreading. Using smaller Zn-dust particles only one major population was 
detected in the SSC and FSC plot, showing good stability over at least 120 min, but 
degradation happening after a 3 hours of incubation. The activity of P450 BM3 F87A in 
presence of the alternative cofactor (Zn/Co(III)-sep) was only slightly reduced in the MTP 
assay applying crude lysate within the reaction mixture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     30 min        1 h              4 h 
 
Fig. 36: FACS-plots of double emulsions, containing E. coli P450 BM3 M3 cells, BCC-acid and Zn/Co(III)-sep 
after 30 min, 1 h and 4.0 h incubation. FL3 [RFU in log scale] = UV-laser signal at λEx 350 nm and λEm 450 nm. 
 
In the flow cytometer analysis, the comparison of emulsions prepared with P450 BM3 
expressing cells and lacking the P450 BM3 gene revealed no detectable activity (Fig. 36),  
that would have been displayed as an increasing fluorescence of the gated population Q2  
(Fig. 36). To obtain not only stable and homogenous, but also an active signal within the 
emulsion, the compartmentalization was repeated varying the emulsification time, the cell 
concentration, the amount of Zn-dust and the temperature. None of these optimization steps 
led to an improvement of the fluorescent signal within the active population.  
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This results were confirmed by fluorescence microscopy and phase contrast analysis of the 
w/o/w-emulsion with P450 BM3, BCC-acid and Zn/Co(III)-sep. A fluorescent signal could 
not be detected. Although the emulsion can be regarded as equally shaped and the size 
distribution mainly homogenous (Fig. 37) more than one cell was encapsulated. 
After sorting encapsulated cells expressing EGFP and P450 BM3 together with BCC-acid, 
Zinc-dust and NADPH, the emulsions were plated on agar plates and incubated overnight, but 
no colonies grew. Cells entrapped by emulsification as well as cells only incubated in 
presence of Zn-dust and without addition were grown overnight on agar plates. In the cases 
where Zn-dust was added, no colonies could be observed; only cells without treatment were 
growing.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 37: Fluorescence microscopy (a1, a2) and phase contrast (b1, b2) of w/o/w-emulsion with P450 BM3, BCC-
acid and Zn/Co(III)-sep.   
 
2.2  Discussion 
The entrapment of P450 BM3 expressing cells (permeabilized with polymixin B), the 
substrate BCC-acid, the water soluble mediator Co(III)-sep and Zn-dust in w/o/w-emulsion 
was performed after optimization of the emulsification process with EGFP cells. When Zn-
dust of particle size <63 µm was used, the emulsion were inhomogeneous. Therefore, Zn-dust 
of smaller particle size was investigated (3.5 and 5 µm), the emulsions were more 
homogenous, but no activity could be detected, nor an increase of the fluorescent signal was 
recorded over time in the flow cytometry measurements. The very low conversion rate in 
presence of the alternative cofactor compared to NADPH could be the reason for the lacking 
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a2 
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b2 Water phase 
Oil phase 
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activity. Possible reason could also be due to the compartementalization procedure that the 
Zn-dust particles get hardly accessible to the mediator and the protein or appearing quenching 
effects.  
Besides the flow cytometry measurements the emulsion were analyzed by fluorescence 
microscopy. No fluorescencent signal could be detected in the fluorescence microscopy of the 
w/o/w-emulsion with P450 BM3, BCC-acid and Zn/Co(III)-sep, because the background 
fluorescence from the oil phase was overlapping with the very low and hardly detectable 
fluorescent signals. 
To exclude as reason for the lacking activity in the emulsified reaction mixture the changed 
Zn-dust brand and particle size, the activity of P450 BM3 F87A in presence of the alternative 
cofactor (Zn/Co(III)-sep) was investigated with crude cell lysate in MTP. Only slightly 
reduced activity was observed with the smaller particle sized Zn-dust (3.5 and 5 µm) 
compared to the usually employed Zn-dust (<63 µm) in the MTP. Nevertheless, the increase 
of the fluorescent signal over time could clearly be observed, showing that P450 BM3 can 
hydroxylate BCC-acid in presence of Zn/Co(III)-sep. In the reaction, 5 mg Zn-dust was 
supplemented with the resin dispenser, which has a decreased accuracy for powders with high 
densities (Zn-dust super fine = 7100 Kg/m³). Subsequently, the activity difference was related 
to the increased quenching caused by the mean density increase.   
In addition to the activity measurements of the encapsulated cells expressing P450 BM3 
together with BCC-acid and NADPH, the survival rate was analyzed. After sorting, the 
emulsions were plated on agar plates and incubated overnight, but no colonies grew. Cells 
entrapped by emulsification as well as cells only incubated in presence of Zn-dust were grown 
overnight on agar plates. In each case, no colonies could be observed indicating that a 
compound within the solution has an inhibitory effect on microbial growth. Zn-dust is widely 
applied as additive in dyes for industrial application to inhibit the microbial growth on 
surfaces exposed to extreme conditions as well as anti-corrosion systems in vehicles, vessels, 
bridges, containers, bulkheads, beams, flood-gates, wind turbines, tanks, screws and rivets 
(www.conmet.de). The inhibitory effect of Zn-dust on the microbial growth does not exclude 
the application as alternative cofactor in a cell free system or when cell recovery can be 
omitted.  
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2.3  Conclusions 
In summary, a flow cytometer-based ultra-high throughput screening assay for directed 
evolution of P450 BM3 towards improved mediated electron transfer with Zn-dust could not 
be developed. On the one hand two requirements for an efficient ultra high throughput 
screening platform could be fulfilled. A fluorogenic compound (BCC-acid) that is 
hydroxylated by a P450 BM3 monooxygenase to a fluorescent reporter could be selected. As 
well as the compartmentalization of the catalyst, the genetic information and the fluorescent 
reporter in a w/o/w-emulsion was performed, but on the other hand two basic requirements 
had to be fulfilled. A reliable distinguishing between active and inactive variants and 
subsequently the enrichment of active clones within a population of cells could not be 
reached.  
The entrapment of P450 BM3 expressing cells (permeabilized with polymixin B), the 
substrate BCC-acid, the water soluble mediator Co(III)-sep and Zn-dust in w/o/w-emulsion 
was successful. Stable emulsion could be generated, but no detectable activity was recorded.  
Neither the fluorescence increases over time nor the regeneration of the cells could be 
obtained. The inhibitory effect of the Zn-dust on the microbial grow was pre-dominent and 
excluded the use of the double emulsion technology for the generation of an assay for the 
evolution of P450 BM3 for mediated electron transfer.   
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Chapter III: Evolution of P450 BM3 for alternative cofactor systems 
 
III.1  Evolution of P450 BM3 towards improved Mediated Electron 
Transfer (MET) 
 
The alternative cofactor system using Zn-dust as electron donor and Co-sep as mediator for 
P450 BM3 which is described as mediated electron transfer was first reported by 
Schwaneberg et al. (Schwaneberg et al., 2000). Subsequently, protein engineering of P450 
BM3 was performed and the best reported variant reached 40% of the turnover compared to 
the natural cofactor NADPH (Nazor and Schwaneberg, 2006). Increased activity in presence 
of the Zn/Co(III)-sep and turnover rates comparable to the natural cofactor NADPH would 
make this system synthetically attractive. 
This chapter of the thesis aims to further engineer P450 BM3 towards improved Mediated 
Electron Transfer (MET) by directed evolution. Starting variant was the mutant M3 (R47F 
F87A M354S D363H) reported by Nazor et al. with a 2.3 fold improved Kcat for the MET 
(Nazor and Schwaneberg, 2006). In previously performed experiments this variant was 
engineered and another variant (N543S) with 1.3 fold improvement was selected from an 
epPCR library. The random library was screened with the pNCA assay (Schwaneberg et al., 
1999a), already reported for successful identification of improved P450 BM3 variants for 
MET. However, the parent gene (M3) as well as the improved variant (N543S) had an 
additional mutation R471C.  
In this thesis, the evolution of P450 BM3 M3 was started first by generating focused mutant 
libraries to investigate the impact of the single position (R471 and N543). Subsequently, the 
obtained best variant (P450 BM3 M3 R471C N543S) was evolved in the next round of 
directed evolution by random mutagenesis approaches. An epPCR and a SeSaM library were 
generated and enriched with the developed high throughput flow cytometer whole cell 
screening system before screening in the MTP for improved activity towards the MET (see 
section II.1). Finally, the positions identified in the random approaches were individually 
saturated and recombined to select the most beneficial amino acid combination for improved 
MET in P450 BM3.  
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1.1   Activity assays for P450 BM3 in presence of Zn-dust and protein 
purification 
 
1.1.1  Fluorescent MTP assay in presence of Zn/Co(III)-sep 
The pNCA assay was reported to be successful for the evolution of P450 BM3 towards 
improved MET (Nazor and Schwaneberg, 2006). To simplify the investigation and enhance 
the sensitivity of the assay the application of a fluorescent MTP assay was established. The 
MTP assay based on the conversion of BCCE (section II.1) could be adapted to determine the 
activity in presence of the alternative cofactor system Zn/Co(III)-sep, additionally to the 
natural cofactor NADPH. The assay could be used as endpoint assay or to perform continuous 
measurements of P450 BM3 activity. The coefficient of deviation was determined to be 13% 
if only one endpoint measurement was recorded after 30 min or 26% in continuous 
measurement mode with 20 sec intervals (Fig. 38).  
 
 
 
 
 
 
 
 
  
Fig. 38: Coefficient of variation of the fluorescent BCCE assay in continuous measurements (a) and as endpoint 
measurement (b).  
 
1.1.2  Calibration curve of 7-Hydroxy-3-Carboxy-Coumarin Ethyl ester (3-CCE) 
The calibration curve of 3-CCE, the obtained product after hydroxylation of BCCE by P450 
BM3, was performed under the same condition as in the reaction mixture. The reaction 
scheme is shown in Fig. 39 and described in the assay development (section II.1) 
 
 
 
 
 
Fig. 39: Scheme of the BCCE conversion catalyzed by P450 BM3. 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 20 40 60 80 100
Sl
op
e 
[R
FU
/m
in
]
Number of clones
26%
0
500
1000
1500
2000
2500
3000
0 20 40 60 80 100
R
FU
 [-
]
Number of clones
(b)(a) 
13% 
Results – Chapter III: Evolution of P450 BM3 for alternative cofactor systems  84 
 
The linear fit of the calibration curve (Fig. 40) in presence of NADPH or the alternative 
cofactor system Zn/Co(III)-sep was used for calculation of the kinetic parameters in section 
III.1.2 and section III.1.3. 
 
 
Fig. 40: Calibration curve of 3-CCE in presence of NADPH (a) or Zn/Co(III)-sep (b) in the reaction mixture 
monitored at λex 400 nm, λem  440 nm. 
 
1.1.3  Thin Layer Chromatography analysis of the BCCE conversion 
In addition to the fluorescent measurements, the activity of the P450 variants was monitored 
by Thin Layer Chromatography (TLC) analysis. The reaction of the BCCE conversion by 
P450 BM3 was analyzed after extraction by TLC to visualize the product formation. The 
products were extracted from the reaction mixture using Dichlormethane (DCM), Ethyl 
acetate (EtAc) or Chloroform (CHCl3) and spotted together with the reference 3-CCE 
(product of the BCCE hydroxylation) (Fig. 41). The upper spot corresponds to the BCCE 
hydroxylation product, the 3-CCE and the lower spot corresponds to the substrate BCCE 
according to the references spotted in line 5/6 and 7. The reaction mixtures extracted with the 
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different organic solvents have both spots indicating that the hydroxylation of the BCCE is 
occurring and the product can be visualized on the TLC.  
 
 
 
 
 
 
 
 
Fig. 41: TLC analysis of the BCCE conversion by P450 BM3 F87A, monitored under UV-light. Lane 1: 
Reaction mixture without substrate; Lane 2-4: Reaction mixture extracted respectively in DCM, EtAc or CHCl3; 
Lane 5 and 6: BCCE hydroxylation product, 7-Hydroxy-3-Carboxy-Coumarin Ethyl ester (3-CCE); Lane 7: 
Substrate BCCE (7-Benzoxy-3-Carboxy-Coumarin Ethyl ester). Eluent DCM : EtAc in ratio 20:1, TLC-plates of 
Silica gel with fluorescence indicator UV254 (Macherey-Nagel, Düren, Germany),  
 
1.1.4  P450 BM3 purification and concentration determination 
Kinetic characterization of selected variants was performed using purified P450 BM3 protein. 
Variants mentioned and selected in the evolution of P450 BM3 for improved DET and MET 
as well as in the flow cytometer assay development were purified. The purification of the 
analyzed P450 BM3 variants was achieved applying a well established purification protocol 
(Schwaneberg et al., 1999b). Exemplarily, the chromatogram of the anion exchange 
purification step and the SDS-page of one selected variant P450 BM3 WT is shown (Fig. 43). 
Peak 1 represents the flow through of the column, containing all proteins which cannot bind 
to the matrix. The proteins which were bound to the column and are eluted at low salt 
concentration (150 mM NaCl) were monitored when the concentration of the elution buffer 
was adjusted to 7% (Peak 2). The P450 BM3 monooxygenase was eluted when the salt 
concentration was elevated to 260 mM NaCl (13% of the elution buffer) and collected in the 
fractions 5-8 (Peak 3). All remaining proteins were eluted at concentration of 2 M NaCl (Peak 
4) to separate from all particles. 
The protein purity was monitored by SDS-page and calculated by determination of the P450 
BM3 concentration at the ratio of the total protein amount determined by BCA-kit. In all 
cases the purity was above 85%. The fractions obtained during the protein elution are shown 
in Fig. 42. On the left side 1 µl purified protein was loaded and on the right side the gel was 
overloaded with 4 µl to monitor residual impurities.  
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Fig. 42: Elution fraction of P450 BM3 purification separated on 10% acrylamide gel and stained with coomassie 
brilliant blue (3-5 ml per fraction). Red arrow indicates the P450 BM3 at 120 kDa; M: pre-stained protein ladder 
from NEB.  
 
 
 
 
 
 
 
Fig. 43: Chromatogram monitored during the purification of P450 BM3 WT by anion exchange chromatography. 
Blue line: UV-detector at 280 nm; Red line: conductivity; Green line: concentration of elution buffer. Peak 1: 
flow through (unbound proteins); Peak 2: elution at 150 mM NaCl; Peak 3: elution at 260 mM NaCl; Peak 4: 
elution at 2 M NaCl.  
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The P450 concentration was determined by CO-normalization (Fig. 44) according to Omura 
et al. (Omura and Sato, 1964a) and calculated according to equation (2) (see 2. Material and 
Methods). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 44: Absorption spectra of P450 BM3 (dilution 1:8) after CO gassing and with subtracted background. 
Background consist of the sample with protein and without CO gassing. P450 concentration: ((0.126-(-
0.032))*8)/91 = 0.014 mM. 
 
 
1.2   Saturation mutagenesis at positions N543 and R471 
Starting from the reported variant P450 BM3 M3, which was engineered by random 
mutagenesis for improved MET, the position N543 and R471 selected in previous directed 
evolution rounds were saturated using a NNK degenerated codon (Reetz et al., 2008). From 
each library 400 clones were screened with the pNCA assay in presence of the alternative 
cofactor system Zn/Co(III)-sep. The screening of the site saturation library at position N543 
did not lead to the identification of improved variants. At position R471, two improved 
variants could be identified and revealed after sequencing (the substitution R471T). In the 
previous directed evolution experiment the parent gene also posed the substitution R471C, 
increasing the complexity of the analyzed and compared variants. No improvement in the 
single mutant (M3+N543S) could be identified.   
To investigate the impact of the position N543, the following variants M3 N543S (R47F 
F87A M354S D363H N543S); M3 N543S R471C (R47F F87A M354S D363H R471C 
N543S); M3 R471C (R47F F87A M354S D363H R471C); M3 R471T (R47F F87A M354S 
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D363H R471T) were generated by site directed mutagenesis (SDM) and after purification the 
kinetic parameters were compared to the variant M3 (R47F F87A M354S D363H) (Table 3). 
All variants showed activity with the natural cofactor NADPH. The single mutant N543S and 
the R471T have a lower Km and R471C an unmodified Km but no significant activity increase 
could be observed. Interestingly, a synergistic effect could be observed in the double mutant 
N543S R471C, the Kcat was 2 fold improved leading to 3 fold increased catalytic efficiency 
(Fig. 45).  
 
Table 3: Kinetic characterization of P450 BM3 variants hydroxylating 12-pNCA in presence of Zn/Co(III)-sep. 
Novel substitutions in the parent P450 BM3 M3 are highlighted as bold letters. 
Variant kcat [a] Km [mM] Keff [b] 
P450 BM3 M3   3.46 0.68 5.0 
P450 BM3 M3 R471C 4.1 0.60 6.8
P450 BM3 M3 R471T 2.48 0.44 5.6
P450 BM3 M3 R471C N543S 8.66 0.50 17
P450 BM3 M3 N543S 4.62 0.50 9.3
      [a] [mmol product min-1 mmol–1 P450]; [b] [min-1 mM-1]; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 45: Plot of the activity measurements used to determine the kinetic parameters of P450 BM3 M3 N543S 
R471C (R47F F87A M354S D363H R471C N543S) (●), and P450 BM3 M3 (R47F F87A M354S D363H) (■). 
Fitting according to the hill equation was performed. 
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1.3   Directed evolution towards improved MET 
To identify new hot spots and improved P450 BM3 M3 variants for the MET, five epPCR- 
and four SeSaM-libraries were generated. The newly developed high throughput flow 
cytometer screening assay for P450 BM3 (section II.1) was applied to enrich and pre-screen 
active clones from the random mutant libraries. Sorted variants were re-screened in MTP 
using substrate BCCE (reported in section II.1).   
 
1.3.1  Generation and screening of error-prone Polymerase Chain Reaction (epPCR) 
libraries 
EpPCR libraries of M3 N543S R471C using 0.4, 0.2, 0.1, 0.05, 0.2 mM MnCl2 were 
generated and enriched three times with the whole cell flow cytometer assay. Fig. 46 shows 
the vector backbone amplification and the generated epPCR products transformed in BL21 
(DE3) Gold LaqIQ1 cells after hybridization by PLICing (Blanusa et al., 2010b) in the vector 
pALXtreme-1a. 104 clones were expressed, sorted and enriched for active clone population.  
 
 
 
 
 
 
 
 
 
 
Fig. 46: PCR products separated by agarose gel electrophoresis and stained with GelRed. Lane M: 1 kb DNA 
Ladder; Lane 1-5 epPCR products of P450 BM3 (3150 bp) with respectively 0.4, 0.2, 0.1, 0.05, 0.2 mM MnCl2; 
Lane N: negative control, PCR reaction mixture without template DNA; Lane 6 and 7: pALXtreme-1a vector 
backbone amplification (~2.5 kDa). 
 
The flow cytometer plot (Fig. 47) shows the enrichment of the active population. Each plot 
indicates the percentage of fluorescent particles above the settled threshold (Q2). The 
threshold was adjusted prior to each measurement and sorting procedure by analyzing cells 
with the pET28a(+) vector lacking the P450 BM3 gene. The population Q2 indicates the 
amount of fluorescent particles in regard to all analyzed elements which are monitored in the 
by size gated population R1. The gated population R1 indicates the particles of similar size 
forming a homogenous population which is considered in the other plots and subtracted from 
the background. The fluorescent population Q2 increased from 2.5 % in the first enrichment 
   M    1      2     3     4     5   N M       6        7     N 
Results – Chapter III: Evolution of P450 BM3 for alternative cofactor systems  90 
 
round to 5.5 % after the second sorting and to 7.8 %  after the third enrichment round 
compared to 1.8 % fluorescent particles in gate Q2 when cells with the pET28a(+) vector 
lacking the P450 BM3 gene are analyzed. The increase of the population in the selected gate 
underlies the enrichment of the active variants.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                    
          Negative control                          Sort 1                                 Sort 2                                     Sort 3 
 
Fig. 47: Flow cytometry plot of the negative control, cells containing pET 28 a(+) lacking P450 BM3 gene; cells 
expressing P450 BM3 epPCR library after three rounds of enrichment. 
 
Finally, the enriched library was re-screened with the fluorescent assay in MTP for improved 
activity in presence of the alternative cofactor system Zn/Co(III)-sep. The selected variants 
(P450 M3 DM-1: R47F F87A M354S D363H R471C N543S R255H; P450 M3 DM-2: R47F 
F87A M354S D363H R471C N543S R203H I401V F423L) for improved activity with 
NADPH and BCCE revealed also to be the most active ones with the alternative cofactor 
system Zn/Co(III)-sep. In addition to the characterization with NADPH, the kinetic 
parameters were determined for Zn/Co(III)-sep (Table 4).  
Table 4: Kinetic characterization of P450 variants converting BCCE in presence of Zn/Co(III)-sep. Novel 
substitutions in the parent P450 BM3 M3 DM are highlighted as bold letters. 
Variant 
Zn/Co(III)-sep NADPH 
kcat [a] Km [µM] Keff [b] kcat [a] Km [µM] Keff [b] 
P450 BM3 M3 DM (R471C N543S) [c] 1.8 44 0.04 4.2 25.2 0.17 
P450 BM3 M3 DM-1 (R255H) 3.0 62 0.05 28.8 25.3 1.14
P450 BM3 M3 DM-2 (R203H I401V F423L)  6.8 63.4 0.10 14.4 34.3 0.42
[a] [mmol product min-1 mmol–1 P450]; [b] [min-1 µM-1]; [c] Starting variant P450BM3 M3 DM = P450BM3 M3 (Nazor et al., 2008) 
+ N543S R471C 
 
The Km values for BCCE in presence of Zn/Co(III)-sep are increased and nearly doubled 
compared to the Km values for BCCE with NADPH. The catalytic efficiency is reduced with 
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Zn/Co(III)-sep compared to NADPH. The NADPH improved variant P450 BM3 M3 DM-1 
(R255H) is only slightly improved with Zn/Co(III)-sep and reaches 10 % of the conversion 
obtained with NADPH. In contrary, the variant P450 BM3 M3 DM-2 (R203H I401V F423L) 
which showed a 3 fold improved Kcat with NADPH reaches 50 % of the NADPH conversion 
with Zn/Co(III)-sep and remains 3 fold improved. This variant P450 BM3 M3 DM-2 (R203H 
I401V F423L) is more efficient than P450 BM3 M3 DM-1 (R255H) with Zn/Co(III)-sep in 
contrary to NADPH where it was found to be vice versa.  
 
1.3.2  Generation and screening of SeSaM libraries 
The next round of evolution was proceeded by the generation and screening of SeSaM mutant 
libraries (Mundhada et al., 2011; Ruff et al., 2012a). The advanced random mutagenesis 
method SeSaM-R reported in Chapter I of this thesis was applied to evolve P450 BM3 for 
MET. The libraries were treated similar to the epPCR libraries enriched by the reported whole 
cell flow cytometry assay and screened with the fluorescent assay in MTP.  
SeSaM was reported to be efficient with genes up to 1500 bp sizes (Wong et al., 2004b). As 
P450 BM3 (3150 bp) exceeds this limitations, the gene was divided (2 times 1500 bp) and the 
two generated libraries were assembled after individual mutagenesis using the PLICing 
cloning technology (Blanusa et al., 2010b) (Fig. 48).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 48: Scheme of the generated SeSaM libraries. 
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Exemplarily, the different steps of the P450-HEME library generation with the SeSaM-R 
method are shown. SeSaM libraries generated with the published SeSaM Tv+ protocol 
(Mundhada et al., 2011) and biased by using the P-base as well as SeSaM libraries including 
the R base following the SeSaM-R protocol (Ruff et al., 2012a) of the P450 BM3 M3 
(reported by Nazor et al. (Nazor et al., 2008)) were generated. The heme and the reductase 
domain were mutagenized individually and recombined by the PLICing method. In total, 16 
individual libraries were generated: for the heme as well as the reductase domain each the 
following 8 combinations: forward and reverse P-library targeting the A and G base; forward 
and reverse R-library targeting the T and C base. In the end, due to the recombination by 
PLICing 92 combination were possible. For example, P-based library of the heme domain 
combined with non mutated reductase domain, or a R-based library of the reductase domain 
and vice versa (Fig. 48, summarized the applied mutagenesis scheme).  
 
The agarose gels and the Experion data were recorded similar for the other libraries (P450-
HEME with SeSaM-P method, P450-reductase with the SeSaM-P and SeSaM-R method). 
 
Preliminary step – optimization of optimal phosphorothiolated nucleotides concentration:  
The optimal ratio of phosphorothiolated nucleotides to unmodified nucleotides for the T and 
C base had to be determined preliminary to the library generation. The agarose gel shows the 
decreasing intensity of the 1.5 kb band and the increasing amount of cleaved smaller 
fragments with increasing concentration of phosphorothiolated nucleotides. The selected 
optimal phosphorothiolated nucleotide concentration was for T reverse 18%, for C reverse 
25%, for T forward 20% and C forward library 30% (Fig. 49).  
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Fig. 49: Agarose gel of the optimal phosphorothiolated nucleotides concentration determination for C or T 
reverse- (A) and C or T forward-library (B). 0-40 indicates the ratio in % of phosphorothiolated nucleotides to 
unmodified nucleotides.  
 
Preliminary step – Preparation of double stranded template-DNA for Step 1 and Step 3: 
The second necessary preliminary step for the SeSaM library generation is the template 
generation for Step 1 and Step 3 of the gene of interest (2.12.2-3). The SeSaM specific 
sequence is attached by PCR to the gene (2.12.2). Fig. 50 shows the agarose gel of the PCR in 
which only one band corresponding to P450 BM3 at 1500 bp is appearing, no unspecific 
binding could be observed.  
 
Fig. 50: Agarose gel stained with GelRed of the preliminary template generation for Step 1 and Step 3. Lane 1: 
forward template for Step 1; Lane 2: reverse template for Step 3; Lane 3: template up for Step 3; Lane 4: 
template down for Step 4. Size of the P450 BM3-Heme gene is 1.5 kb.  
          Reverse C      M               Reverse T 
 
 0     10    20    25    30    35   40             0    10     15    20    25   30    40  
          Forward C         M               Forward T 
 
0     10     20     25    30     35    40              0     10     15     20     25    30    40  
     1        1          2         2          3        3          4         M 
1.5 kb 
A 
B 
Results – Chapter III: Evolution of P450 BM3 for alternative cofactor systems  94 
 
Step 1: Generation of ssDNA fragment pool with random length distribution: 
The generated ssDNA fragment pool with random length distribution can be visualized on 
agarose gels or with the automated electrophoresis system. Fig. 51 indicates the fragments 
displayed with the Experion after cleavage of the phosphorothiolated nucleotides which were 
randomly incorporated by PCR. The band of the uncleaved fragment at 1.5 kb is decreased 
and the number of ssDNA fragments with random length is homogenously distributed. The 
ladder did not run appropriately, the upper band should have a size of 1.5 kb and not like 
stated by the marker on the level of 3 kb. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 51: Automated gel electrophoresis pictures of the ssDNA fragment pool with random length distribution 
analyzed with the RNA-chip-kit (BioRad). Lane L: RNA ladder misleading as it did not run appropriately the 3 
kb band corresponds to the 1.5 kb band; Lane 7: Forward library targeting the C base; Lane 8: reverse library 
targeting the C base; Lane 9: Forward library targeting the T base; Lane 10: reverse library targeting the T base. 
 
Step 2: Enzymatic elongation of single stranded DNA with dRTP and Step 3: Synthesis of 
the full length gene. 
The results of both steps were not recorded. Due to very low yield (<10ng/kb SeSaM 
template) the PCR products could not be visualized on agarose gels.  
 
Step 4: Replacement of universal bases. 
In Step 4 the universal base is replaced by unmodified nucleotides and the PCR product is 
visualized on agarose gels. In a successful generated library the PCR product of step 4  
remains in only one band according to the targeted gene size. In Fig. 52 the resulting library 
of P450 BM3-HEME (1.5 kb) separated by agarose gel electrophoresis is shown. The double 
stranded DNA fragments were used after purification for the hybridization in the expression 
vector. 
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Fig. 52: Agarose gel of the generated PCR products in Step 4 of SeSaM mutagenesis method. CF: Forward 
library targeting the C base, CR: reverse library targeting the C base; TF: Forward library targeting the T base; 
TR: reverse library targeting the T base. of 1.5 kb. Size of the resulting P450 BM3-HEME library is 1.5 kb. 
 
 
After hybridization into expression vector pALXtreme-1a and transformation into Bl21 (DE3) 
Gold lacIQ1 cells, around 104 colonies were expressed and enriched two times with the whole 
cell flow cytometer screening system. The flow cytometer plots (Fig. 53) show size (FSC) and 
shape (SSC) distribution of the target population as well as activity (FL3). Identical criteria 
for screening and selection of active clones were used as for epPCR library. The sorted and 
targeted population Q2 decreased from 29.19% fluorescent particles to 3.73% during the 
enrichment rounds. Nevertheless, the positive and negative control could clearly be 
distinguished; the gated population Q2 includes only 0.36% fluorescent elements in the 
negative control compared to 44.3% with cells expressing P450 BM3 F87A, proving that the 
calibration was performed well and the lasers were operating. The effective enrichment of the 
population could not be reached due to technical problems with the flow cytometer device, 
which were unsolvable in a near time frame. The sorting chamber is required for enrichment 
and sorting of events but not for the analysis of population. For this reason the experiment 
was aborted after the second round of enrichment and 400 colonies after the first enrichment 
round as well as 400 colonies after the second round were randomly selected and screened 
with the fluorescent MTP assay.  
 
 
 
 
 
 
  M        CF      CR       TF       TR        M 
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Fig. 53: Flow cytometry plot of the negative control, cells containing pET 28 a(+) lacking P450 BM3 gene; 
Positive control, cells expressing P450 BM3 F87A; SeSaM library of P450 BM3 M3 after two rounds of 
enrichment (sort 1 and sort 2). 
 
Out of the 800 screened colonies in MTP, 3 % were re-screened and finally 5 with a 1.3-2.3 
fold activity improvement were selected for sequencing (Fig. 54). An influence of the 
substrate concentration on the catalytic efficiency could be observed in the selected variants. 
At low substrate concentrations (25 µM) the variants were up to 2.3 fold improved compared 
to the variant M3, but with increasing BCCE concentration (50 µM) the activity accounts only 
1.3 fold improvement. 
 
 
 
 
 
 
 
 
 
 
Fig. 54: Activity of P450 BM3 variants selected in the SeSaM library screening and re-screening. Conversion of 
BCCE (25 µM and 50 µM) in presence of Zn/Co(III)-sep monitored at λex 400 nm, λem 440 nm. Measurements 
were done in triplicate. Error-bare indicate the error range of the assay. 
 
Sequencing results revealed that all variants had only the substitution F87A, none of them had 
the parent gene configuration (P450 BM3 M3: R47F F87A M354S D363H).  
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255      423      M
 In summary, the screening of random mutagenesis library generated with the SeSaM method 
could not identify new hot spots or variants with improved activity. Nevertheless, the selected 
variant (F87A) had a 2 fold improved activity for the MET compared to the reported variant 
P450 BM3 M3.  
 
1.4   Saturation and iterative recombination of selected hot spots (R255, R203, 
I401, F423) for improved MET  
The position (R255, R203, I401, F423) detected in the screening of the 
random mutagenesis library were saturated in the starting gene P450 
BM M3 DM (R471C N543S) using the degenerated codon NNK. The 
NNK codon was selected instead of NNN to reduce the number of stop 
codons without reducing the number of obtainable amino acid. 200 
clones from each library were screened with the fluorescent MTP 
assay in presence of the alternative cofactor Zn/Co(III)-sep. 
Additionally, the saturation of position R255 in the variant P450 BM3 
M3 DM I401V was screened (Fig. 55). 
Fig. 55: PCR product of the site saturation mutagenesis at position R255 and F423 separated on 1 % agarose gel 
and stained with GelRed. Band at 8000 bp corresponding to the gene P450 BM3 (3150 bp) in the vector 
pET28a(+) (5000 bp). 
 
In all libraries, except the saturation at position R255 in the variant P450 BM3 M3 DM 
I401V, improved variants compared to the variant P450 BM3 M3 could be detected, but none 
of them had an increased activity when compared to variant P450 BM3 M3 DM-2 (R203H 
I401V F423L). Sequencing results of the improved variants showed that on position F423 the 
amino acid substitution to a leucin was predominant, out of 2 sequenced clones both had the 
substitution F423L like in the triple mutant P450 BM3 M3 DM-2 (R203H I401V F423L). At 
position R203 out of 3 sequenced clones 2 had the amino acid substitution R203G and one the 
substitution R203V. At position R255 the substitution R255Q and like in the triple mutant 
P450 BM3 M3 DM-2 (R203H I401V F423L) the amino acid substitution R255H could be 
observed. At position I401, the amino acid substitution I401V could be noticed. The 
additional saturation of position R255 in variant P450 BM3 M3 I401V didn’t lead to 
improved variants. Concluding, from the single site saturation experiments all detected 
positions are relevant for the MET, but substitution at position R255 in addition to I401V 
were not beneficial since variants with reduced activity were observed.  
Since the single mutants were more active than the mutant P450 BM3 M3 DM-1 (R255H), 
the amino acid substitutions were iteratively introduced by SDM into P450 BM3 M3 DM 
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(R471C N543S). The variants were sequenced, expressed and after CO-normalization the 
activity with Zn/Co(III)-sep was compared. The generated variants as well as the selected 
variants in the epPCR-screening are summarized in Table 5.  
 
Table 5: Generated and selected variants which were compared in the activity assay with Zn/Co(III)-sep. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The activity of this generated variants was monitored by the BCCE conversion in the presence 
of the alternative cofactor and is summarized and compared to the improved variants detected 
in the first round of directed evolution (epPCR library) (Fig. 56). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 56: Activity of the P450 BM3 variants generated in the iterative site saturation mutagenesis libraries (lila 
bar) or by site directed mutagenesis (blue bar) and compared to the improved variants selected in the first round 
of directed evolution (red bar). As reference the pET28a(+) vector lacking the P450 BM3 gene is included (green 
bar). Conversion of BCCE in presence of Zn/Co(III)-sep monitored at λex:400 nm, λem: 440 nm after protein 
normalization.  
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Concluding, position R255 and R203 as well as F423 are relevant for the improved MET. Out 
of the tested variants (Table 5), the variant Re-6 (R203V R255Q) and Re-B (F423L R255Q) 
were 1.4 fold respectively 1.15 fold improved compared to the selected variant in the first 
round of directed evolution (DM-2: R203H F423L I401V). Several combinations are 
beneficial, but the best showed to be P450 BM3 Re-6 (R203V R255Q). If the substitution 
I401V was included in addition to substitution at position 423 or 203 (Re-1 and Re-E), the 
activity dropped drastically under the values monitored for the variant P450 BM3 M3 DM-2. 
In addition, the combination of substitution I401V with amino acid substitution at position 
R255 did not lead to any further improvement.  
The evolution pathway starting from the reported P450 BM M3 and leading to the variant 
P450 BM3 Re-6 (R203V R255Q) is summarized in Fig. 57. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 57: Scheme of the evolution pathway starting from P450 BM3 M3 and summarizing the selected variants 
improved for MET. Red trapeze indicates identified positions; blue frames indicate the characterized variants.  
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1.5  Discussion 
This chapter of the thesis describes the aim to further engineer P450 BM3 towards improved 
MET by directed evolution. Besides the preliminary experiments to setup a suitable screening 
system, the purification as well as the determination of the P450 concentration were settled 
according to published protocols (Omura and Sato, 1964a; Schwaneberg et al., 1999b).  
The reported fluorescent MTP assay based on the conversion of BCCE (II.1 and III.1.1.1) 
could be adapted to determine the activity in presence of the alternative cofactor system, 
applying Zn/Co(III)-sep as electron source and mediator. The coefficient of deviation was 
determined to be around 13 % using a single endpoint measurement after 30 min which was 
in the range of applied assays for screening. Standard deviations of less than 15% were 
reported successful for application in directed evolution campaigns (Wong et al., 2005b). 
However, in continuous mode, the coefficient of deviation was nearly doubled (26%) and not 
suitable to be applied as single method to select improved variants in the screening. One 
reason could be the high deviation in the beginning (first 60 sec) of the kinetic measurement 
in which the equilibrium between Zn-dust and Zn2+ in solution is adjusted (Schwaneberg et 
al., 2000). 
In addition to the fluorescent measurements, the product formation by the P450 variants 
catalyzed conversion of BCCE was analyzed by Thin Layer Chromatography (TLC) analysis. 
The reaction of the BCCE conversion by P450 BM3 was analyzed after extraction by TLC. 
The product formation could clearly be visualized allowing the use of this method as fast 
activity check. Furthermore, the product detection was confirmed by this TLC method 
excluding that not only a substrate depletion leading to the fluorescence increase was 
occurring. 
The evolution of  P450 BM3 M3 was undertaken by the screening of saturation mutagenesis 
libraries followed by the generation of focused mutagenesis at position N543 and R471 in 
which a variant P450 BM3 N543S R471C with a 3 fold improved catalytic efficiency as well 
as a 2 fold improved Kcat could be identified. Interestingly, a synergistic effect could be 
observed in the double mutant N543S R471C, the Kcat was improved whereas the single 
mutant P450 BM3 M3 N543S and P450 BM3 M3 R471C did not show any improvement. In 
Fig. 58 the interaction of the amino acid N543 is shown. Both positions are located at the 
FMN-Heme interface, but the amino acid substitution R471 cannot be displayed because 
lying in the non resolved crystal structure part. Therefore, the assumption why a synergetic 
effect between N543S and R471C was observed is difficult to predict. Nevertheless, one of 
the reasons could be that substitutions at position N543 would loss the hydrogen bonds to the 
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amino acid S489 lying in close proximity. Leading to the hypotheses that due to the possible 
weakening of the constitution of two loops a better access of the Co(III)-sep to the e-transport 
chain was reached.  
 
 
 
 
 
 
 
 
 
 
Fig. 58: Crystal structure of P450 BM3. The interaction between amino acid N543 and S489 are displayed. 
 
To identify further improved P450 BM3 M3 variants for the MET, five epPCR as well as four 
SeSaM libraries were generated, enriched with the flow cytometer and screened in MTP with 
the fluorescent assay. The selected variants in the epPCR libraries (P450 M3 DM-1: R47F 
F87A M354S D363H R471C N543S R255H; P450 M3 DM-2: R47F F87A M354S D363H 
R471C N543S R203H I401V F423L) for improved activity with NADPH and BCCE revealed 
also to be the most active ones with the alternative cofactor system Zn/Co(III)-sep. A major 
difference could be observed compared to the obtained kinetic parameters with NADPH; the 
variant P450 BM3 M3 DM-2 (R203H I401V F423L) (3 fold improved Kcat) is more efficient 
than P450 BM3 M3 DM-1 (R255H) with Zn/Co(III)-sep. The best variant with NADPH was 
P450 BM3 M3 DM-1 (R255H). Demonstrating that for the MET the position R203, F423 and 
I401 play an important role. The inefficiency of the alternative cofactor system compared to 
the natural cofactor NADPH is underlined by the increased Km values for BCCE and the 
decreased catalytic efficiency in presence of Zn/Co(III)-sep. In addition, the conversion 
obtainable with Zn/Co(III)-sep only reaches 10 % (P450 BM3 M3 DM-1 (R255H)) and 50%  
P450 BM3 M3 DM-2 (R203H I401V F423L) compared to NADPH. 
 
The identified positions (R203, R255, F423, I401) were individually saturated and the 
beneficial amino acid substitutions were iteratively recombined (Fig. 59). The generated 
variants were compared and the variants Re-6 (R203V R255Q) and Re-B (F423L R255Q) 
      Ser489 
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showed a 1.4 and 1.15 fold activity increase compared to P450 BM3 M3 DM-2 (R203H 
I401V F423L).  
 
 
 
 
Fig. 59: Crystal structure of  P450 BM3: Displayed are the amino acids beneficial for the MET. The upper 
picture shows the amino acid R203 and R47 and a general overview to localize the position mentioned in the 
lower picture. The amino acid R47, F87, R255, M354, D363, I401, F423 are displayed in the lower picture.  
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position F87. Position I401 is located beneath the heme, which allows direct interaction. The 
amino acid substitution I401P is reported to influence conformations of the heme center, and 
most probably also the electron transfer. This would indicate that the electrons are transferred 
from this site to the oxygen in the active center (Whitehouse et al., 2009). 
Amino acid substitution at position R255 are reported beneficial in a variant selected for the 
conversion of short chain alkanes (Glieder et al., 2002; Fasan et al., 2008), indicating that in 
the variants selected for improved MET, the position R255 lying in close proximity to the 
position F87A in the catalytic center is relevant for the substrate conversion and probably not 
influencing electron transfer properties.  
 
In total, out of ten considered and mutated amino acids four arginine (R203, R255, R47, 
R471) and two phenylalanine residues (F423 and F87) were targeted for saturation 
mutagenesis. Thus, mainly amino acids (arginine) with electrically positively charged side 
chains were substituted. Indicating the relevance of positively charged amino acids which are 
beneficial for the transfer of the negatively charged electrons. At amino acids located in near 
proximity to the heme iron cluster or in the substrate entrance channel substitution to amino 
acids with hydrophobic side chains were observed (R47F, F87A, F423L). The amino acid 
located on the surface of the protein at position R203 and R255 were substituted by epPCR to 
amino acids with chemical similar properties, arginine substitute to a histidin in both cases. 
But the best variant in the site saturation library revealed a substitution to an amino acid with 
a hydrophobic side chain at position R203 (R203V), located on the surface of the protein and 
to an amino acid with a polar uncharged site chain at position R255 (R255Q). At position 
I401 and N543 the property of the amino acids remained unchanged.  
Position R203 is located on the surface similar to the previously detected position M354 and 
D363 located in a surface region and reported as relevant for the MET (Nazor et al., 2008). 
Up to now, P450 BM3 crystals soaked with the mediator could not be generated and solved. 
The binding of the mediator or the electron transfer way is not yet described. Two possible 
hypotheses for the interaction principle between the mediator Co(III)-sep and the protein 
P450 BM3 can be postulated. On the one hand the mediator is not entering the protein matrix 
but is shuttling the electron from the outside to the electron transfer chain within the protein 
(Nazor et al., 2008; Güven, 2011). This hypothesis is supported by the finding of hot spots 
located in surface region of the protein. On the other hand the mediator may bind in close 
proximity to the electron transfer chain or near the heme-FMN interface. The electron transfer 
Results – Chapter III: Evolution of P450 BM3 for alternative cofactor systems  104 
 
chain is not entirely described (Whitehouse et al., 2012) but several amino acids (I401, 
W1046) which play a crucial role were identified (Sevrioukova et al., 1999a, 1999b).  
In contrast, the screening of random mutagenesis libraries generated with the SeSaM method 
could not identify any new hot spots. Despite the successful generation of the SeSaM library, 
which was confirmed by sequencing of randomly selected clones, the unsuccessful selection 
of improved variants after screening stays not understood. Additionally, the enrichment step 
using the flow cytometer was not successful to enrich the active population over 3 rounds of 
enrichment to reduce the screening efforts. The decrease of the active population during the 
enrichment rounds was due to technical problems operating the sorting device. Nevertheless, 
the screening of the SeSaM library was proceeded in MTP and variants with improved 
activity could be selected. Sequencing revealed only the substitution (F87A) in all five 
sequenced clones, none of them had the parent gene configuration (M3: R47F F87A M354S 
D363H). This was an unexpected result as F87A variant was not used as template DNA. A 
contamination by the template DNA used for the vector backbone amplification could be 
excluded as in the PCR reaction, pALXtreme-1a P450 BM3 M3, was used as template DNA.  
Interestingly, the selected variant F87A had a 2 fold improved activity for the MET with 
BCCE as substrate compared to the reported variant M3 (Nazor et al., 2008). The Kcat of the 
selected variant depended on the employed substrate concentration. At low substrate 
concentration a 2.3 fold improvement compared to a 1.3 fold improvement at higher substrate 
concentration (BCCE) was observed. The results obtained in this Thesis with BCCE were 
contradictory to the results reported by Nazor. When the F87A variant was identified as 
improved variant for MET, the screening was performed with the pNCA assay and the variant 
M3 was reported as improved for MET compared to F87A variant. (Nazor and Schwaneberg, 
2006). Considering that the kinetic data are dependent on the substrate used to determine the 
activity for MET, the kinetic data reported by Nazor, which were recorded for pNCA, can 
hardly be compared to the data obtained in this thesis for BCCE.  
Nevertheless, the results obtained in this thesis are coherent to the measurements reported by 
Ley et al. (Ley et al. 2012, submitted). Several variants including the M3 and the F87A were 
compared to their catalytic performance in the eMTP. The enzyme in presence of the mediator 
Co(III)-sep was driven in solution by an electrical current, which replaced the Zn-dust as 
electron donor (Ley et al. 2012, submitted). In these experiments F87A was selected as the 
most efficient variant for the MET.  
Altogether these presented data underline the importance to consider the performance defined 
in the electrochemical setup together with obtained kinetic data in solution to ensure that 
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selected variants were improved for the MET. In solution, using Zn/Co(III)-sep as alternative 
cofactor system instead of NADPH, only a statement about the activity and product formation 
rate can be formulated. This data doesn’t allow an assertion about the electron transfer rate. 
Therefore an electrochemical characterization would be required.  
Additionally considering the analysis of crystals soaked with the mediator Co(III)-sep and 
extensive modeling work would furthermore allow to verify the obtained experimental data 
and underline the formulated hypotheses which key amino acid has are responsible and 
important for MET. 
 
1.6   Conclusions 
The evolution of P450 BM3 M3 reported by Nazor et al. for improving the MET could further 
be extended towards increasing activity in presence of the alternative cofactor system 
Zn/Co(III)-sep. Subsequent random mutagenesis libraries were generated by epPCR and with 
the SeSaM method enriched with the flow cytometer assay and screened with the BCCE 
fluorescent assay in MTP. Variant P450 BM3 M3 DM (N543S R471C) with 3 fold improved 
catalytic efficiency (Keff = 17 min-1 mM-1) compared to the variant P450 BM3 M3 (Keff = 5 
min-1 mM-1) and subsequently variant P450 BM3 DM-2 (R203H F423L I401V) which had a 
nearly 4 fold improved Kcat (P450 BM3 DM-2: Kcat = 6.8 min-1, P450 BM3 DM: Kcat = 1.8 
min-1) were identified. Four new hot spots (R255, R203, F423, I401) could be identified, 
which were not reported before for the MET. These identified positions were individually 
saturated and the recombination of the beneficial amino acid substitution led to variants (Re-6 
(R203V R255Q) and Re-B (F423L R255Q) ) respectively 1.4 fold and 1.15 fold improved in 
activity compared to P450 BM3 M3 DM-2 (R203H F423L I401V). Summarizing, the selected 
improved variants give valuable information, which amino acid substitutions are relevant for 
the MET but further investigation through an electrochemical characterization would be 
necessary to confirm an improved electron transfer rate.  
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III.2  Evolution of P450 BM3 towards improved Direct Electron 
Transfer (DET) 
 
The alternative cofactor system using a conductive polymer as electron donor for P450 BM3, 
which is described as direct electron transfer (DET) was reported first by Nazor at al. (Nazor, 
2007). The evolution of P450 BM3 by screening of focused mutagenesis libraries with the    
4-AAP assay was reported to improve P450 BM3 for DET. The best reported variant P450 
BM3 Y51F T577G was 100 fold increased in activity in presence of Baytron P compared to 
the natural cofactor NADPH.   
In this chapter of the thesis, the aim is to further engineer P450 BM3 towards improved DET 
by directed evolution. The PEDOT/PSS formulation is used as reduced polymer modeling the 
DET. Starting variant for the work performed in this thesis is the reported activity improved 
variant P450 BM3 Y51F T577G (Nazor, 2007).  
The conductive polymer used in previous experiments was Baytron P (obtained from H.C. 
Starcks, Leverkusen, Germany).  Baytron P is a conductive polymer containing mainly PSS 
and PEDOT in a ratio of 1 to 2.5. In 2009 the Baytron P formulation was renamed as Clevios 
P by H.C Starcks, but the composition remained similar and unchanged in the ratio of PSS to 
PEDOT, as stated by the company. In this thesis, only the new batch of conductive polymer 
(Clevios P) was available and could be used. Preliminary experiments showed that P450 BM3 
could not hydroxylate the target substrate 3-phenoxytoluene in presence of Clevios P with the 
reported product formation rates for Baytron P. No product formation in presence of only the 
conductive polymer could be observed. Therefore the prerequisites for an efficient screening 
system had to be optimized prior to the mutagenesis and evolution of P450 BM3. The 4-
aminoantipyrine (4-AAP) assay was optimized, the linear detection range was determined and 
the coefficient of deviation of a 96 well plate was calculated. Subsequently, the variant P450 
BM3 was evolved first by focused mutagenesis approach and then by a random mutagenesis. 
Finally, the reaction performed with purified protein was analyzed in detail to elucidate if the 
obtained signal during the activity measurements correlated with product formation or was 
due to the deviation of the background signal.  
 
2.1  Colorimetric screening assay for activity detection in presence of a 
conductive polymer as alternative cofactor 
 
Prerequisite for a successful directed protein evolution is a medium or high throughput 
screening assay allowing to sample the diversity of the generated libraries in an efficient and 
reliable way (Tee and Schwaneberg, 2007). Various medium throughput microtiter plate 
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screening assays were reported for P450 BM3 (Whitehouse et al., 2012). Widespread assays 
are based on depletion of NADPH (Arnold and Georgiou, 2003) as well as others like indol 
hydroxylation (Li et al., 2000, 2008) or pNCA assay (Schwaneberg et al., 1999a). All these 
assays were reported to be very efficient and successfully applied in directed evolution 
campaigns to engineer P450 BM3 towards properties such as activity, stability as well as 
mediated electron transfer (Tee and Schwaneberg, 2007; Whitehouse et al., 2012).  
The 4-AAP assay is a 60 years old detection system developed by Emerson and already used 
in the 1950 by Ettinger and coworkers to detect µg/L levels of phenol in water (Powell et al., 
1984). A phenol-4-aminoantipyrine dye complex is formed by an oxidative coupling reaction 
mechanism (Faust and Mikulewicz, 1967), leading to a p-quinoid species. The extended 
conjugated system causes the change in color from uncolored to purple-red. A screening assay 
based on this phenol detection principle was reported for successful evolution of P450 BM3 
for hydroxylation of aromatic compounds to phenolic products (Wong et al., 2005b). Scheme 
in Fig. 60 describes the 4-AAP detection system reported by Wong et al. (Wong et al., 
2005b). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 60: Scheme of the 4-AAP detection system (Wong et al., 2005b). 
 
In the present study the 4-AAP assay was selected, due to its high sensitivity (50 to 500 µM) 
and reliability to screen for improved P450 BM3 variants. This assay was reported as 
successfully applied to screen for activity improved P450 BM3 variants in presence of a 
conductive polymer (Baytron P) as alternative cofactor system. Fig. 61 shows the reaction 
scheme of the P450 BM3 catalyzed hydroxylation of 3-phenoxytoluene. The subsequently 
formed product, 3-phenoxytoluene, can be detected by the 4-AAP detection system (Wong et 
al., 2005b). 
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Fig. 61: Scheme of the P450 BM3 catalyzed reaction used in the screening assay to improve the catalyste for the 
direct electron transfer. 
 
 
2.1.1 Optimization of 4-AAP assay  
Screening systems with standard deviation less than 15 % have successfully been used in 
directed evolution experiments (Schwaneberg et al., 1999a; Wong et al., 2005b). Preliminary 
experiments showed that P450 BM3 could not hydroxylate the substrate 3-phenoxytoluene in 
presence of Clevios P with the reported product formation rates for Baytron P. The reported 
protocol for the 4-AAP screening system in presence of Baytron P could not be alienated to 
the use of Clevios P. Using this protocol, no activity in presence of Clevios P could be 
detected. This first experiments already indicated that most probably no direct electron is 
present and the previous reported data could not be confirmed. The addition of only the 
polymer without regeneration system, might limit the reaction.  
The very low conversion rates and subsequently the only hardly detectable signal to 
background ratio lead to the addition of NADPH to the reaction mixture in supplementary to 
the presence of the conductive polymer. Just with a clearly detectable activity, the different 
assay parameters could be analyzed and optimized. The described 4-AAP screening assay had 
to be optimised to a 96- well plate format ensuring an easy to handle screening procedure with 
a low standard deviation in presence of the conductive polymer Clevios P. 
Therefore, the amount of buffer (100-500 µl), the buffer type (KPI, Tris/HCl), the buffer 
concentration (0.1-1 mM), the volume of crude lysate (20-300 µl), the cell permeabilization 
method (lysozyme or polymixin B), the substrate concentration (2-10 mM 3-phenoxytoluene) 
and the volume of conductive polymer were varied. Neither the high buffer concentrations nor 
the type of buffer influenced the activity of the protein. The enzyme showed the highest 
activity in a pH range from 7 to 8.5 with an optimum at pH 7.8. Lyzozyme lysed cells 
increased the activity compared to polymixin B permeabilized cells. Increased substrate 
concentration did not increase the activity, proving that the substrate was not a limiting or 
inhibiting factor. Similar, increased DMSO concentration did not increase the activity of the 
protein. On the contrary, the activity decreased with DMSO concentration higher than 5 %.  
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Analogue, no activity could be detected by increasing the volume of cell lysate or the 
concentration of conductive polymer. The conductive polymer Clevios P decreased pH within 
the reaction mixture. The Clevios P stock solution had a pH of around 4. Therefore, only 10 
% clevios could be added to the reaction mixture without any drastic pH drop (pH of the 
reaction between 7.0 and 7.8), involving an enzyme inactivation at low pH range. 
Furthermore, the concentration of the colorimetric reaction compounds (4-aminoantypyrin (4-
AAP) and peroxodisulfate solution) was varied to increase the difference between the 
detectable signal and the background reaction. The colorimetric reaction was reported to be 
efficient at pH > 9 by addition of 0.18 mg/ml of each compound. Due to the acidic pH of 
Clevios P the volume of supplemented quenching buffer (0.1 M  NaOH, 4M Urea) was 
increased from 25 µl (Wong et al., 2005b) to 35 µl, when using in the deepwell format 180 µl 
supernatant to efficiently elevate the pH above 9. By varying the amount of 4-AAP and 
peroxodisulfate solution from 0.075-0.4 mg/ml no increase in the detectable signals could be 
reached. Therefore, the addition of 0.2 mg/ml of 4-aminoantipyrine and potassium 
peroxodisulfate solution (Arnold and Georgiou, 2003) was maintained. In the experimental 
part the screening assay protocol with finally employed concentrations is described.  
 
2.1.1.1 Removal of the conductive polymer  
Besides the optimisation of the screening system parameters an important fact was the 
effective precipitation of the conductive polymer in the reaction mixture to perform the 
colorimetric detection. After enzymatic conversion with permeabilized cells expressing P450 
BM3, the plates were centrifuged to obtain a clear supernatant which was analysed by the     
4-AAP colorimetric reaction and the amount of phenolic products quantified. Since, Clevios P 
is a water soluble dispersion, it was not removable from the reaction mixture by 
centrifugation, the cell free supernatant stayed light gray to black, which disturbs the 
colorimetric detection (Fig. 62).  
 
 
 
 
 
Fig. 62: Reaction mixture of the 3-phenoxytoluene conversion by P450 BM3 (cell free supernatant) with Clevios 
P, after centrifugation. Light gray: Clevios 1:10 dilution; dark black: Clevios P undiluted. 
  
The employed conductive polymer Clevios P had an absorption maximum in the reduced state 
at 650 nm. Fig. 63 shows the adsorption spectrum of Clevios P under reduced and oxidized 
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condition. Even in a dilution of 1:10, corresponding to employed concentration in the 
enzymatic reaction, the absorption spectra was interfering with the detection wavelengths of 
the 4-AAP, measured at 509 nm and 600 nm. The obtained background of the conductive 
polymer was not negligible and was depending on the volume of lyzed protein. Absorption of 
~ 0.35 was reached with a Clevios dilution of 1:10, which corresponds to the concentration 
used in the enzymatic reaction. Additionally, Fig 63 proves that Clevio P is in an oxidized 
state when added to the enzymatic reaction, which is contrat productive as reduced polymer 
with a redoxpotential > -400 mV is required reduction of the enzyme and effective enzymatic 
conversion.  
 
 
 
   
 
 
 
 
 
 
 
Fig. 63: Absorption spectrum of oxidized (■), reduced (▲) and non treated Clevios P (1:10 dilution) (♦). Clevios 
P was oxidized with potassium peroxodisulfate and reduced with Natriumdithionite.  
 
With the aim to develop a screening assay for DET, the interference of the conductive 
polymer with the colorimetric detection had to be solved and was investigated by the addition 
of different additives, filtration and precipitation methods. All parameters mentioned in 
section 2.1.1 assay optimisation, did not solve the challenges applying Clevios P as alternative 
cofactor. Thus, first as simplest method reported effective for Baytron P, the precipitation of 
Clevios was tried by centrifugation. The reactions mixture was centrifuged from 1000 to 
11000 g force as well as at different temperatures. In addition a pH shift and heating the 
reaction mixture up to 95°C was applied before centrifugation. No precipitation of Clevios in 
the reaction mixture could be achieved. Clevios P could only be partially removed from the 
reaction mixture in presence of lyzed cells, observed during the assay optimization. The 
hypothesis was postulated that Clevios P probably binds to an unidentified compound in the 
cell lysate. For this reason, cell debris from cells expressing the empty vector was prepared by 
 
▲  Reduced  
 
♦   No treatment 
 
■    Oxidized 
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sonification and supplemented to the enzymatic reaction. Again, no precipitation could be 
obtained by this treatment. Furthermore, the addition of additives like agarose, SDS, alginat, 
gelatine, binding the polymer to anion, cation exchange and size exclusion matrix like used 
for the protein purification, addition of metal iones (Cu, Co, Zn), filtration though 22 µM 
filters or membranes (cellulose, PVDF, nylon) were investigated without success. Finally, the 
reaction mixture was supplemented with BSA, polymixin B sulfat and lysozyme at high 
concentrations (100 mg/ml). Polymixin B had no effect, after centrifugation the polymer 
stayed in solution. In fact, only lysozyme had an effect. After addition of 5-50 mg/ ml 
lysozyme, Clevios could effectively be precipitated by centrifugation and the supernatant 
remained as clear solution. Fig. 64 shows the supernatant of the enzymatic reaction after 
conversion and Clevios precipitation as pellet using lysozyme.  
Concluding, the conductive polymer could efficiently be separated from the reaction mixture 
so that the color detection was not interferred. The observed correlation between the presence 
of lyzed cells and the increasing Clevios P precipitation became explainable. As the lysozyme 
concentration was increased proportional to the amount of cells in the reaction mixture, the 
improved Clevios precipitation in fact was related to the increasing lysozyme concentration.  
 
 
 
 
 
 
 
 
Fig. 64: Reaction mixture after Clevios P precipitation. a) Reaction mixture identical to the one in Fig. 62 with 
lysozyme treatment before centrifugation. b) Colorimetric assay performed with the supernatant from the 3-
phenoxytoluene conversion with Clevios P.    
 
 
2.1.1.2 Influence of the conductive polymer formulation 
The detectable activity in presence of the conductive polymer remained very low, also after 
the described optimisation of the assay. To improve the enzymatic conversion rate several 
conductive polymer formulation similar to Clevios P were tested (Table 6). The formulation 
contended different ratios of PEDOT/PSS and additives like organic solvents and polymeric 
binders.  
 
 
 
 
a 
b 
3. Results – Chapter III: Evolution of P450 BM3 for alternative cofactor systems 112 
 
60
70
80
90
100
110
120
PH 510 P PH FCPP SHT FE
R
el
at
iv
e 
ac
tiv
ity
 c
om
pa
re
d 
to
 
C
le
vi
os
 P
Clevios formulation
Table 6: Overview of the available Clevios formulations and the specifications (Quelle: H.C. Starcks). 
 
  
moderate conductivity                     high conductivity 
 
After addition of 5% Demethylsulfoxid              
PEDOT:PSS 
ratio 
Viscosity at  
100 s-1 [mPas] 
Solid Content 
[%] 
Clevios P  1:2.5 60-100 1.2-1.4 
Clevios PH  1:2.5 Max. 25 1.2-1.4 
Clevios PH 510  1:2.5 20-100 1.5-1.9 
Clevios S HT  1:2.5 3-5 dPas Not specified 
Clevios F CPP 105 DM  1:2.5 30-60 1.0-1.4 
Clevios F E  1:2.5 40-80 2.2-2.6 
                                         
 
The activities of the enzymatic conversion in presence of the conductive polymer formulation 
were determinated and compared to the activity obtained with Clevios P, considering the 
addition of equal Clevios P volumes for the enzymatic reaction (Fig. 65). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 65: Influence of Clevios P formulation on the enzymatic activity 
 
With the assumption that the signal obtained in the activity assay can be considered as 
activity, Clevios FE showed the highest product formation rate. Nevertheless, the difference 
in activity was less than 12%, which is in the error range of the 4-AAP assay (Wong et al., 
2005b). Clevios P was maintained for further experiments as the activity increased not more 
than 10%. More probable would be the conclusion that no product formation is obtained. Due 
to this observation and to keep data comparable to cooperation partners and previous 
measurements Clevios P was used for further investigations.  
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2.1.2 Linear detection range of the 4-AAP assay  
The adapted assay allowed the detection of phenolic product in presence of the conductive 
polymer Clevios P in a range from 0.1–0.6 mM. Hydroxylated 3-phenoxytoluene was not 
commercially available, therefore phenol was selected as reference compound according to 
Wong et al. (Wong et al., 2005b). The calibration curves were established in triplicate 
maintaining the same conditions as in the assay procedure (Fig. 66). To avoid the influence of 
lysozyme or Clevios P on the phenol concentration in the samples, calibration curves were 
performed with and without addition, but no adsorption of phenolic compounds could be 
observed. Equation (1) and (2) were obtained by linear fitting of the calibration curve data and 
applied for calculation of generated product amounts.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 66: Calibration curve of the 4-AAP assay for phenol detection. 
 
 
 
2.1.3 Activity check and standard deviation in 96 well plate format 
 
The detectable activity in presence of the conductive polymer remained very low, also after 
optimisation of the MTP screening assay. Commonly, the product formation rate was 10 fold 
lower with the alternative cofactor as with the natural cofactor NADPH. The detected     
OD509 nm increase after 1h conversion was around 0.03 with Baytron P compared to 0.3-0.8 
with NADPH, which was in case of Clevios P under the reported detection limit for the 4-
AAP assay. Nevertheless, the standard deviations of 96 well plates were determinated with 
Clevios P to be 7.4% for P450 BM3 WT, 3.7% for P450 BM3 Y51F and 4.8% for P450 BM3 
Y51F T577G (Fig. 67). All assay optimization and activity check were performed with the 
assumption that the signal obtained in the activity assay can be considered as product 
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formation and is not due to deviation of the background signal. The absorbance values of the 
cells expressing empty vector were high compared to the expected active and improved 
variant P450 BM3 Y51F T577G. Concluding, the absorbance difference between the non 
mutated P450 BM3 WT, the reported improved variant Y51F T577G, and the empty vector 
was hardly detectable. Leading to the conclusion that no activity could be detected. This is 
only due to the lack of a suitable electron donor, Clevios P without applying a reducing 
potential and without regeneration system cannot deliver electrons to the enzyme. The 4-AAP 
assay itself is working because when NADPH is supplemented to the reaction, a clear activity 
increase and difference between the empty vector and the P450 BM3 variant can be measured.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 67: Standard deviation in 96 well plates format of the 3-phenoxtoluene conversion in presence of the 
conductive polymer Clevios P as alternative cofactor system by P450 BM3-WT (♦), pET28a(+) empty vector 
(●), P450 BM3-Y51F (▲) and P450 BM3-Y51F T577G (●). Product detection with the 4-AAP assay. 
 
Mutations inside the P450 BM3 genes were verified by sequencing and the activity 
measurements done in triplicate to ensure that a permute of the plasmids could be excluded. 
However, after solving the main problem which made measurements in 96 well formatted or 
with crude cell lysate impossible, the detectable activity stayed very low and was hardly to 
differentiate from the vector lacking the P450 gene (Fig. 67), the product formation rates of 
P450 BM3 WT were even lower. Only variant P450 BM3 Y51F T577G showed higher 
absorption values as pET28a(+) vector lacking the P450 BM3 gene. 
Nevertheless, the optimised assay could be employed to evolve P450 BM3 for DET since the 
assay has a low standard deviation. The detection of variants with improved activity would be 
possible. As for proteins engineered and screened for new properties the starting gene does 
not or only very barely pose the ability of the targeted properties.  
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2.2  Protein engineering of P450 BM3 for improved direct electron 
transfer (DET)  
 
The hypothesis formulated by Nazor et al. that mutations at the FMN interface could widen a 
water access channel for the polymer PEDOT/PSS to the FMN domain facilitating the 
electron transfer was traced for Clevios P. Additionally, screening of focussed mutant 
libraries at positions in proximity to the FMN binding site yielded a mutant bearing the amino 
acid exchange T577G with a significantly improved activity with the conducting polymer 
Baytron P (PEDOT/PSS) (Nazor, 2007). Therefore, based on crystal structure investigations, 
four amino acid positions were selected with the aim to bring the water-soluble conducting 
polymer PEDOT/PSS in close proximity to the electron transfer chain of P450 BM3. The 
structure guided approach was complemented by a random mutagenesis approach, in which 
epPCR libraries were generated to detect new hot spots and evolve the catalyst P450 BM3 for 
improved direct electron transfer (DET). 
 
2.2.1 Role of the FMN in P450 BM3 Y51F T577G 
 
Besides the evolution of P450 BM3 for improved DET, the understanding of the function 
relationship of the DET is of importance. Screening of a site-saturation library at amino acid 
position 577 close to the cofactor flavinmononukleotide (FMN) yielded a mutant bearing the 
amino acid exchange T577G with a significantly improved activity using a conducting 
polymer such as Baytron P (PEDOT/PSS) (Nazor, 2007). Nazor et al. proposed that the 
conductive polymer is binding in close proximity to the FMN binding site and could directly 
transmit electrons to the electron transfer chain. This raised up the question for the importance 
of the bound FMN cofactor. The T577G substitution might lead to breaking of hydrogen 
bonds to W574 or FMN (Nazor, 2007).  Loss of either of them would allow more flexibility 
in the polypeptide backbone, leading to a destabilization of the FMN in its binding cavity 
(Nazor, 2007). The variant Y51F T577G was reported to show no activity with the natural 
cofactor NADPH, this postulated the hypotheses that the FMN is lost due to the mutation 
T577G and the FMN cavity is increased, which would allowed easier access of the conductive 
polymer to the electron transfer chain.  
Hence, it was reasonable first to verify the fate of the cofactor FMN upon substitution at 
position T577 before choosing further amino acid positions for the construction of further 
structure guided mutant libraries of P450 BM3. FMN can be detected through his specific 
absorption or fluorescence spectrum. Absorption maxima at 370 nm and 450 nm as well as 
fluorescent properties (λex 450 nm and λem 520 nm) (Viñas et al., 2004) are characteristic for 
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the unbound form of  FMN. Since the cofactor flavinadenindinukleotide (FAD) of the 
reductase-domain shows a very similar fluorescence spectra compared to FMN, reductase-
deficient mutants were constructed. The truncated versions of P450 BM3 Y51F and P450 BM 
3 Y51F T577G were constructed by PCR amplification and cloned in pET28a(+) by the 
restriction enzymes NcoI/EcoRI and T4-ligase (Fig. 68).  
 
 
Fig. 68: Scheme of the generated FAD deficient P450 BM3 variant. P1-P4 indicates the primer used, sequences 
are given in the Table S1 (Appendix 6.1). 
 
Both proteins were expressed and purified according to standard protocols (Schwaneberg et 
al., 1999b). The purity of both variants was checked on a SDS-gel (Fig. 69: Lane 2 and 3). 
The truncated protein has a size of around 75 kDa and purity with up to 90 % were generated.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 69: SDS-page of the purified P450 BM3 Y51F T577G truncated protein. Lane M: PageRuler Prestained 
Protein Ladder (Fermentas), Lane 1: non bond protein washing fraction, Lane 2 and 3: purified P450 BM3 Y51F 
T577G truncated at the FMN domain.  
 
To identify the presence of the FMN, absorption and fluorescence spectra were recorded and 
compared (Fig. 70). The obtained data for variant P450 BM3 Y51F T577G was compared to 
the truncated P450 BM3 Y51F to investigate the impact of the substitution T577G on the fate 
of the FMN. 
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(b) 
 
 
 
 
 
 
 
 
 
 
(c)  
 
 
 
 
 
 
 
 
 
 
Fig. 70: Fluorescence emission spectra from 460 – 700 nm of (a) FMN, (b) purified Heme-FMN-domain of P450 
BM3 Y51F and (c) purified Heme-FMN-domain of P450 BM 3 Y51F T577G (λex 440 nm). 
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Fig. 71: Absorption spectra from 350–600 nm of Buffer (♦) (KPI 0.1M pH 7.5), purified Heme-FMN-domain of 
P450 BM3 Y51F (■) and purified Heme-FMN-domain of P450 BM3 Y51F T577G (▲). 
 
Recorded fluorescence spectra indicated that the FMN is not lost after introducing amino acid 
substitution T577G (Fig. 71). The characteristic peak for FMN at 520 nm was observed in the 
absorption/fluorescence spectra as well as in the full sized P450 BM3 protein and the 
truncated variants (Y51F and Y51F T577G). The characteristic spectrum was not observed in 
fractions which were earlier eluted from the purification column and only contained very low 
P450 BM3 amounts. No differences in the absorption spectra could be observed. Each 
spectrum of the variants revealed an absorption maximum at 417 nm, corresponding to the 
heme iron cluster. This peak was overlaying the absorption maxima at signal 370 nm and 450 
nm which are characteristic for the FMN. However, the FMN cannot clearly be distinguished 
within the absorption spectra. T577G compared to the non mutated variants, the FMN is not 
missing.  
 
2.2.2  Structure guided mutant libraries  
 
Accordingly to the results in section 2.1, five residues in the FMN-cavity of P450 BM3 were 
selected to enhance the activity of the monooxygenase with the conducting polymer Clevios 
P. Based on bioinformatics and structural analysis of P450 BM3 four structure-guided mutant 
libraries of P450 BM3 Y51F T577G at positions 488, 536, 537 and 574, which most likely 
interact with FMN through hydrogen bonds, were constructed (Fig. 72). Additionally, 
position 471 was selected, which was indicated as being essential for P450 BM3 activity in 
libraries generated for Mediated Electron Transfer (MET) (section III.1). 
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Fig. 72: Crystal structure of the P450 BM3 FMN-binding site. Displayed are the cofactor FMN (green), residue 
T577 (orange) and the four residues G488, Y536, N537 and W574 (yellow, blue, tan, orange) which were 
selected for site-saturation mutagenesis. 
 
 
2.2.2.1  Screening of SSM libraries  
  
All sites (R471, G488, Y536, N537, and W574) selected for the structure guided mutant 
libraries were NNK saturated using P450 BM3 variant Y51F T577G as template. Amino acid 
residue W574 was additionally saturated in the variant Y51F. 400 clones of each library (in 
total 1600 colonies) were screened with the 4-AAP assay and the substrate 3-phenoxytoluene 
for improved activity with the conducting polymer. The screening result of one plate is 
represented as example in Fig. 73. The activity increase of the improved variants compared to 
the starting variant P450 BM3 Y51F T577G stayed below 15 %.  
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Fig. 73: Example of screening results from one 96 well plate from SSM 471 library. () clones from SSM 
library, () clones with improved activity, () wells with only media, () clones with parent gene Y51F T577G 
served as reference, (▬▬) represents the arithmetic average of the activity from the starting variant, serving as 
threshold to select improved variants.  
 
After re-screening of the best variants (10 % of each library), relative activities with crude 
lysate compared to the parent P450 BM3 Y51F T577G were determined (Fig. 74). 
Subsequently, two to four selected clones of each library were send for sequencing to obtain 
an overview which AS substitutions were predominant (Fig. 75). Sequenced mutants (G488E; 
G488E; T533K A534E Y536S; Y536S; W574I) which showed an improved activity were 
subcloned by PCR (primer P6/P7, Table S1, Appendix 6.1) in pCWori(+) vector. The 
restriction sites BamHI/EcoRI and T4-ligase were used to ligate the insert in adequately 
prepared vector. 
 
Fig. 74: Relative activities of several P450 muteins with the conducting polymer PEDOT/PSS and the 4-AAP 
assay compared to the parent P450 BM3 Y51F T577G. Variant P450 BM3 Y51F T577G was the starting variant 
and is labelled in grey.  
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Almost all amino acids exchanges were from hydrophobic to charged amino acids. 
Interestingly, the best variant (1.4 times the activity of the parent) carries two additional and 
unexpected amino acid exchanges at position 533 and 534 besides the anticipated substitution 
at position 536 (probably due to misannealing of the mutagenic primer).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 75: Sequencing results of selected variants of structure guided mutant libraries. Blue labelled substitution 
showed a minor (>10 %) activity improvement. 
 
 
2.2.2.2  Simultaneous saturation of position G488 and W574 
 
In parallel to the consecutive SSM strategy (section 2.2.2.3) a simultaneous SSM was 
generated by overlap extension PCR. The position G488 and W574 lying in close proximity 
were simultaneously NNK saturated in the variant P450 BM3 Y536S T533E A534E which 
was selected in the focussed mutant library (section 2.2.2.1). The scheme in Fig. 76 describes 
the PCR setup. Three separated PCR fragments A, B and C were generated and purified by 
gel electrophoresis. The fragments were annealed and amplified by overlap extension PCR to 
generate a full length fragment of 2670 bp (Ho et al., 1989). The restriction sites MfeI/EcoRI 
and T4-ligase were used to ligate the insert in the variant P450 BM3 F87A to generate the full 
length gene (3150 bp). Screening of 1800 clones was done with the 4-AAP assay and the 
substrate 3-phenoxytoluene. The ratio of inactive clones in the mutant library was higher than 
40%. Nevertheless, no variants with improved activity could be identified.  
 
 
 
 
 
 
 
P450 BM3 Y51F T577G 
P450 BM3 Y51F  
 G488 → G488M, G488E, G488F, G488S 
 
 Y536 → Y536S, Y536S T533K A534E 
SSM 
 N537 → N537K, N537L 
 
 W474 → W574P
SSM W574 → W574I, W574I, W574A, W574S 
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Fig. 76: Scheme of the overlap extension PCR used to generate a multiple SSM at position G488 and W574 in 
the variant P450 BM3 Y536S T533E A534E. 
 
 
2.2.2.3 Iterative SSM libraries 
The saturated positions (G488, Y536, N537, and W574) in section 2.2.2.1 were iteratively 
recombined, even if the obtained variants showed minor (1.1-1.4 fold) activity improvements. 
400 clones of each generated library were screened with the 4-AAP assay and the substrate 3-
phenoxytoluene and 10 % were re-screened.  Finally, three clones were selected and sent for 
sequencing. Table 7 gives an overview of the generated libraries and the obtained results. 
Saturation of the position W574 (without T577G) in the Y536S and G488E variant did not 
lead to improved variants and the selected clone in case of Y536S-library revealed to be the 
template gene. Only two selected clones of the saturation at position 574 (with T577G) in the 
variant Y536S showed minor improvement (1.1-1.2 fold) compared to the starting gene Y51F 
  F87A-fwd  
488-rev 
488-fwd 
574-fwd
574-rev
P450-rev-EcoRI 
NNK 
NNK 
  Fragment A: 1203 bp 
 Fragment B: 258 bp 
Fragment C: 1425 bp 
261 bp   1464 bp     1722 bp    3150 bp 
Fragment A & B & C : 2889 bp
P450-rev-EcoRI
F87A-fwd 
 MfeI 
 
 
  458 
  EcoRI 
 
 
   3150 
488     Y536S           574 
 
NNK   NNK 
Step 1: Generation by PCR of three fragments A, B, C  
Step 2: Overlap Extention PCR, annealing of the fragments (A, B, C) 
Step 3: Restriction enzyme cloning of the full length gene by MfeI/EcoRI and T4-ligase  
3. Results – Chapter III: Evolution of P450 BM3 for alternative cofactor systems 123 
 
T577G, but the activity was comparable to the template gene (Y536S). The identified amino 
acid substitution was W574T and occurred in two sequenced clones.  
 
Table 7: Overview and sequencing results of the generated iterative SSM libraries. 
Template gene SSM at position 
Sequencing results 
of improved variants 
Activity 
improvement 
P450 BM3 Y51F G488E 574 - no improvement 
P450 BM3 Y51F G488F 574 - no improvement 
P450 BM3 Y51F Y536S T533K A534E 574 template gene no improvement 
P450 BM3 Y51F Y536S T533K A534E T577G 574 W574T (2 clones) 1.2 fold 
 
Summarizing, this results covered the findings of the multiple site saturation mutagenesis 
(section 2.2.2.2) iteratively as simultaneous saturation of position G488 and W574 did not 
enhance the activity of P450 BM3 for the conductive polymer (Clevios P). 
 
 
2.2.2.4 Summary of results from structure guided mutant libraries  
Selected variants in the focussed mutant libraries were only compared after protein 
concentration normalized by the automated gel electrophoresis. This system could be 
identified as not suitable for the determination of the P450 concentration (see section 2.2.3.2 
where the two methods to determine the concentration were compared). Therefore, the 
product formation rate of the selected variants were re-analysed with CO-normalized protein 
concentrations.  
In summary, out of the 20 selected variants from the structure guided mutant libraries, which 
showed improved activities in the screening, nearly all revealed to be expression variants or 
showed after CO titration only minor improvements compared to the parent strain (4 out of 20 
analyzed clones). Additionally, no variants with improved activity could be identified by 
screening the iterative SSM and the simultaneous SSM libraries at the position G488, Y536, 
N537 and W574. Only the SSM at position R471 revealed a variant (R471C) with 1.5 fold 
enhanced activity for the conductive polymer in crude cell lysate after CO normalization  
(Fig. 77). 
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Fig. 77: Relative activity of improved variants in presence of the conductive polymer Clevios P compared to 
P450 BM3 Y51F T577G after CO normalization. Variant P450 BM3 Y51F T577G was the starting variant and 
is labelled in grey.  
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2.2.3  Random mutagenesis libraries 
The semi rational evolution of P450 BM3 for DET was not successful; no significantly 
improved variants could be identified. Therefore, additionally to the structure guided mutant 
libraries, P450 BM3 was evolved for DET by a random mutagenesis approach to identify new 
hot spots. Two rounds of directed evolution were performed and screened in MTP for 
improved variants.  
 
2.2.3.1  First round of directed evolution – mutagenesis and screening 
In the first directed evolution round, random mutagenesis libraries were generated by error-
prone PCR (epPCR) and screened with the 4-AAP assay for phenol detection (Wong et al., 
2005b). Beside P450 BM3 Y51F T577G a pool of plasmid DNA from the structure guided 
mutant libraries (section 2.2.2) were used as template. In standard epPCR method the gene of 
interest is amplified by PCR under error prone conditions and afterwards ligated by restriction 
enzymes and ligase in the expression vector. In this thesis the standard protocol was followed 
for the epPCR (generation of the insert) but instead of restriction cloning the generated 
epPCR libraries were hybridized by PLICing in the expression vector (Blanusa et al., 2010b). 
For the insert amplification the primer PP3/PP4 and for the vector the primer PP1/PP2 were 
used (see Table S1, Appendix 6.1). The size of the PCR products were checked by agarose 
gel electrophoresis, no unspecific primer binding could be observed, since only one band of 
expected size was present (P450 BM3 = 3150 bp) (Fig. 78). The generated epPCR libraries 
were cloned into the commercially available expression vector pET28a(+) using the PLICing 
cloning technology (Blanusa et al., 2010b). 
 
 
 
 
 
 
 
 
 
Fig. 78: Four epPCR products separated by agarose gel electrophoresis. Lane 1: negative control, PCR reaction 
mixture without template, Lane 2-5: Insert of the P450 BM3 epPCR libraries (3150 bp), respectively library I 
(0,05 mM MnCl2 and 2,5 mM MgCl2), library II (0,05 mM MnCl2 and 5 mM MgCl2), library III (0,1 mM 
MnCl2 and 5 mM MgCl2); Lane 6: Gene Ruler 1 kb DNA Ladder. 
 
 1        2          3          4           5          6 
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P450 BM3 variants were expressed in E. coli (DE3) Gold cells. The ratio of inactive clones 
for each library was determined with the 4-AAP assay in 96 well plate format.  
The libraries had an inactivation ratio of 100% when compared to Y51F T577G which did not 
show activity. The coefficient of deviation was low; library I: 15.4%, library II: 13%, and 
library III: 12% and Y51F T577G: 13%, consequently, all three libraries were selected for 
screening. In total, 1000 clones from library I (balanced dNTPs, 0,05 mM MnCl2 and 2,5 mM 
MgCl2), 500 from library II (balanced dNTPs, 0,05 mM MnCl2 and 5 mM MgCl2)  and 500 
from library III (balanced dNTPs, 0,1 mM MnCl2 and 5 mM MgCl2) were screened with the 
4-AAP assay. Five percent were re-screened and the arithmetic average of six measurements 
was calculated. For evaluation the adsorption at 600 nm was subtracted from the 509 nm 
values as well as the arithmetic average of the background signal (results of 4-AAP assay 
with cells expressing empty vector) according to Nazor at al. (Nazor, 2007). The arithmetic 
average A509 – 600 nm of P450 BM3 Y51F T577G was settled as 100 % and the relative activity 
of the muteins was calculated. (Fig. 79 shows as example the obtained screening results of 
one plate from the epPCR library.)  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 79: The relative activity of the muteins compared to the template gene P450 BM3 Y51F T577G (colored 
grey) is displayed. The red bare indicates the arithemetic average of the starting variant P450 BM3 Y51F T577G 
activities, serving as threshold to select improved variants.  
  
After re-screening, 11 variants were selected for further analysis and the protein expression 
was monitored by SDS-Page (Fig. 80), out of eleven mutants five did not show P450 
expression. As none of the tested variants revealed a higher expression level as P450 BM3 
Y51F T577G, the probability of expression mutant presence was decreased considering the 
total protein amount. 
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Fig. 80: SDS page of the expressed muteins from the first evolution round. The red box marks the expected 119 
kDa band. Lane 1-12 respectively: P450 BM3 B1-P1-H2; P450 BM3 B2-P3-A2; P450 BM3 B1-P1-E12; P450 
BM3 B3-P1-A5; P450 BM3 B1-P1-C5; pET28a(+); P450 BM3 Y51F T577G; P450 BM3 B3-P10-C6; P450 
BM3 B3-P10-H4; P450 BM3 B3-P5-B10; P450 BM3 B2-P4-A3; P450 BM3 B3-P3-E2; Lane 13: PageRuler 
Prestained Protein Ladder in kDa.  
 
After determination of the enzyme concentration by automated gel electrophoresis, the 
activity assay was repeated with adjusted catalyst amount. Only one variant called P450 BM3 
B3-P10-C6 had a 10 % activity increase which was in the error range of the 4-AAP assay. 
This variant was selected for sequencing. For the first round of evolution, the template DNA 
was a pool of plasmids which comprise the amino acid substitutions: Y51F, Y488E, W574R, 
T577G. In addition, 6 further mutations were present in P450 BM3 B3-P10-C6, 3 silent 
mutations at positions L432, E688 und H932H and the amino acid substitution S305N, 
G577T und P898L. Accordingly this mutant (P450 BM3 B3-P10-C6) was named P450 BM3 
Y51F S305N G488E W574R P898L.  
  
2.2.3.2  Second round of directed evolution  
Similar to the first evolution round a second random mutagenesis library was generated by 
epPCR and screened for improved DET. As template the variant from the first round (P450 
BM3 Y51F S305N Y488E W574R P898L) and variant P450 BM3 Y51F T577G were used to 
generate epPCR libraries as described before. Due to the high mutational load in the first 
epPCR libraries milder condition (balanced dNTPs and 0.2 mM MnCl2) were used.  The pre-
screening of 700 colonies and re-screening of 30 colonies was done with the 4-AAP assay as 
described in Material and Methods (section 2.13.1.2).  
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Comparison of methods used for determination of the P450 BM3 mutein concentrations  
After screening and re-screening the selected variants which showed an activity improvement 
in presence of the conductive polymer Clevios P, were compared with normalized protein 
concentrations. Two methods to determine the protein concentration were applied, the 
automated gel electrophoresis and the P450 titration by CO-gassing.  The activity 
improvement with P450 concentrations normalized by both methods were compared and 
evaluated to identify which method is most suitable for the determination of P450 
concentration. 
The comparison was performed on the example of the selected variants in the epPCR 
screening.  Out of 26 selected variants in the re-screening 4 showed a minor improved activity 
(1.2-1.4 fold) compared to P450 BM3 Y51F T577G. To exclude expression mutants the 4 
variants were analyzed with the Experion Pro260 Analysis kit (BioRad) (Fig. 81) for protein 
quantification. The expression of the variants P450 BM3 B4-P4-F2 and P450 BM3 B4-P3-
G10 was 1.7 fold, respectively 1.5 fold lower as the starting variant. The variant P450 BM3 
B4-P4-H2 had a comparable expression level (~4.2 µg/µl) to the P450 BM3 Y51F T577G. 
Thus none of the variants were expression mutants.  
 
Fig. 81: Experion automated gel electrophoresis analysis of the 
selected improved variants from second directed evolution 
round. The red box indicates the expected band at 120 kDa, 
corresponding to P450 BM3. Lane L: Ladder in kDa; Lane 7: 
P450 BM3 Y51F T577G; Lane 8: P450 BM3 B4-P4-F2; Lane 
9: P450 BM3 B4-P4-H2; Lane 10: P450 BM3 B4-P3-G10. 
 
 
 
 
 
 
Additionally to the determination of the enzyme concentration by the automated gel 
electrophoresis system the active P450 concentration was quantified by CO titration (Fig. 82) 
(Omura and Sato, 1964a). The obtained absorbance spectra in Fig. 82 correspond to a typical 
P450 spectrum. Only variant C8 (─) had a higher ratio of inactive P450 (presence of a peak at 
420 nm). The P450 BM3 concentration ranged from 12 and 35 µM. 
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Fig. 82: Absorption spectra of the selected variants after CO-gassing used to determine the P450 concentration. 
Shown are the chromatograms after background subtraction (Reference without CO gassing is subtracted from 
the CO treated sample).   
 
The activity assay was repeated at determined enzyme concentration with NADPH and the 
conductive polymer Clevios P. Fig. 83a shows the activity measurements correlated to the 
concentration determined by the automated gel electrophoresis system and Fig. 83b the 
activity normalized after concentration determined by CO-normalization. In all samples the 
activity with NADPH was higher compared to samples containing the conductive polymer as 
electron donor. A discrepancy between the two measurements was obtained. The enzyme 
concentration correlated by Experion system revealed that two variants were improved. The 
highest activity was observed for variants P450 BM3 B4-P3-G10 and P450 BM3 B4-P4-H2 
(Fig. 83a). Contrary, the CO-normalization shows no improved variants. Thus the 
determination of the P450 concentration is reliable if proceed by titration with CO-gassing 
and the results are not comparable to the automated gel electrophoresis system.  
 
(a) Activity normalized to enzyme concentration determined by automated gel electrophoresis 
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Fig. 83: Result of the 4-AAP activity assay with normalized enzyme concentration by automated gel 
electrophoresis system (a) or CO-normalized enzyme concentration (b). The Y-axis shows the A509 nm values 
with subtracted background (reaction mixture without substrate) and divided by the enzyme concentration.  
 
Nevertheless, even if no variant with improved activity could be identified the activity assay 
was repeated with purified proteins to elucidate the obtained results. The variants P450 BM3 
B4-P3-G10 und B4-P4-H2 were purified and the purity was monitored by SDS-page. Both 
proteins were active with NADPH, but no activity in presence of the conducting polymer 
Clevios P could be detected (Fig. 84). An inactivation during purification process could be 
excluded, otherwise P450 BM3 would display no activity with the natural cofactor. Further 
investigation concerning this observation can be found in the following section 2.3. 
 
 
 
 
 
 
 
 
 
 
Fig. 84: Activity with NADPH and Clevios P of the purified variants selected in the epPCR library screening 
(B4-P3-G10 and B4-P4-H2) determined by the 4-AAP assay. 
 
Sequencing results are summarized in Table 8. Sequencing of P450 BM3 B4-P3-G10 
revealed two silent mutations at positions (L432 and K778) and amino acid substitutions 
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(L418V, R683Q and I864V). In the variant P450 BM3 B4-P4-H2 three mutations were 
present, beside  two silent substitutions at positions L432 and G496, a substitution from alanin 
to valin at position 865 was observed. Accordingly P450 BM3 B4-P3-G10 was named P450 
BM3 Y51F L418V T577G R683Q I864V and P450 BM3 B4-P4-H2 was named P450 BM3 
Y51F T577G A865V.  
 
Table 8: Sequencing results of the improved variants selected in the second directed evolution round. 
 
Variant Sequencing results
Silent mutations                            Amino acid substitutions 
P450 BM3 B4-P3-G10 L432, K778 L418V, R683Q, I864V 
P450 BM3 B4-P4-H2 L432, G496 A865V 
 
2.2.3.3  Summary of the random mutagenesis libraries 
The random mutagenesis libraries were successfully generated by epPCR and cloned with the 
PLICing method. In two rounds of directed evolution 1700 colonies were screened with the  
4-AAP assay for improved activity in the presence of the conductive polymer Clevios P. In 
the first round, a variant which had increased (1.1 fold) activity improvements could be 
selected (P450 BM3 Y51F S305N Y488E W574R P898L). The second evolution round was 
performed under milder PCR conditions and two variants with improved activity were 
selected whereas expression mutant could be excluded. The variants P450 BM3 Y51F L418V 
T577G R683Q I864V and P450 BM3 Y51F T577G A865V were purified and the activity 
with the natural cofactor NADPH and the conductive polymer as artificial electron source was 
determined.  
In summary, the random mutagenesis approach to improve the activity with the conductive 
polymer did not lead to activity improved variants for DET. Three variants with minor 
improvements in the crude lysate could be selected but no activity with purified protein in the 
presence of the conductive polymer was observed. The activity with the natural cofactor 
NADPH remained unchanged and no activity improvement could be detected. Accordingly to 
this, the mutants could not be characterized using Clevios P as only electron donor. 
Mutagenic “hot spots” could not be selected but the substitution indicated that a modified 
interaction with the reductase domain might be present, as nearly all mutations were located 
in the reductase domain. The lacking activity with the purified protein and the location of the 
substitutions support the analyzed hypotheses (section 2.2) that no direct interactions between 
the conductive polymer and the protein is present. Nevertheless the comparison of the 
methods used to determine the P450 concentration revealed significant differences in the 
activity measurements. 
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2.2.4  Summary of the P450 BM3 evolution for improved DET 
 
The evolution of P450 BM3 for improved DET was investigated by a structure guided 
focused mutagenesis approach as well as by random mutagenesis rounds. In total 8200 clones 
generated by 5 focused libraries SSM (450 clones/library), 4 libraries of combination of 
beneficial mutations (360 clones/library), 1 multiple SSM (1800 clones/library), and 2 
random epPCR libraries (1700 clones) were screened with the 4-AAP assay. Summarizing, 
the activity improvement of the variants selected in the screening of the structure guided 
mutant libraries or in the random mutant libraries generated by epPCR were in the error range 
of the 4-AAP assay and did not exceed the standard deviation values. Only the variant R471C 
showed a minor improvement (1.5 fold). Improvements due to substitution at position R471 is 
very likely not related to an improved direct electron transfer but likelihood to an improved 
stability.  
Surprisingly, all variants selected in the screening, displayed no activity as purified enzymes 
in presence of the conductive polymer. This interesting finding was investigated in detail and 
is reported in the following section (section 2.3). Altogether, neither a structure guided 
approach nor directed evolution could improve activity of P450 BM3 for DET. Concluding, 
the undetectable product formation of the starting variants and since no variant able to 
perform the direct electron transfer with Clevios P as electron source was identified, no 
electron transfer without regeneration system is feasible.    
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2.3 Activity measurements with purified protein in the presence of the  
conducting polymer Clevios P 
 
As reported in section 2.2, the conversion of 3-phenoxytoluene with purified protein in 
presence of the conducting polymer Clevios P could not be observed Already, the first 
activity measurements in presence of only Clevios P with the variant reported as improved, 
indicated that no product formation could be observed. This unexpected and interesting result 
was common in all selected variants in the screening (see section 2.2.4). Purification and 
analysis of selected variants in screening occurred, but never the starting variant P450 BM3 
Y51F T577G was included which was reported as activity improved variant in presence of the 
conductive polymer Baytron P. Therefore, further investigations were performed to clarify 
why discrepancies in the activity measurements between purified protein and cell lysate are 
present. In the following sections, first the activity of purified P450 BM3 Y51F T577G was 
analysed and then the generated products in presence of the conducting polymer with cell 
lysate were detected by GC. Finally, the impact of mediators on the activity with purified 
protein was investigated by analysing a coupled enzyme reaction to exclude a NAPH based 
reaction. 
 
2.3.1 Activity of purified P450 variant Y51F T577G 
 
To compare and maybe elucidate the discrepancy of the activity measurements between 
purified P450 BM3 protein and cell lysates, the starting variant Y51F T577G was purified and 
the activity with the 4-AAP assay was monitored. Fig. 85 shows the activity with 3-
phenoxytoluene in the NADPH consumption assay. As control, the same reaction with DMSO 
was carried along. The decrease in absorption at 340 nm in the sample with substrate 
compared to a constant adsorption when the substrate is replaced by DMSO, proves the 
presence of active P450 BM3 Y51F T577G enzyme with the natural cofactor NADPH. 
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Fig. 85: a) NADPH consumption assay with purified P450 BM3 Y51F T577G. Conversion of the substrate 3-
phenoxytoluene and negative control without substrate only DMSO addition, b) Detection of 3-phenoxytoluene 
conversion products by the 4-AAP assay with the natural cofactor NADPH (N), the alternative cofactor Clevios 
P (C) (C1:50= Clevios P diluted 1:50), or without addition serving as negative control (DMSO).  
 
The activity with NADPH demonstrates that the expression system and purification was 
effective and led to active and right folded proteins, even if substitution T577G is present. 
The same sample was analysed with the 4-AAP detection principle in presence of the 
conducting polymer Clevios P as alternative cofactor system or with addition of NADPH 
(Fig. 85). The colorimetric reaction proves that no activity in presence of the conductive 
polymer Clevios P was detected, but with NADPH. Nevertheless, activity in presence of the 
conductive polymer Baytron P was reported (Nazor, 2007). To exclude any influence coming 
from the expression system, or the substitution Y51F, the substitution T577G was introduced 
in WT P450 BM3 and in F87A variant. The purification and all measurements were done in 
duplicate. No activity for any of the constructed strains could be detected in presence of 
Clevios P, but the activity with NADPH remained.  
 
Additionally, to exclude an influence of the selected detection method on the obtained data 
and to confirm the obtained data by other detection principles, the activity measurements were 
repeated and analyzed using alternative activity detection systems for P450 BM3.  Three 
detection principles were applied: The pNCA assay, a fluorescent based assay and the 4-AAP 
assay with another substrate.  
Changing the substrate to enhance the sensitivity of the assay included the subcloning of the 
variants (generated variants are listed in Table 9). The experiments were performed with the 
starting variant Y51F T577G and the 5 selected variants with the amino acid substitutions 
C N+C C(1:50) N
N DMSO N C
b)
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identified in the screening of the focussed mutant libraries: Y536S T533K A534E W574T, 
G488E, Y536S T533K A534E, G488F, R471C). 
 
Table 9: Generated variants used to compare the activity assay employed with purified protein. 
Variant Amino acid substitutions Generated by  
WT-T577G T577G SDM T577G in P450 BM3 WT 
F87A-T577G F87A T577G SDM F87A in P450 BM3 WT-T577G 
WT-Ethoxy-T577G K187E I162G T577G SDM in WT-T577G 
WT-Ethoxy K187E I162G SDM in P450 BM3 WT 
WT-G488E T577G G488E 
Subcloning by MfeI/NcoI in P450 
BM3 WT 
F87A-G488E F87A T577G G488E 
Subcloning by MfeI/NcoI in P450 
BM3 F87A 
F87A-W574T Y51F Y536S T533K A534E T577G W574T 
Subcloning by MfeI/NcoI in P450 
BM3 F87A 
F87A-Y536S Y536S T533K A534E 
Subcloning by MfeI/NcoI in P450 
BM3 F87A 
F87A-G488F G488F 
Subcloning by MfeI/NcoI in P450 
BM3 F87A 
WT-R471C R471C 
Subcloning by MfeI/NcoI in P450 
BM3 WT 
F87A-R471C F87A R471C 
Subcloning by MfeI/NcoI in P450 
BM3 F87A 
 
Detection of p-nitrophenol by the pNCA assay in presence of the conducting polymer 
The pNCA assay was selected to investigate the hydroxylation of a natural like substrate in 
the presence of the conductive polymer. Product detection of the pNCA hydroxylation occurs 
at 405 nm and should not interfere with the absorption spectra of the conductive polymer. The 
substitution F87A was reported as beneficial for efficient conversion of pNCA (Schwaneberg 
et al., 1999a). For this purpose, the five selected variants and the Y51F T577G were 
subcloned in the F87A variant using the restriction sites MfeI/NcoI to exclude the Y51F 
mutation and to introduce the F87A substitution. The variants (F87A-G488E, F87A-W574T, 
F87A-Y536S, F87A-G488F, F87A-R471C, F87A-T577G) were purified and the pNCA 
conversion in presence of Clevios P assayed. The results obtained with the pNCA assay were 
similar to the obtained data with the 4-AAP assay. No activity with purified protein in 
presence of the conductive polymer Clevios P could be observed.  
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Detection of 11-phenoxyundecanoic acid conversion by the 4-AAP assay in presence of 
the conducting polymer 
The conversion of the substrate 11-phenoxyundecanoic acid in presence of the conductive 
polymer was tested. The product of the 11-phenoxyundecanoic acid hydroxylation is a phenol 
and detectable with the 4-AAP assay. The experimental setup was comparable to the used 
screening system consisting of the 3-phenoxytoluene conversion and the 4-AAP detection 
principle (Wong et al., 2005b). Exchanging the substrate by keeping the detection principle 
constant allows excluding an influence of the substrate on the activity in presence of the 
conductive polymer. The activity in presence of Clevios P and NADPH of the six purified 
variants carrying the F87A mutations (F87A-G488E, F87A-W574T, F87A-Y536S, F87A-
G488F, F87A-R471C, F87A-T577G ) and 3 variants lacking the F87A and Y51F 
substitutions (WT-G488E, WT-R471C, WT-T577G) was recorded. However, no activity with 
purified protein in presence of the conductive polymer but with NADPH could be observed 
with this experimental setup.   
 
Fluorescent activity assay in presence of the conducting polymer 
Fluorescent based activity assays were setup to enhance the sensitivity of the detection 
principle. Fluorescent assays can detect product formation in nM scale compared to the 
colorimetric detection methods which are limited to product formation in µM scale (Arnold 
and Georgiou, 2003). This would exclude that the activity remained undetectable due to the 
detection limits of the tested colorimetric assays (pNCA and 4-AAP assay). First the reported 
fluorescent MTP-assay based on the hydroxylation of 7-hydroxycoumarin was performed 
(Park et al., 2010). For this reason, prerequisite was to introduce by SDM the substitution 
I162G and K187E allowing to convert the fluorescent substrate 7-hydroxycoumarin. 
As second the conversion of BCCE was determined (see section II.1). Fundamental for the 
latter was no substitution at position Y51. Therefore the following mutants (WT-G488E, WT-
R471C, WT-T577G, WT-Ethoxy-T577G, WT-Ethoxy) were constructed by SDM or 
subcloning with restriction enzymes.  
The results of the conversion of both fluorescent substrates (7-hydroxcoumarin and BCCE) 
were similar with the eleven investigated variants (F87A-G488E, F87A-W574T, F87A-
Y536S, F87A-G488F, F87A-R471C, F87A-T577G, WT-G488E, WT-R471C, WT-T577G, 
WT-Ethoxy-T577G, WT-Ethoxy). The result of the BCCE conversion by purified P450 BM3 
WT-T577G in presence of NADPH and the conductive polymer is shown in Fig. 86 (λex 400 
nm, λem 440 nm). 
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Fig. 86: BCCE conversion by purified P450 BM3 WT-T577G in presence of NADPH (♦), the conductive 
polymer (■) or without e-donor (▲), and the reaction mixture without enzyme but with NADPH (X), recorded at 
λex 400 nm, λem  440 nm. 
 
An increasing fluorescent signal with addition of NADPH but not in presence of Clevios P 
could be observed with purified protein. All variants only differ in the signal response with 
NADPH most likely due to an improved substrate conversion. The conductive polymer 
displayed furthermore quenching effects on the fluorescent signal or an inhibition of the 
enzyme.  Although applying different variants as well as various fluorogenic substrates, no 
activity signal could be recorded using Clevios P as electron source for P450 BM3. 
The fluorescent activity measurements were also proceeded with cell lysate (Fig. 87), 
indicating a fluorescent signal increase with, but also without addition of Clevios P. The 
signal was very low, when no addition occurred compared to the obtained RFU with addition 
of NADPH.  
 
 
 
 
 
 
 
 
 
Fig. 87: BCCE conversion recorded at λex 400 nm, λem  440 nm with P450 BM3 WT-T577G cell lysate, with 
addition of the conductive polymer Clevios P (■) and without addition of Clevios P (●), pET28a(+) cell lysate 
(●) with addition of the conductive polymer Clevios P, purified P450 BM3 WT-T577G with addition of the 
conductive polymer Clevios P (○). 
 
 
Without addition of Clevios P 
With addition of Clevios P 
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2.3.2  Product detection by GC and GC-MS 
 
The product detection by GC and GC-MS was performed to elucidate if conversion is 
occurring in presence of the conductive polymer. Proving the product formation is essential as 
no activity with purified protein could be detected and the conversion rate with cell lysate in 
presence of the conducting polymer is very low and in the error range of the assay. The 
product detection by GC was repeated for all variants selected as improved in the screening 
and the reported variant P450 BM3 Y51F T577G. The conversion of 3-phenoxytoluene by 
freshly prepared cell lysate and in presence of Clevios P or the addition of NADPH was 
monitored on the GC. The chromatograms were similar for all analysed variants, thus only the 
results for P450 BM3 Y51F T577G are shown (Fig. 88) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 88: GC chromatograms of the 3-phenoxytoluene conversion by P450 BM3. Reaction performed with cell 
lysate of Y51F T577G and with addition of NADPH (a), NADPH and Clevios P (b), Clevios P (c), no addition 
(d), cell lysate of pET28a(+) lacking the P450 gene (e). P1: Indol, P2: Substrate 3-phenoxytoluene,                   
P3: Hydroxylated 3-phenoxytoluene.  
 
 
The presence of hydroxylated 3-phenoxytoluene (Peak 3 at RT:8 min) with NADPH addition 
or even without addition was clearly monitored. The peaks could be indicated by GC-MS 
with a similarity of 86% for 3-phenoxytoluene (Peak 2 in Fig. 88 and Fig. 89 a), 94% for 
e 
d 
c 
b 
a 
P1 
P2 P3 
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indol (Peak 1 in Fig. 88 and Fig. 89b ), and 71% for hydroxylated 3-phenoxytoluene (Peak 3 
in Fig. 88 and Fig. 89c). 
 
(a) Peak 1: Hydroxylated 3-phenoxytoluene, similarity: 71% 
 
 
(b) Peak 2: Indol, similarity: 94% 
 
 
(c) Peak 2: 3-phenoxytoluene, similarity: 86% 
 
 
Fig. 89: GC-MS spectra used for the peak identification of the 3-phenoxytoluene conversion by P450 BM3.  
 
However, the hydroxylate 3-phenoxytoluene could not be monitored in a reaction with cell 
lysate prepared from cells expressing the pET28a(+) lacking the P450 BM3 gene or E. coli 
BL21 (DE3) Gold cell lysate. Underlying that the substrate is not self-degraded or a site 
reaction catalysed by other enzymes present in the cell lysate is not occurring. The monitored 
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activity is not due to addition of the conducting polymer as the hydroxylated product could be 
monitored in the reaction mixture without supplemented electron donor indicating that a 
NADPH based reaction is occurring. Additionally, an inhibitory effect by the conductive 
polymer could be demonstrated. The GC peak areas were correlated to an internal standard 
and the reaction compared (Fig. 90). Reasoning, when Clevios P was added to the reaction 
catalysed by NADPH, the activity was lower compared to the one without addition of 
conductive polymer. This was already observed in the fluorescent activity measurements 
(section 2.3.1).  
 
 
 
 
 
 
 
 
 
 
Fig. 90: GC peak area correlated to an internal standard to determine and compare the product formation rate of 
the 3-phenoxytolunene conversion in presence of Clevios P, no electron donor or NADPH.  
 
2.4   NADPH or mediator based conversion 
The colorimetric, the fluorescent and the GC measurements indicated the presence of a 
NADPH based reaction. Nevertheless, throughout the performed experiments a mediator 
based reaction could not be excluded. Feasible would be the conversion by P450 BM3 cell 
lysate due to the presence of the conducting polymer, but not as direct electron transfer but 
rather as a mediated electron transfer through an undefined constituent present in the cell 
lysate. This undefined constituent would be absent in the purified protein explaining why no 
activity can be detected. The three following experiments were performed to analyze if a 
NADPH or mediator based substrate conversion with cell lysate in the presence of the 
conductive polymer Clevios P is occurring. 
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1. First the prepared cell lysate was stored 48 h at 4°C and the activity was measured with the 
fluorescent assay. In freshly prepared cell lysate, the hydroxylation products could be detected 
using GC (section 2.3.2) as well as in the colorimetric detection systems (section 2.3.1). 
Indeed, after storage no activity could be observed with und without addition of Clevios P 
(See fig. 91 in comparison with Fig. 86). Nevertheless, the activity with supplemented 
NADPH remained, underlying that the monooxygenase was not inactivated by the storing 
procedure.  
 
 
 
 
 
 
 
 
Fig. 91: BCCE conversion recorded at λex 400 nm, λem 440 nm with P450 BM3 WT-T577G cell lysate, with 
addition of the conductive polymer Clevios P (■) and without addition of Clevios P (●), after storage of the cell 
lysate for 48h at 4°C. 
 
2. In the second experimental setup, the cell lysate was purified and the collected fractions 
were recombined before elution of the protein. The aim was to identify a compound separated 
by the purification process which could serve as mediator in the reaction system with Clevios 
P as observed in cell lysate (Fig. 92). The activity test was performed with the fluorescent 
assay after addition of the different fraction to the partially purified protein. NADPH is not 
binding to the purification matrix, ensuring a good separation of the cell lysate constituent 
(P450 BM3 and other enzymes) and the NADPH. Even when recombining all fractions no 
activity was detected with Clevios P. The fluorescent measurements are not shown; the result 
was identical to the obtained data in Fig. 86 and Fig. 91. 
Additionally, cell lysate prepared from E. coli BL21 (DE3) Gold cells was supplemented to 
purified protein before performing the activity measurement. However, all attempts remained 
in no activity in the presence of the conductive polymer. If a mediator or an enzyme would be 
able to serve as electron shuttle between the conductive polymer and P450 BM3 that was 
present in the cell lysate, the system could have been reconstituted by adding cell lysate to the 
purified protein. A positive result of this experiment would question the hypothesis of a 
mediator based reaction with P450 BM3. 
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Fig. 92: SDS-page of the collected fraction during purification. Lane 1-4: fraction before protein elution; Lane 5-
9: fraction after protein elution; Lane 11-14: protein elution fraction, red frame indicates P450 BM3 at 120 kDa; 
Lane 10: prestained protein ladder.  
 
 
3. Finally the third control experiment was performed with a coupled enzyme assay. The 
NADPH in the cell lysate was consumed by the addition of a second enzyme, the Glutathione 
disulphide reductase. The Glutahione reductase converts oxidized Glutathione (GSSG) under 
consumption of NADPH to reduced Glutathione (GSH) (Michal, 1998).  
  
 
 
 
 
 
After treatment of the cell lysate with the Glutathione reductase, this mixture was used with 
BCCE in presence of Clevios P to determine monooxygenase activity. No activity could be 
detected by addition of Clevios P (Fig. 93). Supplementing NADPH to the Gluthathione 
reductase treated reaction, activity was monitored underlying the hypotheses that a NADPH 
based reaction is present. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 93: BCCE conversion by P450 BM3 T577G crude extract after GSSG reductase treatment in presence of 
Clevios P (●) and without addition (■) recorded at λex 400 nm, λem  440 nm. 
Glutathione oxidized 
(GSSG) 
Glutathione reductase 
Glutathione reduced 
(GSH) 
NADPH + H+          NADP+
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Concluding, the activity detectable in the cell lysate by the fluorescent assay as well by the 
colorimetric assays is based on the NADPH present in the cell lysate and not due to the 
addition of the conductive polymer and/or the presence of a mediator. 
The lack of activity in the absence of NADPH was underlined on the one hand by the 
NADPH consumption through a second enzymatic reaction (Glutathione reductase) or by 
storage procedure in which the enzymes present in the cell lysate consumed the remaining 
NADPH, on the other hand by the separation of the NADPH from the protein fractions during 
the purification process.  
 
 
2.5   Discussion 
 
In this chapter, the evolution of P450 BM3 towards improved Direct Electron Transfer by 
directed evolution was investigated. Starting variant for this work is the reported activity 
improved variant P450 BM3 Y51F T577G in the presence of the conductive polymer Baytron 
P (Nazor, 2007) for 3-phenoxytoluene. Preliminary conversion experiments showed that P450 
BM3 could not hydroxylate efficiently the substrate 3-phenoxytoluene in presence of Clevios 
P as previously reported for Baytron P. The reported protocol for the 4-AAP screening system 
in presence of Baytron P could not be alienated to the use of Clevios P. Using this protocol, 
no activity in presence of Clevios P could be detected. Several mutants as well as several 
activity assays were applied to analyze the product formation rate. Leading to the conclusion 
that no direct electron could be detected. This is only due to the lack of a suitable electron 
donor, Clevios P without electrochemical reduction and without regeneration system cannot 
deliver electrons to the enzyme. The assay used for product detection (4-AAP assay) itself is 
working because when NADPH is supplemented to the reaction, a clear activity increase and 
difference between the empty vector and the P450 BM3 variant can be measured. The product 
formation could be proven by GC only when NADPH was supplemented. 
 
Theoretical, the conductive polymer Clevios P, which is only soluble in the oxidized state 
cannot serve as electron donor and cannot reduce the Enzyme. A conductive polymer in the 
reduced state with a redoxpotential  higher than -400 mV, which correspond to the 
redoxpotential of the enzyme and a regeneration system would be required to assure the  
efficient electron shuttle. Clevios P is not suitable for this approach, to use a conductive 
polymer in solution as exclusive electron source. An electrode coated with the conductive 
polymer and embedded P450 BM3 would be a suitable approach. On the electrode the 
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conductive polymer would be generated by electrochemical polymerization and build a thin 
film. Through the application of a redoxpotential lower than the enzyme redoxpotential the 
polymer would be in the reduced state and electrons could be shuttle to the enzyme enabling 
substrate conversion.   
 
The non reproducible results from Nazor et al. were due to the employed conductive polymer. 
Beside the consideration mentioned above that theoretically Clevios P cannot serve as 
electron donor, the conductive polymer solution was questionable. The conductive polymer 
used in previous experiments was Baytron P produced by H.C. Starcks.  In 2009 the Baytron 
P formulation was renamed as Clevios P by H.C Starcks, but the composition remained 
similar and unchanged in the ratio of PSS to PEDOT, as stated by the company. In this thesis, 
only the new batch of conductive polymer (Clevios P) was available and could be used. 
Subsequently, an unforeseeable event was the influence of the commercial available Clevios 
P, which was not identical to the previously employed Baytron P. The first alertness of an 
occurring change in the product was given by the different behaviour in the reported 4-AAP 
assay protocol. The conductive polymer Clevios P could not be precipitated after the 
enzymatic conversion by centrifugation (section 2.1.1.1). Clevios P stayed in solutions and 
interfered with the colorimetric reaction necessary to quantify the generated product amounts. 
Nevertheless, prerequisite for a successful directed protein evolution is a medium or high 
throughput screening assay allowing to sample the diversity of the generated libraries in an 
efficient and reliable way (Tee and Schwaneberg, 2007). To optimize the 4-AAP six 
conductive polymer formulations from H.C. Starcks with different properties were tested and 
compared to Clevios P. The aim was to identify one formulation with similar properties to 
that of Baytron P. Unfortunately, no activity or even no activity improvement could be 
detected applying all these polymers to P450 BM3 Y51F T577G. Several parameters, like 
buffer concentration, reaction volume, substrate concentration were modified without success. 
Finally, the main problem was solved after investigating additives and separation methods to 
effectively precipitate the polymer by the addition of lysozyme to the reaction mixture. The 
interaction principle of lysozyme and the conductive polymer in aqueous solution could not 
be explained.  
Even if no activity could be detected, the 4-AAP assay in presence of the conductive polymer 
could be used for screening and selection of activity improved variants, because the 
coefficient of variation was determined to be between 3.7 and 7.5% depending on the 
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analyzed variant. Screening systems with standard deviation less than 15 % have successfully 
been used in directed evolution experiments (Schwaneberg et al., 1999a; Wong et al., 2005b).  
 
Role of the FMN in P450 BM3 Y51F T577G 
Screening of a site-saturation library at amino acid position T577 yielded a mutant bearing the 
amino acid exchange T577G with a significantly improved activity using the conducting 
polymer Baytron P (PEDOT/PSS) (Nazor, 2007). Nazor et al. proposed that the conductive 
polymer is binding in close proximity to the FMN binding site and could directly transmit 
electrons to the electron transfer chain. This rose up the importance of the bound FMN 
cofactor. The fluorescent and absorption spectra of truncated variants (FAD deficient 
mutants) were compared to the P450 BM3 WT. The FMN could clearly be detected, 
concluding that the FMN is not lost when the amino acid substitution T577G is present. Thus, 
a direct connection between the conducting polymer and amino acids in the FMN-binding 
cavity might not be due to the loss of the cofactor FMN. The hypothesis established by Nazor 
et al. that T577G substitution might lead to breaking of hydrogen bonds to W574 or FMN and 
the loss of either of them would allow more flexibility in the polypeptide backbone, leading to 
a destabilization of the FMN in its binding cavity could not be verified by the shown 
experiments. 
 
Screening of Focused mutant libraries for improved DET 
The evolution of  P450 BM3 for DET was undertaken as promising results were published 
and the fact that Clevios P was not suitable to be applied without regeneration system as 
alternative cofactor system was recognized delayed. 
The evolution of P450 BM3 for improved DET was performed first by screening of structure 
guided mutant libraries. Five residues (positions G488, Y536, N537 and W574) were selected 
which very likely interact with FMN through hydrogen bonds in the FMN-cavity of P450 
BM3. The positions were NNK saturated and screened to enhance the activity of the 
monooxygenase with the conducting polymer Clevios P. The loop spanning residues Y536-
P541 and its interactions with the cofactor in P450 BM3 are reported crucial for the stability 
and flexibility of the turn (Kasim et al., 2009). Almost all amino acids substitutions selected 
in the focused mutant libraries screened for improved DET were from hydrophobic to charged 
amino acids. These observations show that drastic structural changes in the FMN binding site, 
mainly towards charged amino acids, create an interface supporting a better connection to the 
conducting polymer (Nazor, 2007).  
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The asparagine residue on position 537 can form hydrogen bonds between the backbone 
amide and the FMN N5. Substitution at position N537 are reported to eliminate the 
asparagine side chain interactions (N537A) or to alter the turn stability (N537G) and structure 
(N537G/G538A, N537A/G538A) (Kasim et al., 2009). Position G538 is reported to be crucial 
in maintaining the type I turn conformation in the FMN binding cavity (Kasim et al., 2009). 
Therefore it is not unexpected that during the screening of focussed mutant libraries at 
position N537 no activity improvement could be observed.  
Substitution at position Y536 to amino acids with basic residues (H or R) did not significantly 
influence the redox properties of the FMN or the accumulation of the anionic semiquinone but 
substitutions to charged amino acids (D) the FMN binding is affected, the variants contained 
less than half as much FMN as FAD and the FMN was lost during the purification (Kasim et 
al., 2009). 
In the loop region Y536-P541 the tandem Pro-Pro sequence at position P540-P541 anchors 
and „regidifies“ the loop, these positions were not selected for mutagenesis as it was 
favorable to keep this design.  The positions P540A/P541A are reported to alter the 
conformation and flexibility could not be reconstituted with the FMN cofactor (Kasim et al., 
2009). 
Amino acid G488 was selected for mutagenesis due to the beneficial impact observed in the 
MET results of position S489. Amino acid G488 is lying in close proximity to the considered 
loop Y536-P541. A probably loss of the hydrogen bond formation between N543 and S489 
were observed in the variant N543S R471C with improved activity in presence of the 
alternative cofactor system Zn/Co(III)-sep. The screening of the saturation library at position 
G488 identified the amino acid substitution G488E and G488F which revealed only minor 
improved mutants.  
Thus, several beneficial amino acid substitutions were identified by the screening of the SSM 
libraries at the position G488, Y536, N537 and W574. Altogether, no variants with 
significantly improved activity could be identified, as activity of all selected variants was in 
the error range of the assay. The coefficient of deviation was 7.5% for the 4-AAP (Y51F 
T577G) assay and the improvements were between 5-10%.  
Only the SSM at position R471 revealed a variant (R471C) with 1.5 fold enhanced activity for 
the conductive polymer in crude cell lysate and after CO normalization. Position R471 was 
not reported in literature as important for the electron transfer or as crucial for interaction in 
the FMN binding cavity. Position R471 is located in the naturally occurring loop of the P450 
BM3 (residues R471-N479), which is used to fuse the heme domain with the reductase 
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domain of non self-sufficient monooxygenase for engineering artificial redox chains by 
molecular 'Lego' (Sadeghi et al., 2000; Gilardi et al., 2002). Interestingly position R471 was 
also found in an epPCR library screened for improved MET (section III.1). R471C is reported 
as beneficial for DMSO resistance and explains why this mutantion was identified in the 
improved variants. The variants were resistant to the applied DMSO concentration. DMSO 
was used as co-solvent to increase the substrate concentrations. Leading to the conclusion that 
R471C is not relevant for the DET and MET.  
 
Screening of simultaneous and consecutive SSM for improved DET 
Employing the 4-AAP assay and the substrate 3-phenoxytoluene, 1800 clones of the 
simultaneous saturation library were screened. The ratio of inactive clones in the mutant 
library was determined to be 60 %. Even if two clones were verified by sequencing to ensure 
a good annealing and revealed no mistake, the unfavourable annealing during the overlap 
extension PCR may be a reason for the high inactive ration. Additionally, a reason could be 
the cooperative effects obtained by combining substitutions at position W574 to substitutions 
in close proximity. A high inactive ratio was already observed in the single saturation at 
position W574 with around 12 %.  Indicating that W574 is a crucial position for the cofactor 
binding. Position W574 has an important role in the flow of the electrons between the P450 
BM3 heme and reductase domains and binds relatively high level of FMN (Klein and Fulco, 
1993). Replacement of W574 with nonpolar residues has been shown to abolish FMN binding 
and conserved aromatic side chains, (Klein and Fulco, 1993). The variant W574Y displayed 
less activity compared to the WT enzyme and high activity of W574F mutant upon addition 
of as little as 10 µM FMN, the cyt c reductase activity increased to a level about 15% above 
that of the P450 BM3 WT (Klein and Fulco, 1993). Screening of focussed libraries at position 
W574 revealed amino acids with polar uncharged side chain (W574S, W574T) and 
hydrophobic side chains (W574I, W574A).  
In summary, iterative as well as simultaneous saturation of position G488 and W574 did not 
enhance the activity of P450 BM3 for the conductive polymer Clevios P. Both approaches 
were performed since in literature the simultaneous saturation is described beneficial 
compared to the iterative approaches (Reetz et al., 2006). 
 
Screening of random mutagenesis libraries  
The semi rational evolution of P450 BM3 for DET was not successful; no significantly 
improved variants could be identified. Therefore, additionally to the structured guided mutant 
3. Results – Chapter III: Evolution of P450 BM3 for alternative cofactor systems 148 
libraries, P450 BM3 was evolved for DET by a random mutagenesis approach to identify new 
hot spots. Two rounds of directed evolution were performed by generating epPCR libraries 
screened with the 4-AAP assay in the presence of Clevios P.  
After the first round of mutagenesis and screening, only one P450 BM3 variant could be 
detected displaying a minor improvement in presence of the conductive polymer as alternative 
electron source. Drasticall substitutions from amino acids with polar side chain to basic were 
found at position S305, serin to asparagine in the variant P450 BM3 Y51F S305N G488E 
W574R P898L. Additionally at position P898 in the reductase domain, the substitution P898L 
(non-polar to hydrophobic) occurred. Position P896 is located near to the position S965, 
R966, K972 reported as crucial in the coenzyme selectivity in the P450 BM3 FAD/NADPH 
domain (Dunford et al., 2009).  
The only partially available (AS 20-630) crystal structure of P450 BM3 WT restricted the 
analysis of the amino acid substitutions. The substitution at position L418 and S305 (variant 
selected in the first evolution round) could be displayed only as model (Fig. 94) and the 
remaining substitution (position: 864, 865, 683, 898) were located in the, till today, unsolved 
reductase domain.  
 
 
Fig. 94: Structure model of the P450 BM3. The heme domain is colored in gray with the Heme in red and the 
FMN domain is schown in blue with the FMN in green. The amino acid substitution T577 (red), S305 (yellow), 
Y51 (yellow) and L418 (purple) are highlighted.  
 
Localization of the substitution in the reductase domain might indicate an improved or at least 
modified interaction with the cofactor NADPH. None of the mutations was located in the 
Heme-FMN (P472 – C592) interface which was defined as relevant in the electron transfer 
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pathway and the cofactor interaction (Klein and Fulco, 1993; Kasim et al., 2009). The lacking 
activity using the purified protein and the location of the substitutions supported the 
hypotheses that no direct interactions between the conductive polymer and the protein is 
present. 
 
Comparison of methods used for determination of the protein concentration  
The automated gel electrophoresis as well as the P450 titration by CO-gassing (Omura and 
Sato, 1964a) was employed and the activity profiles obtained after protein normalization of 
the variants selected from the epPCR libraries were compared.  
Enzyme concentrations correlated by automated gel electrophoresis (Experion system from 
BioRad) revealed that 2 variants were activity improved in presence of Clevios P. The highest 
activity was observed for variants P450 BM 3 B4-P3-G10 and P450 BM 3 B4-P4-H2. 
Contrary, the CO-normalization shows no improved P450 BM3 variants This can be 
explained by the fact that in the P450 BM3 titration by CO-gassing only active P450 BM3 is 
quantified, but in the automated gel electrophoresis the total amount of P450 BM3 protein is 
calculated. If the ratio of inactive to active protein differs in the selected variant, this leads to 
activity improved variants in the assay when the concentration is determined by the 
automated gel electrophoresis system.  Concluding, the concentration determine by CO-
gassing allows precise and reliable results. Therefore, all variants selected from focused 
mutant libraries were re-analyzed after CO-gassing and the comparison of product formation 
rate reconsidered.   
 
In summary, the focused as well as the random mutagenesis approach to improve the activity 
with the conductive polymer did not lead to activity improved variants for DET. Variants with 
minor improvements in the crude lysate could be selected but no activity with purified protein 
in the presence of the conductive polymer was observed. The activity for the natural cofactor 
NADPH remained unchanged and no activity improvement could be detected for Clevios P. 
Accordingly to this, the mutants could not be characterized in detail using Clevios P as only 
electron source for P450 BM3.  
 
NADPH or mediator based conversion  
The hypothesis of an undefined component in the cell lysate which serves as mediator 
allowing activity improvement in presence of the conductive polymer was investigated by 
three experimental setups.  
 
3. Results – Chapter III: Evolution of P450 BM3 for alternative cofactor systems 150 
First the conversion of 3-phenoxytoluene with purified protein in presence of the conducting 
polymer Clevios P was analysed. No activity in presence of Clevios P could be observed, 
even though other colorimetric (pNCA) or fluorescent detection assay (7-Ethoxycoumarin and 
BCCE conversion) as well as several variants bearing the substitution F87A or K187E I162G 
were used for assaying P450 BM3 activity with the conductive polymer. Subsequently, the 
generated products in presence of the conducting polymer with cell lysate were detected by 
GC and GC-MS. The monitored activity is not due to addition of the conducting polymer as 
the hydroxylated product could be monitored in the reaction mixture without supplemented 
electron donor. This indicates that a NADPH based reaction is occurring. Additionally, an 
inhibitory effect by the conductive polymer could be demonstrated. The product could not be 
monitored in the reaction performed with cell lysate from cells lacking the P450 gene 
underlying that the substrate is not self-degraded or a site reaction catalysed by other enzymes 
present in the cell lysate is not occurring. Finally, the hypotheses of an undefined mediator 
present in the cell lysate and his impact on the activity was investigated.  
When the NADPH remaining in the freshly prepared cell lysate is consumed by a coupled 
enzyme reaction with GSSG reductase or consumed in the storage procedure by other 
enzymes present in the cell lysate or separated from the protein during the purification, no 
activity in presence of Clevios P could be detected. These results supported the formulated 
hypotheses of an NADPH based activity and excluded a mediator present in the cell lysate. If 
a mediator separated by the purification process from the protein would have been present, 
the system could have been reconstituted by addition of prepared cell lysate to the purified 
protein.   
All variants selected in the random mutagenesis and focused mutant libraries were probably 
improved in resistance to the conductive polymer which shows an inhibitory effect on the 
protein. The inhibitory effect was observed in the fluorescent measurements as well as for the 
product detection by GC. The product formation rate with NADPH supplemented with 
Clevios P was lower than compared to the addition of only NADPH. The obtained activity 
improvements by using different Clevios P formulations are most probably due to a reduced 
inhibition rather than an increase in activity. The improvements cannot be related to an 
activity increase rather than to a stability enhancement for variants including the amino acid 
exchange R471C or in the case of mutation in the reductase domain (epPCR mutants) to an 
efficient NADPH consumption. The presence of several amino acid substitutions in the 
reductase domain selected from epPCR libraries indicate a modified interactions with the 
NADPH.  All variants selected as improved were in the error range of the assay and the 
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activity could not clearly be determined as improved, this is mainly due to the very low 
conversion. The NADPH remaining in the cell lysate is very low and could not serve as 
electron donor to convert significant amounts of substrate, leading to very low product 
formation rates, hardly detectable in the 96 well MTP format.   
Nevertheless, even if no activity in presence of Clevios P with purified protein could be 
monitored, and the claimed 100 fold improved activity with Clevios P with purified Y51F 
T577G in presence of Baytron P could not be reproduced with Clevios P this results cannot be 
compared. The conductive polymer Clevios P was similar but could not be stated as identical 
to Baytron P. Concluding, the evolution of P450 BM3 in presence of the conductive polymer 
Clevios P could not be achieved. The remaining unsuccessful evolution of P450 BM3 leads to 
a deep literature research and contest the previous published results. This revealed that 
PEDOT/PSS solutions have a redoxpotential of around -400 mV and are generated by 
oxidative polymerization. Meaning that the applied polymer in the enzymatic reaction was in 
an oxidized state and didn’t fulfil the requirements for an electron donor to P450 BM3. The 
reductase of P450 BM3 has a redoxpotential of -388 mV and requires a mediator in a reduced 
state (<-400 mV) coupled to an adequate regeneration system, otherwise no efficient electron 
transfer and substrate conversion would occur.  
 
2.6   Conclusions  
 
In this chapter of the thesis, the evolution of P450 BM3 towards improved Direct Electron 
Transfer by directed evolution was investigated.  
Staring variant was the reported activity improved variant P450 BM3 Y51F T577G in the 
presence of the conductive polymer Baytron P. This results could not be confirmed as no 
activity in presence of Clevios P could be detected. Nevertheless, the evolution of  P450 BM3 
for DET was undertaken as promising results were published and the fact that Clevios P was 
not suitable to be applied without regeneration system as alternative cofactor system was 
recognized delayed.   
The evolution was performed by a focused mutagenesis approach as well as by random 
mutagenesis. The generated libraries were screened with the 4-AAP assay for improved 
activity in presence of the conductive polymer Clevios P. Clevios P could not be precipitated 
by centrifugation like it occurred for Baytron P, therefore the 4-AAP assay was optimized. 
Several parameters, like buffer concentration, reaction volume, substrate concentration were 
varied. However, no improvement was achieved the product formation could not be increased 
and was not detectable. Then, six conductive polymer formulations from H.C. Starcks with 
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different properties were tested and compared to Clevios P to identify one formulation with 
similar properties as the Baytron P which could be used as artificial electron donor in the 
P450 hydroxylation reaction. None of the tested formulations affects significantly the activity. 
Finally, the main problem of an insufficient precipitation was solved after investigating 
additives and separation methods, and the polymer could effectively be precipitated by the 
addition of lysozyme to the reaction mixture. Using the improved protocol, the coefficient of 
variation was determined to be between 3.7 and 7.5% depending on the analyzed variant. 
Besides the evolution of P450 BM3, the fate of FMN in the variant Y51F T577G was 
investigated. The FMN could clearly be detected in FAD deficient variants, concluding that 
the FMN is not lost when the amino acid substitution T577G is present. Thus, a direct 
connection between the conducting polymer and amino acids in the FMN-binding cavity 
might not be due to the loss of the cofactor FMN. The directed evolution of P450 BM3 to 
enhance the activity of the monooxygenase with the conducting polymer Clevios P was 
performed by a semi rational evolution approach as well as the random mutagenesis approach 
to identify new hot spots. The iteratively as well as the simultaneous saturation of position 
G488 and W574 in addition to the saturated position (positions G488, Y536, N537 and 
W574)  and the screening of the epPCR libraries did not enhance the activity for the 
conductive polymer, no variants with improved activity could be identified. During the 
screening of epPCR libraries, the P450 titration by CO-gassing was compared to the P450 
quantification by automated gel electrophoresis. Resulting, that the P450 concentration 
determined by CO-gassing allows more precise and reliable results. Transferring this 
observation to other protein, which are no monooxygenase indicates that the protein 
concentration determined by automated gel electrophoresis is not reliable to efficiently avoid 
expression mutants.  
The subsequent identified lacking activity with the purified protein and the location of the 
substitutions supported the analyzed hypotheses that no direct interactions between the 
conductive polymer and the protein is present.  
To exclude the presence of a mediator in the cell lysate and analyse if a NADPH or mediator 
based conversion is occurring, control experiments were performed. First the conversion of 3-
phenoxytoluene with purified protein in presence of the conducting polymer Clevios P was 
analysed. No activity in presence of Clevios P could be observed, even though other 
colorimetric (pNCA) or fluorescent detection assays (7-Ethoxycoumarin and BCCE 
conversion). Subsequently, the generated products in presence of the conducting polymer 
with cell lysate were detected by GC and GC-MS. Concluding, the monitored activity is not 
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due to addition of the conducting polymer as the hydroxylated product could be monitored in 
the reaction mixture without supplemented electron donor indicating that a NADPH based 
reaction is occurring. Additionally, an inhibitory effect by the conductive polymer could be 
demonstrated. Finally, the hypothesis of an undefined mediator present in the cell lysate and 
his impact on the activity was investigated by recombining the cell lysate with purified 
protein. Concluding, the protein has no detectable activity with the conductive polymer 
Clevios P. Selected mutants from the screening were improved for resistance towards Clevios 
P or stability with NADPH but the activity for direct electron transfer and the electron transfer 
rate did not increase. 
Subsequent analysis and discussion revealed that Clevios P could not be identified as a 
suitable alternative cofactor system when used alone in solution without regeneration system.  
The PEDOT/PSS polymer is generated through oxidative polymerization with Fe-salts and 
synthesized in its oxidized state, which would not be suitable to drive P450 BM3. The 
reductase of P450 BM3 has a formal redox potential of -388 mV. An efficient electron donor 
for P450 BM3 requires a redox potential, which is more negative than the P450 BM3’s redox 
potential (< -400 mV). The formal redox potential of a PEDOT/PSS (Baytron P) solution is 
reported to be around -400 mV and because of existing reaction over potentials it is not 
suitable to function as electron donating “battery”. 
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4.  Appendix Chapter: Summarizing collaborative projects with 
P450 BM3 
 
In this chapter of the thesis the research performed within the framework of the EU-Project 
Oxygreen besides the main topic of the P450 BM3 evolution for alternative cofactor systems 
is summarized. These projects were done in collaboration with the Dechema (Frankfurt, 
Germany), DWI (Aachen, Germany), TU Graz (Graz, Austria) and coworker from our group 
working on other work packages.  
 
4.1  Directed Evolution of P 450 BM 3 into a p-Xylene Hydroxylase 
 
Collaborator: Alexander Dennig (RWTH Aachen) 
 
Publication: Directed Evolution of P 450 BM 3 into a p-Xylene Hydroxylase  
Alexander Dennig, Jan Marienhagen, Anna Joelle Ruff, Lukas Guddat, Ulrich Schwaneberg 
 
Abstract4: 1“2,5-Dimethylphenol (2,5-DMP) is of high interest for the production of temperature stable 
polymers (>500 K) as well as a building block for “next-generation” plastics. The presented reengineered P450 
BM3 variant (R47I/Y51WI401M) has a good catalytic activity (kcat 1950 min-1), excellent coupling efficiency 
(66 %) and selectivity (>98 %) for 2,5-DMP production.” (Dennig et al., 2012) 
 
 
4.2  Electrochemical characterization of P450 BM3 variants 
 
Collaborator: Claudia Ley, Dirk Holtmann, Jens Schrader (Dechema, Frankfurt) 
 
The aim of the collaboration with the Karl-Winnacker Institute at the Dechema (Frankfurt, 
Germany) was to electrochemical evaluate the variants generated in this thesis for their MET 
transfer abilities. Besides the variants selected in the screening for improved MET, molecular 
biological tasks were realized to generated variants with attached tags for their 
electrochemical analysis. Several P450 BM3 variants were constructed, expressed and 
provided in mg scale for an evaluation with the recently developed eMTP (Ley et al., 2012, 
submitted). 
 
                                                 
4 Copied from Publication: Directed Evolution of P 450 BM 3 into a p-Xylene Hydroxylase, Alexander Dennig, Jan 
Marienhagen, Anna Joelle Ruff, Lukas Guddat, Ulrich Schwaneberg, ChemCatChem, 2012, 4, 771-773 
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1) P450 BM3 M4 and M5 were reconstituted by SDM as 
published by Nazor (Nazor et al., 2008) with the purpose 
to compare generated mutants to previously published data 
(Fig. 95). 
 
 
 
 
Fig. 95: PCR product of variant P450 BM3 M4 and M5 generated by  
SDM and separated by agarose gel electrophoresis.  
 
 
2) P450 BM3 M3 with a N-terminal Lys-Taq was generated by PCR for evaluation of 
planned immobilization methods on the electrode. The sequence of the Lys-Tag as 
well as the used primers is given in Table S1 in the Appendix (section 6.1). 
 
3) P450 BM3 variants with a HIS-tag (P450 BM3 M3, P450 BM3 F87A, P450 BM3 
WT) were generated by PCR and confirmed by sequencing. The constructs were used 
to investigate the influence of charges on immobilization on electrodes according to 
the employed methods used by Ley (Ley et al., 2011).  
 
 
4.3   Surface modification of P450 BM3 for immobilization on gold 
particles 
 
Collaborator: Patrick van Rijn (DWI, Aachen) 
 
Gold surfaces are reported to covalently bind monooxygenase via sulphur containing amino 
acids (Aryal et al., 2006; Ferrero et al., 2008; Mak et al., 2010). Rational introduction of 
amino acid substitutions to cysteine or lysins allow to orientate the monooxygenase on the 
electrode surface (Mak et al., 2010). P450 BM3 has many lysins (Fig. 96) but no cysteins on 
the surfaces. Aim of the project was to covalently attache P450 BM3 to gold Janus particles in 
an orientated manner to maintain the catalytic activity at interphase (hexane/aqueous buffer). 
The approach to use the lysins present on the surface failed, the particles were completely 
covered with P450 BM3 and no catalytic activity could be detected.   
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a)      b) 
 
 
 
 
 
 
 
 
 
Fig. 96: a) Lysins displayed on the surfaces of P450 BM3. b) S450 and S555 located on the surfaces of P450 
BM3 and displayed in red.   
 
Therefore cystein modifications on the protein surface of P450 BM3 were performed to 
orientate the protein. The appointed substitution from serin to cysteine at position 450 located 
in the heme domain and position 555 located in the reductase domain were introduced by 
SDM. The variants were generated by SDM and purified according to standard protocols 
starting with the variant P450 BM3 I162G K187E improved for 7-Ethoxycoumarin 
conversion as well as for Indol hydroxylation (Park et al., 2010). Variant P450 BM3 I162G 
K187E was selected to enable the use of an easy to handle and sensitive fluorescent or robust 
colorimetric assay to determine the activity of the P450 BM3 I162G K187E in an 
immobilized state.  
In collaboration with Patrick Van Rijn (DWI an der RWTH Aachen e.V.), the attachment of 
variant P450 BM3 I162G K187E S450C or P450 BM3 I162G K187E S555C to the gold 
surfaces was achieved and analysed. The immobilization was successful, but the catalytic 
activity of the generated assembly was lost.  
 
 
4.4  Monooxygenase mutein database (MuteinDB) 
 
The literature search, data collection and implementation in a format sheet which could be 
integrated in the Mutein DataBase (MuteinDB) was performed for P450 BM3; more than 50 
publication were considered and 800 muteins were collected and integrated in the mutein 
database which was managed by A. Braun (TU Graz, Austria).   
 
 
S450
S555
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Collaborator: Andreas Braun (TU Graz, Austria) 
 
Publication: MuteinDB: The mutein database linking substrates, products and 
enzymatic reactions directly with genetic variants of enzymes 
Andreas Braun, Bettina Halwachs, Martina Geier, Katrin Weinhandl, Michael Guggemos, Jan 
Marienhagen, Anna Joelle Ruff, Ulrich Schwaneberg, Vincent Rabin, Daniel E. Torres Pazmino, 
Gerhard G. Thallinger, Anton Glieder 
 
Abstract5: 2 “Mutational events as well as the selection of the optimal variant are essential steps in the 
evolution of living organisms. The same principle is used in laboratory to extend the natural biodiversity to 
obtain better catalysts for applications in biomanufacturing or for improved biopharmaceuticals. Furthermore, 
single mutations in genes of drug metabolizing enzymes can also result in dramatic changes in pharmacokinetics. 
These changes are a major cause of patient-specific drug responses and are therefore the molecular basis for 
personalized medicine. 
MuteinDB systematically links laboratory-generated enzyme variants (muteins) and natural isoforms with their 
biochemical properties including kinetic data of catalysed reactions. Detailed information about kinetic 
characteristics of muteins is available in a systematic way, and searchable for known mutations and catalysed 
reactions as well as their substrates and known products. MuteinDB is broadly applicable to any known protein 
and their variants and makes mutagenesis and biochemical data searchable and comparable in a simple and easy-
touse manner. For the import of new mutein data, a simple, standardised, spreadsheet-based data format has been 
defined. To demonstrate the broad applicability of the MuteinDB, first data sets have been incorporated for 
selected cytochrome P450 enzymes as well as for nitrilases and peroxidases. 
Database URL: http://www.MuteinDB.org” (Braun et al., 2012) 
 
 
 
 
                                                 
5 Copied from Publication: MuteinDB: The mutein database linking substrates, products and enzymatic reactions directly 
with genetic variants of enzymes, Andreas Braun, Bettina Halwachs, Martina Geier, Katrin Weinhandl, Michael Guggemos, 
Jan Marienhagen, Anna Joelle Ruff, Ulrich Schwaneberg, Vincent Rabin, Daniel E. Torres Pazmino, Gerhard G. Thallinger, 
Anton Glieder, Database, 2012, Databases Vol. 2012, doi:10.1093/database/bas028 
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5. Summary  
 
In this thesis entitled “Advances in directed monooxygenase evolution: From diversity 
generation and flow cytometry screening to tailor-made monooxygenases”, methodological 
advancements in the two key steps of directed protein evolution, the diversity generation and 
high throughput screening were achieved. The methodological advances were complemented 
by the directed protein evolution of P450 BM3 towards improved activity with alternative 
cofactor systems.  
 
Directed evolution Step 1 consisting of generation of high quality mutant libraries was 
advanced by developing an improved SeSaM protocol in which a universal base 
complementary to the P-base was employed to generate more diverse libraries. Employing a 
second degenerated base allows for the first time to introduce transversion mutation at all four 
nucleotides. Step 2 was advanced by generating the first reported whole cell high throughput 
screening assay for monooxygenases allowing to efficiently sample the diversity generated in 
Step1. Subsequently, the SeSaM-R-base advanced protocol and the flow cytometry screening 
system were applied to evolve P450 BM3 for alternative cofactor systems in iterative rounds 
(Step 3) of diversity generation and screening. These developed methods (flow cytometer 
assay for P450 BM3 and advanced SeSaM method) are of main interest for the researchers 
focusing on protein engineering and contribute to improved directed evolution protocols 
which can be efficiently applied for protein engineering. 
 
Chapter I of the thesis focus on the advancement of the SeSaM method. Herein, the 
application of the R-base as universal base complementary to the P-base was investigated to 
further increase the amino acid sequence space that can be generated by the SeSaM method is 
reported. SeSaM-P/R allows for the first time to introduce at all four nucleotides in a gene 
transversion mutations which are homogeneously distributed over the targeted gene and 
which mutates each nucleotide. Advancements compared to SeSaM-P lie in the more diverse 
fragmentations patterns, omitting the use of template-DNA (Step 3), doubling the mutation 
frequency, and chemical diversity due to parallel employment of the P- and R-base. The 
SeSaM-P/R method nearly doubles the number of by epPCR unobtainable amino acid 
substitutions when compared to previous SeSaM methods. Transversions cause amino acid 
substitutions that are naturally not or barely occurring leading to chemically diverse amino 
acids substitution patterns. The latter mutational bias might become beneficial for protein 
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reengineering challenges such as improving solubility of proteins in water, increasing thermal 
resistance or stability in organic solvents.  
Second approach to advance the SeSaM method was tackled with modified bases on the 3’ 
position of the sugar backbone through protecting groups to gain control over the number of 
added bases. The latter was not achieved efficiently.  
Chapter II of the thesis reports the development of the first flow cytometer based ultra-high 
throughput screening platform that can be applied in directed evolution campaigns of P450 
monooxygenases. The whole cell high throughput screening assay for P450 BM3 is based on 
a coumarin derivative (7-Benzoxy-3-Carboxy-Coumarin Ethyl ester (BCCE)) and allows 
sorting and enrichment of P450 variants at an excellent throughput of 500 events per second. 
Variants with up 7-fold increased activity (P450 BM3 DM-1) could be identified from a 
random mutant library. Furthermore, the presented BCCE screening platform is not only 
restricted to P450 monooxygenases, and will very likely be applicable to all P450 
monooxygenases that can be expressed in E. coli and catalyze an O-dealkylation of coumarin 
derivatives (e.g. human CYP3A4). It could further be used in metagenomic screenings, 
improving protein expression and screening of recombination libraries of P450 
monooxygenases as well as corresponding reductases.  
A flow cytometer based ultra-high throughput screening assay for directed evolution of P450 
BM3 towards improved mediated electron transfer with Zn-dust as electron source could not 
be settled despite that the entrapment of P450 BM3 expressing cells (permeabilized with 
polymixin B), of the substrate BCCE-acid, the water soluble mediator Co(III)-sep and Zn-dust 
in w/o/w emulsion was successful. Stable emulsion could be generated but no detectable 
activity was recorded. The inhibitory effect of the Zn-dust on the microbial grow was pre-
dominent and excluded the use of the double emulsion technology for the generation of an 
assay for the evolution of P450 BM3 for mediated electron transfer. 
In Chapter III, the advanced methods developed in Chapter I and II were employed to 
generate P450 BM3 libraries to evolve the monooxygenase towards alternative cofactor 
systems (mediated and directed electron transfer). Random mutant libraries were generated 
with the SeSaM method and by epPCR, enriched with the flow cytometer assay and screened 
with the BCCE fluorescent assay in MTP for improved mediated electron transfer. P450 BM3 
M3 could further be engineered towards increasing activity in presence of the alternative 
cofactor system Zn/Co(III)-sep. In the first step by the screening of focused saturation 
mutagenesis libraries at position N543 and R471, the variant P450 BM3 M3 N543SR471C 
could be selected with a 3 fold improved catalytic efficiency (Keff = 17 min-1 mM-1) compared 
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to the variant P450 BM3 M3 (Keff = 5 min-1 mM-1). Subsequent directed P450 BM3 M3 
N543S R471C evolution yielded the variant P450 BM3 M3 DM-2 (R203H F423L I401V) 
which had a nearly 4 fold improved Kcat (Kcat = 6.8 min-1) vs. the engineered variant P450 
BM3 M3 DM (N543S R471C) (Kcat = 1.8 min-1). Four new hot spots (255, 203, 423, 401) 
which were not reported before as relevant for the MET could be identified. Finally, the 
individual saturation of the identified position and the recombination of the beneficial amino 
acid substitution led to variants (Re-6 (R203V R255Q) and Re-B (F423L R255Q) ) which 
were respectively 1.4 fold and 1.15 fold improved in activity compared to the selected variant 
in the first round of directed evolution (DM-2: R203H F423L I401V).  
The second investigated alternative cofactor system, the Direct Electron Transfer was studied 
by directed P450 BM3 evolution to enhance activity in presence of the conducting polymer. 
The selected BM3 mutants were improved for resistance towards Clevios P or stability with 
NADPH but the activity for direct electron transfer and the electron transfer rate did not 
increase. 
Furthermore, in this thesis related collaborative P450 BM3 projects within the Oxygreen 
funding networks are reported. These comprise the collection of data for the mutein database 
(MuteinDB), the reengineering of P450 BM3 for altered substrate specificity and surface 
modifications of P450 BM3 for electrochemical characterization.  
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6.1  List of strains and primers 
Table S1: Primer used in experimental section. 
Primer Sequence (5’-3’) Purpose used 
PP1 b CATGGGCATGACAATTAAAGAAATGCCTCAG PLICing P450 BM3 
PP2 b CGACGGAGCTCGAATTCTTATTACCCAGC PLICing P450 BM3 
PP3 b CGAGCTCCGTCGACAAGCTTGCG PLICing P450 BM3 
PP4 b GTCATGCCCATGGTATATCTCCTTC PLICing P450 BM3 
P1 GACCGGCGCTCAGTTGGAATTCTAG SeSaM Chapter I 
P2 CACACTACCGCACTCCGTCGGACCATGATTACGCCAAGCTTGC SeSaM Chapter I 
P3 GTGTGATGGCGTGAGGCAGCGACCGGCGCTCAGTTGGAATTCTAG SeSaM Chapter I 
P4a [Biotin] CAC ACT ACC GCA CTC CGT CG SeSaM Chapter I 
P5 CCTGTTACCAGTGGCTGCTGCCAGTGG SeSaM Chapter I 
P6 CTATAGTGAGTCGTATTAATTTCGAACATGTGAGC SeSaM Chapter I 
P7 CTAACAAAGCCCGAAAGGAAGCTGAGTTG SeSaM Chapter I 
P8 GCTATGAGAAAGCGCCACGCTTCCCG SeSaM Chapter I 
P9 GGCAAGATCCTGGTATCGGTCTGCG SeSaM Chapter I 
P10 b CGTCGATTTTTGTGATGCTCGTCAG SeSaM Chapter I 
P11 b CTAGCTAGGATCCGGTACCGGTATG SeSaM Chapter I 
P12 CTAGCTAGGATCCGGTACCGGTATGGTGR SeSaM Chapter I 
P13 CTAGCTAGGATCCGGTACCGGTATGGTGRR SeSaM Chapter I 
P14 CTAGCTAGGATCCGGTACCGGTATGGTGRRR SeSaM Chapter I 
P15c [FITC] GCAATACGCAAACAGTCTCTCT SeSaM Chapter I 
P16 
TGGAATTCACTTGTGGCCGTCTACTCGCGAGATCGTCGCCGTCCAGCTC
GACCAGGATGGGCACCACCCCGGTGAACAGCTCCTCGCCCTTXXXCAC
CATACCGGTACC 
XXX = CCC, TTT, AAA, GGG, AGA, GAG 
SeSaM Chapter I 
P17 TAATACGACTCACTATAGGG BM3 SEQUENCING-T7 promoter 
P19 CTTTAACAGCTTTTACCGAGATCAGC BM3 SEQUENCING-Primer 2.1 
P20 CAGCTTAAATATGTCGGCATGGTC BM3 SEQUENCING-Primer 3 
P21 GTGCTATACGGTTCAAATATGG BM3 SEQUENCING-Primer 4 
P22 GTTTTCAACGAACGTCGTAGC BM3 SEQUENCING-Primer 5 
P23 GTCGATGAAAAACAAGCAAGC BM3 SEQUENCING-Primer 6 
P24 CGGAAAAGATCCAGAAAC BM3 SEQUENCING-N-seq-2/4 
P25 GCA ACGCTTGATTCACAC BM3 SEQUENCING-N-seq-3/4 
P26 CGGTCATCCGCCTGATNNNGCAAAGCAATTTGTCGAC SSM 543-Fwd 
P27 GTCGACAAATTGCTTTGCNNNATCAGGCGGATGACCG SSM 543-Rev 
P28 CAGTCTGCTAAAAAAGTANNNAAAAAGGCAGAAAACGCTC SSM 471-Fwd 
P29 GAGCGTTTTCTGCCTTTTTNNNTACTTTTTTAGCAGACTG SSM 471-Rev 
P30 GGATGCGGCGATAAAAACNNKGCTACTGGCTATCAAAAAG SSM 574-T577G-Fwd 
P31 CTTTTTGATAGCCAGTAGCMNNGTTTTTATCGCCGCATCC SSM 574-T577G-Rev 
P32 GCGCTGTATTTCTTAGGCAAAAATCCACATGTATTAC SDM V281G-Fwd 
P33 GTAATACATGTGGATTTTTGCCTAAGAAATACAGCGC SDM V281G-Rev 
P34 GATCTAGCGGATCCATGACAATTAAAGAAATG Heme/FMN expression BamHI 
P35 GATCTAGCGAATTCTTACCCAGCCCACACGTCTTTTGC P450 BM3 Rev EcoRI 
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P36 GCGGCTTTAACTATCGCATTAACAGCTTTTACCGAGATCAG Substrat 7-Ethoxycoumarin und coumarin SDM F162I 
P37 CTGATCTCGGTAAAAGCTGTTAATGCGATAGTTAAAGCCGC Substrat 7-Ethoxycoumarin und coumarin  SDM F162I 
P38 GGATGAAGCAATGAACGAACTGCAGCGAGCAAATCC Substrat 7-Ethoxycoumarin und coumarin SDM K187E 
P39 GGATTTGCTCGCTGCAGTTCGTTCATTGCTTCATCC Substrat 7-Ethoxycoumarin und coumarin  SDM K187E 
P40 GATCTAGCCCATGGATGACAATTAAAGAAATG Heme-FMN bp 1-471 FAD DEFFICIENT MUTANT 
P41 GATCTAGCGAATTCTTATTACGTTGAAAACGCACCGTG Heme-FMN bp 1-664 FAD-defficient mutant 
P42 GTTATCAGGCGGATGACCMNNATAAGACGCCGTTAC SSM 537-Rev 
P43 GTA ACG GCG TCT TAT NNK GGT CAT CCG CCT GAT AAC SSM 537-Fwd 
P44 GGATGCGGCGATAAAAACNNKGCTACTACGTATCAAAAAG SSM 574-Fwd 
P45 CTTTTTGATACGTAGTAGCMNNGTTTTTATCGCCGCATCC SSM 574-Rev 
P46 CGCTGCTTGTGCTATACNNKTCAAATATGGGAACAGC SSM 488-Fwd 
P47 GCTGTTCCCATATTTGAMNNGTATAGCACAAGCAGCG SSM 488-Rev 
P48 GTATTAATTGTAACGGCGTCTNNKAACGGTCATCCGCCTG SSM 536-Fwd 
P49 CAGGCGGATGACCGTTMNNAGACGCCGTTACAATTAATAC SSM 536-Rev 
P50 GATACCATGGGCAAAAAGAAGAAGAAAAAGAAAATGACAATTAAAGAAAT
G N-term Lys tag (Fwd) 
P51 GGTCGTGTAACGCGCTTTTTATCAAGTCAGCGTC SDM Y51F-Fwd 
P52 GACGCTGACTTGATAAAAAGCGCGTTACACGACC SDM Y51F-Rev 
P53 GGCGATAAAAACTGGGCTACTGGCTATCAAAAAGTG CCTGCT SDM T577G-Fwd 
P54 AGCAGGCACTTTTTGATAGCCAGTAGCCCAGTTTTT ATC GCC SDM T577G-Rev 
P55 CCTCAGCTTCACCGTCATAAAACAATTTGGGGA SDM D363H-Fwd 
P56 TCCCCAAATTGTTTTATGACGGTGAAGCTGAGG SDM D363H-Rev 
P57 GCAGGAGACGGGTTAGCTACAAGCTGGACGCATG SDM F87A-Fwd 
P58 CATGCGTCCAGCTTGTAGCTAACCCGTCTCCTGC SDM F87A-Rev 
P59 GAAAAAGGCGACGAACTAAGCGTTCTGATTCCTCAG SDM M354S-Fwd 
P60 CTGAGGAATCAGAACGCTTAGTTCGTCGCCTTTTTC SDM M354S-Rev 
P61 CAGTCTGCTAAAAAAGTATGCAAAAAGGCAGAAAACGCT SDM R471C-Fwd 
P62 AGCGTTTTCTGCCTTTTTGCATACTTTTTTAGCAGACTG SDM R471C-Rev 
P63 CGGTCATCCGCCTGATAGCGCAAAGCAATTTGTCGAC SDM N543S-Fwd 
P64 GTCGACAAATTGCTTTGCGCTATCAGGCGGATGACCG SDM N543S-Rev 
P65 GGCTTTGTGGTAAAAGCAAAATGCAAAAAAATTCCGCTTGGCGGTATTC SDM S450C-Fwd 
P66 GAATACCGCCAAGCGGAATTTTTTTGCATTTTGCTTTTACCACAAAGCC SDM S450C-Rev 
P67 GTCGACTGGTTAGACCAAGCGTGTGCTGATGAAGTAAAAGGCGTTC SDM S555C-Fwd 
P68 GAACGCCTTTTACTTCATCAGCACACGCTTGGTCTAACCAGTCGAC SDM S555C-Rev 
P69 CGCTTGATGACGAGAACATTNNKTATCAAATTATTACATTC SSM 255-Fwd 
P70 GAATGTAATAATTTGATAMNNAATGTTCTCGTCATCAAGCG SSM 255-Rev 
P71 GCTTATGATGAAAACAAGNNKCAGTTTCAAGAAGATATCAAG SSM 203-Fwd 
P72 CTTGATATCTTCTTGAAACTGMNNCTTGTTTTCATCATAAGC SSM 203-Rev 
P73 GATGCTAAAACACTTTGACNNKGAAGATCATACAAACTACG SSM 423-Fwd 
P74 CGTAGTTTGTATGATCTTCMNNGTCAAAGTGTTTTAGCATC SSM 423-Rev 
P75 GCTTATGATGAAAACAAGGTGCAGTTTCAAGAAGATATCAAG SDM R203V-Fwd 
P76 CTTGATATCTTCTTGAAACTGCACCTTGTTTTCATCATAAGC SDM R203V-Rev 
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P77 CGCTTGATGACGAGAACATTNNKTATCAAATTATTACATTC SDM R255H-Fwd 
P78 GAATGTAATAATTTGATAMNNAATGTTCTCGTCATCAAGCG SDM R255H-Rev 
P79 CGCCTGTCACCCGCTGCTTGTGCTATACGGTTC SesSaM BM3 FMN-up 
P80 CACACTACCGCACTCCGTCGCCGCTGCTTGTGCTATACGGTTC SesSaM BM3 FMN-Fwd 
P81 CGCTTGATGACGAGAACATTNNKTATCAAATTATTACATTC SSM R255-Fwd 
P82 GAATGTAATAATTTGATAMNNAATGTTCTCGTCATCAAGCG SSM R255-Rev 
P83 GATGCTAAAACACTTTGACCTGGAAGATCATACAAACTACG SDM F423L-Fwd 
P84 CGTAGTTTGTATGATCTTCCAGGTCAAAGTGTTTTAGCATC SDM F423L-Rev 
P85 CAGCGTGCGTGTNNKGGTCAGCAGTTC SSM 401-Fwd 
P86 GAACTGCTGACCMNNACACGCACGCTG SSM 401-Rev 
P87 CGACTCACTATAGGGGAATTGTGAGCGGA Amplification MCS pET-vectors 
P88 CGGGCTTTGTTAGCAGCCGGATCTCAG Amplification MCS pET-vectors 
P89 CACACTACCGCACTCCGTCGCGACTCACTATAGGGGAATTGTGAGCGGA SeSaM library of genes cloned in pET-vectors 
P90 GTGTGATGGCGTGAGGCAGCCGGGCTTTGTTAGCAGCCGGATCTCAG SeSaM library of genes cloned in pET-vectors 
P91 CGCCTGTCACCGACTCACTATAGGGGAATTGTGAGCGGA SeSaM library of genes cloned in pET-vectors 
P92 GCGGACAGTGCGGGCTTTGTTAGCAGCCGGATCTCAG SeSaM library of genes cloned in pET-vectors 
P93 [Biotin]CACACTACCGCACTCCGTCG SeSaM library of genes cloned in pET-vectors 
P94 [Biotin]GTGTGATGGCGTGAGGCAGC SeSaM library of genes cloned in pET-vectors 
 
a [Biotin] represents 5’-biotin 
b bold letters represent phosphorothiolated nucleotides 
c [FITC] represent 5’ fluorescein isothiocyanate 
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Table S2: List of strains used or generated in this work. 
 
Strain Origin 
E. coli DH5a pET28a(+) P450 BM3 M4 (R47F F87A V281G M354S) SDM V281G in  pET28a(+) P450 BM3 M2 
E. coli DH5a pET28a(+) P450 BM3 M5 (R47F F87A V281G M354S 
D363H) 
SDM V281G in pET28a(+) P450 BM3 M3 
E. coli DH5a pET28a(+) P450 BM3 Y51F 
SDM Y51F in pET28a(+) P450 BM3 WT 
E. coli DH5a pET28a(+) P450 BM3 Y51F T577G SDM T577G in pET28a(+) P450 BM3 Y51F 
E. coli BL21 (DE3) pET28a(+)P450 BM3 M2 (R47F F87A M354S) 
Strain collection (Nazor et al., 2006) 
E. coli BL21 (DE3) pET28a(+)P450 BM3 M3 (R47F F87A M354S 
D363H) Strain collection (Nazor et al., 2006) 
E. coli BL21 (DE3) pET28a(+)P450 BM3 M4 (R47F F87A V281G 
M354S) Plasmid isolated from E.coli DH5a pET28a(+) P450 
BM3 M4 
E. coli BL21 (DE3) pET28a(+)P450 BM3 M5 (R47F F87A V281G 
M354S D363H) E.coli BL21 (DE3) Gold pET28a(+) P450 BM3 M5 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 Y51F  Strain collection  (Wong et al., 2008) 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 Y51F T577G 
Strain collection  (Nazor et al., 2006) 
E. coli DH5a pCWORI P450 BM3 Y51F T577G  
Strain collection  (Nazor et al., 2006) 
E. coli DH5a pCWORI P450 BM3 Y51F 
Strain collection  (Nazor et al., 2006) 
E. coli BL21 (DE3) pET28a(+) Commercial Vector from Merck 
E. coli DH5a Strain collection  
E. coli BL21 (DE3) Gold Strain collection  
E. coli BL21 (DE3) lacIQ Strain collection  
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 F87A T577G Restiction cloning MfeI/EcoRI from pET28a(+) P450 
BM3 Y51F T577G in pET28a(+) P450 BM3 F87A 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 Y51F F162I K187E 
T577G 
SDM F162I K187E in pET28a(+) P450 BM3 Y51F 
T577G 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 Y51F F162I  
T577G 
SDM F162I in pET28a(+) P450 BM3 Y51F T577G 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 Y51F K187E T577G 
SDM K187E in pET28a(+) P450 BM3 Y51F T577G 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 F162I K187E T577G Restiction cloning MfeI/EcoRI from pET28a(+) P450 
BM3 Y51F F162I K187E T577G in pET28a(+) P450 
BM3 WT 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 F162I K187E T577G 
Y536S T533L A534G 
Restiction cloning MfeI/EcoRI from pET28a(+) P450 
BM3 Y51F F162I K187E T577G in pET28a(+) P450 
BM3 WT 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 Y51F T577G Y536S 
T533L A534G 
Generated in this thesis – SSM Y536S 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 F162I K187E T577G 
G488E 
Restiction cloning MfeI/EcoRI 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 Y51F T577G G488E 
SSM G488 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 T577G 
SDM T577G in pET28a(+) P450 BM3 WT 
E. coli BL21 (DE3) Gold pAlXtreme-1a P450 BM3 F87A 
Subcloning from pET28a(+) P450 BM3 F87A 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 F87A T577G 
SDM F87A in pET28a(+) P450 BM3 T577G 
E. coli BL21 (DE3) Gold pALXtreme-1a P450 BM3 
Strain collection 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 F162I K187E S450C 
T577G 
SDM S450C in pET28a(+) P450 BM3 F162I K187E 
T577G 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 F162I K187E S555C 
T577G 
SDM S555C in pET28a(+) P450 BM3 F162I K187E 
T577G 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 R471C T577G 
SSM R471 
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E. coli BL21 (DE3) Gold pALXtreme-1a P450 BM3 M3 (R47F F87A 
M354S D363H) 
Subcloning from pET28a(+) P450 BM3 M3 
E. coli BL21 (DE3) Gold LacIQ pALXtreme-1a P450 BM3 M3 R471C 
SSM R471 
E. coli BL21 (DE3) Gold LacIQ pALXtreme-1a P450 BM3 M3 R471T 
SSM R471 
E. coli BL21 (DE3) Gold LacIQ pALXtreme-1a P450 BM3 M3 N543S 
SDM N543S in pET28a(+) P450 BM3 M3 
E. coli BL21 (DE3) Gold LacIQ pALXtreme-1a P450 BM3 M3 R471C 
N543S 
SDM R471C in pET28a(+) P450 BM3 M3 N543S 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S 
R203V I401V 
Generated in this thesis – epPCR screening 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 DM-2 (R47F F87A 
M354S D363H R471C N543S F423L I401V) 
Generated in this thesis – epPCR screening 
E. coli BL21 (DE3) Gold pET28a(+)  P450 BM3 M3 R471C N543S 
I401V 
SSM I401 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S 
R255Q 
SSM 255  
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 DM-1 (R47F F87A 
M354S D363H R471C N543S R255H) 
Generated in this thesis – epPCR screening 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S 
R203H F423L I401V 
SDM pET28a(+) P450 BM3 M3 R471C N543S 
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S F423L 
I401V R255H 
SDM pET28a(+) P450 BM3 M3 R471C N543S
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S F423L 
R255H 
SDM pET28a(+) P450 BM3 M3 R471C N543S
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S F423L 
R255Q 
SDM pET28a(+) P450 BM3 M3 R471C N543S
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S 
R203H F423L I401V R255Q 
SDM pET28a(+) P450 BM3 M3 R471C N543S
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S 
R203H F423L I401V R255H 
SDM pET28a(+) P450 BM3 M3 R471C N543S
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S 
R203H F423L I401V 
SDM pET28a(+) P450 BM3 M3 R471C N543S
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S 
R203V R255Q 
SDM pET28a(+) P450 BM3 M3 R471C N543S
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S 
R203V R255H 
SDM pET28a(+) P450 BM3 M3 R471C N543S
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S 
R203V F423L I401V R255Q 
SDM pET28a(+) P450 BM3 M3 R471C N543S
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S 
R203V F423L I401V R255H 
SDM pET28a(+) P450 BM3 M3 R471C N543S
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S 
R203V F423L R255Q 
SDM pET28a(+) P450 BM3 M3 R471C N543S
E. coli BL21 (DE3) Gold pET28a(+) P450 BM3 M3 R471C N543S 
R203V I401V R255H 
SDM pET28a(+) P450 BM3 M3 R471C N543S
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6.2  Supplementary information of Chapter I 
 
Table S3: Upper part: Sequencing results of a SeSaM library with R base and in Step 3 employed Vent (exo-) 
polymerase. Lower part: Sequencing results of SeSaM library with R and P base and Vent (exo-) polymerase in 
Step 3. Gray underlined amino acid substitutions are unobtainable by epPCR. 
 
Clone no. Amino acid substitutions Mutated codons Transversion Transition 
1 K4T AAG → ACG +  
2 L196L CTG → CTA  + 
3 K108R AAG → AGG  + 
4 D118E GAC → GAG +  
5 F72L TTC → CTC  + 
6 V62G GTG → GGG +  
7 V62G GTG → GGG +  
8 I162I ATC → ATT  + 
9 R110H CGC → CAC  + 
10 F72L TTC → CTC  + 
11 D77G GAC → GGC  + 
12 V2A GTG → GCG  + 
Y75N TAC → AAC +  
13 I15V ATC → GTC  + 
V17G GTC → GGC +  
14 S31S TCC → TCA +  
F72Y TTC → TAC +  
15 A88V GCC → GTC  + 
I168T ATC → ACC  + 
16 I172I ATC → ATT  + 
L222M CTG → ATG +  
17 H140Y CAC → TAC  + 
F166L TTC → CTC  + 
18 L16M CTG → ATG +  
R123G CGC → GGC +  
19 T98T ACC → ACT  + 
I162I ATC → ATT  + 
20 P76S CCC → TCC  + 
K114N AAG → AAT +  
 D191E GAC → GAG +  
21 
T98I ACC → ATC  + 
L138R CTG → CGG +  
K163Q AAG → CAG +  
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Clone no. Amino acid substitutions Mutated codons Transversion Transition 
1 T226A ACC → GCC  + 
2 K167E AAG → GAG  + 
3 Q178Q CAG → CAA  + 
4 I153N ATC → AAC +  
5 G34C GGC → TGC +  
6 I172N ATC → AAC +  
7 L232H CTC → CAC +  
8 K127Q AAG → CAG +  
9 S206S TCC → TCT  + 
10 L138P CTG → CCG  + 
11 K4E AAG → GAG  + 
12 V2A GTG → GCG  + 
13 
G34C GGC → TGC +  
G175GS176R 
GGC 
AGC →
GGA 
CGC ++  
14 M79T ATG → ACG  + 
D156V GAC → GTC +  
15 
L19L CTG → TTG  + 
G34GE35Q 
GGC 
GAG →
GGA 
CAG ++  
16 Y67N TAC → AAC +  
R110H CGC → CAC  + 
17 G25G GGC → GGG +  
G52G GGC → GGG +  
18 I153N ATC → AAC +  
P14A CCC → GCC +  
19 D211V GAC → GTC +  
F224I TTC → ATC +  
20 L142L CTG → TTG  + 
M154T ATG → ACG  + 
21 N171R AAC → AGA + + 
R169H CGC → CAC  + 
22 E6G GAG → GGG  + 
G34C GGC → TGC +  
23 D37V GAT → GTT +  
P193P CCC → CCT  + 
24 D77H GAC → CAC +  
T119T ACC → ACT  + 
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25 
K4N AAG → AAT +  
E7DL8L 
GAG 
CTG →
GAT 
TTG + + 
26 H170R CAC → CGC  + 
Y201C TAC → TGC  + 
27 F131C TTC → TGC +  
S209G AGC → GGC  + 
28 V69A GTG → GCG  + 
H170Y CAC → TAC  + 
29 D77H GAC → CAC +  
T119T ACC → ACT  + 
30 M79T ATG → ACG  + 
D156V GAC → GTC +  
31 
T60A ACC → GCC  + 
T98D ACC → GAC + + 
T109S ACC → TCC +  
32 
T60I ACC → ATC  + 
V62E GTG → GAG +  
Y152N TAT → AAT +  
33 
F72Y TTC → TAC +  
H82R CAC → CGC  + 
Y201C TAC → TGC  + 
34 
V30G GTG → GGG +  
T51S ACC → AGC +  
P90P CCC → CCT  + 
35 
M1I ATG → ATT +  
G5H GGC → CAC + + 
N106H AAC → CAC +  
36 
K4T AAG → ACG +  
S31S TCC → TCA +  
F72Y TTC → TAC +  
37 V56E GTG → GAG +  
D118E GAC → GAA +  
 M234I ATG → ATC  + 
38 
F72L TTC → CTC  + 
R97L CGC → CTG +  
F224S TTC → TCC  + 
39 
P14A CCC → GCC +  
L54L CTG → CTA  + 
T66T ACC → ACT  + 
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40 
V94V GTC → GTT  + 
V30E GTG → GAG +  
T39I ACC → ATC  + 
T60P ACC → GCC  + 
41 
V69E GTG → GAG +  
V113A GTG → GCG  + 
N150D AAC → GAC  + 
 G161V GGC → GTC +  
42 
V23V GTA → GTG  + 
L43P CTG → CCG  + 
P55P CCC → CCA +  
L222P CTG → CCG  + 
43 
I189T ATC → ACC  + 
L43L CTG → CTA  + 
T66T ACC → ACT  + 
S87T TCC → ACC +  
44 
I48I ATC → ATT  + 
I124T ATC → ACC  + 
N165D AAC → GAC  + 
T204S ACC → TCC +  
G233E GGC → GAA + + 
45 
V69E GTG → GAG +  
V113A GTG → GCG  + 
N150S AAC → AGC  + 
M154T ATG → ACG  + 
G161V GGC → GTC +  
46 
G117S GGC → AGC  + 
I129F ATC → TTC +  
K157R AAG → AGG  + 
Q185L CAG → CTG +  
L237V CTG → GTG +  
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6.3  Vector maps 
 
pET28a(+) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 97: Vector map of pET28a(+) (Merck, Darmstadt, Germany). 
 
 
pCWori(+) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 98: Vector map of pCWori(+) a derivative of plasmid pHSe5 (Barnes, 1996). 
 
pET28a(+) 
8.5 kb 
pCWori(+) 
8.1 kb 
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pALXtreme-1a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 99: Vector map of pALXtreme-1a, derivative of plasmid pET28a(+)  (Dr. A. Schenk, Jacobs University 
Bremen, Bremen, Germany). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pALXtreme-1a 
5.1 kb 
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